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ABSTRACT
MicroRNAs (miRNAs) are a novel class of small (approximately 23 nucleotides long),
highly conserved, non-coding RNAs that function by broadly regulating gene expression. In
animals, this regulation is achieved via interaction with target messenger RNAs (mRNAs),
largely through their imperfect base pairing with the 3' untranslated regions (3' UTRs) of these
target transcripts. Through this imperfect base pairing, miRNAs induce a repression of mRNA
translation that is frequently coupled to enhanced turnover of the targeted transcript. This
miRNA-mediated repression is highly related to that of RNA interference (RNAi), in which
small non-coding RNAs exhibit perfect base pairing with target mRNA transcripts, leading to the
endonucleolytic cleavage and degradation of these targeted mRNAs. Computational algorithms
have been designed to predict putative miRNA binding sites within mRNAs. Using these
predictions, it has been suggested that more than half of all mRNAs within mammals are under
the control of miRNAs.
Some of the earliest discovered miRNAs (characterized by genetic studies in the
nematode Caenorhabditis elegans) were found to control the proliferation and differentiation of
the cells in which they were expressed. As altered control of proliferation and differentiation
frequently manifest in cancer in mammals, it was suggested that miRNAs might contribute to the
development of tumorigenesis. In fact, several miRNAs are frequently deleted or amplified in
human cancer and miRNA expression profiling studies have shown widespread reductions in
steady-state miRNA levels in human cancers relative to normal tissue. These observations have
implied a role for miRNAs in tumorigenesis. However, there is a paucity of functional studies
demonstrating a role for miRNAs in oncogenic transformation.
In the studies described below, we first provide strong evidence for the global loss of
miRNAs in human cancers functionally enhancing cellular transformation and tumorigenesis.
This enhanced transformation only occurred within tumor cells, suggesting that inhibiting
miRNA biogenesis would not be sufficient to induce tumor formation. Moreover, we
demonstrate that inhibition of miRNA processing in cancer must be incomplete, as Dicerl, a
component of the miRNA processing pathway, suppresses tumorigenesis via haploinsufficiency.
Finally, we examine the role of a specific miRNA family, the let-7 family, in the development of
non-small cell lung cancer by showing that let-7 can suppress tumorigenesis via inhibition of its
targets K-Ras and HMGA2. Taken together, these findings offer promise, not just for
understanding the relationship of miRNAs and cancer, but for developing therapeutic agents
against the disease.
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CHAPTER 1: Introduction
Portions of this chapter were originally written in a review "MicroRNAs and cancer" by Andrea
Ventura, Madhu S. Kumar, and Tyler Jacks, submitted to Current Opinion in Genetics and
Development.
MicroRNAs (miRNAs)
Overview
MicroRNAs (miRNAs) are a novel class of short non-coding RNAs that regulate gene
expression through homologous base pairing with target mRNAs in their 3' untranslated regions
(3' UTRs), resulting in both translational repression and enhanced mRNA turnover (Bartel,
2004; Filipowicz et al., 2008). Based on recent computational algorithms, there are thousands of
predicted miRNA targets, implying that miRNAs function to broadly control gene expression
(Bartel, 2009). In particular, many miRNA targets have roles in cellular differentiation,
apoptosis, and proliferation, processes commonly altered during tumorigenesis. Thus, miRNAs
have been ascribed a role in tumorigenesis. Here I will describe the initial discovery of miRNAs,
current knowledge of miRNA biogenesis and function, and the genetic consequences of broadly
and specifically inhibiting miRNAs in mammals.
MiRNA discovery
MiRNAs were initially characterized as genes whose mutation altered larval
developmental timing in the nematode, Caenorhabditis elegans (C. elegans). The initial
mutation, lin-4, was described to encode not a traditional protein-coding gene, but instead a set
of small RNAs, the larger of which (approximately 61 nucleotides) was predicted to be a stem-
loop precursor for the other (approximately 21 nucleotides) (Lee et al., 1993). In addition, it was
shown that this small RNA product was predicted to base pair with the 3' UTR of lin-14, which
led to reductions in Lin-14 protein levels without changes in the levels of the lin-14 transcript
(Lee et al., 1993; Wightman et al., 1993). This led to the idea that the lin-4 RNA regulated
developmental timing by inhibiting translation of the Lin-14 protein via base pairing with the lin-
14 3' UTR. As a short RNA species whose expression was regulated precisely during
development, lin-4 was initially labeled as a small temporal RNA (stRNA).
While the discovery of a second stRNA, let-7 (discussed in greater detail below),
suggested that there were several small RNAs that regulated developmental decisions in C.
elegans, it was not clear whether such RNAs existed in other organisms (Reinhart et al., 2000).
This issue was resolved in two ways. First, it was shown that orthologs of let-7 exist in a variety
of animal species as a small RNA (Pasquinelli et al., 2000). Second, a series of papers described
the isolation, cloning, and sequencing of small RNA populations from a variety of different
animal species (Lagos-Quintana et al., 2001; Lau et al., 2001; Lee and Ambros, 2001).
These studies used polyacrylamide gel electropheresis of RNA from a variety of
invertebrate and vertebrate cell lines and tissues to separate the small (-20 nucleotides long)
RNAs from the bulk RNA population. After adaptor ligation to 5' phosphate groups, these small
RNAs were amplified, sequenced, and mapped to their corresponding genomes. In contrast to the
idea that much of this small RNA would exist as degradation products of the more abundant
cellular RNAs, most of these RNAs mapped to intergenic sequences and were non-randomly
distributed. Furthermore, these sequences were much more highly conserved across species than
other non-protein coding regions of the genome. Moreover, most of these small RNAs were
surrounded by sequences that were predicted to create stem loop structures, as seen in the lin-4
RNA, suggesting their specific biogenesis. This allowed for the eventual prediction of miRNA
genes within a given genome sequence (Lim et al., 2003a; Lim et al., 2003b). Overall, these
initial observations provided powerful evidence for the broad relevance of these small RNAs to
molecular biology.
Using similar approaches, the work of many groups has led to the discovery of thousands
of different miRNAs from a variety of organisms (Griffiths-Jones et al., 2008). More recently,
the development of large-scale, massively parallel sequencing technologies has allowed for more
profound sequencing of such small RNA libraries (Rusk and Kiermer, 2008). Such methods have
not only allowed for the "deep sequencing" and discovery of new miRNAs in complex, multi-
lineage tissues and organisms, it has allowed for the discovery of novel small RNA species, like
piRNAs and 21U-RNAs, whose production within reproductive organs is required for fertility in
a variety of animals (Aravin et al., 2006; Girard et al., 2006; Lau et al., 2006; Ruby et al., 2006;
Vagin et al., 2006). While each class of small RNAs share common sequence elements, they are
not of a defined sequence, as seen for miRNAs. Overall, massively parallel sequencing has
allowed for the discovery of both novel miRNAs and additional small RNA populations.
While such biochemical approaches have the potential to discover new small RNAs, it is
likely that even the most current massively parallel sequencing technologies will miss small
RNAs that are expressed in extremely rare sub-populations. An example of this type of small
RNA missed by cloning is lsy-6, which controls the development of left/right neuronal
asymmetry in the nematode (Johnston and Hobert, 2003). It was isolated as a mutant, similar to
lin-4 and let-7. However, it is expressed within a single neuron in C. elegans, where it controls
the lineage fate of the cell. As lsy-6 is expressed in a single cell in the worm, it is by definition
less abundant than most miRNAs. In fact, even current massively parallel sequencing
technologies are limited in their ability to detect the lsy-6 small RNA product during small RNA
cloning from the whole worm. Thus, genetic approaches serve a vital complement to cloning
techniques in the discovery of functionally relevant miRNAs.
MicroRNA biogenesis
MicroRNA maturation involves a series of regulated processing events from a primary
transcript (Figure 1.1). Within the genome, miRNAs are mapped as hairpin structures that exhibit
significant sequence conservation across related species; in fact, such requirements have been
applied in the development of the program MiRscan, which predicts miRNA genes in various
species (Lim et al., 2003b). In most cases, miRNAs are synthesized as RNA polymerase II
transcripts, with 7-methylguanosine caps and 3' polyadenylation similar to mRNAs (Lee et al.,
2004). After synthesis, these primary miRNA transcripts, or pri-miRNAs, undergo a first round
of processing by the RNAse III-like enzyme Drosha and its dsRNA binding partner,
DGCR8/Pasha, to produce a pre-miRNA hairpin (Denli et al., 2004; Gregory et al., 2004; Lee et
al., 2003). While the majority of miRNAs are intergenic, approximately one-quarter of miRNAs
map within the introns of protein-coding genes and these intronic miRNAs undergo Drosha
processing in tandem with mRNA splicing (Kim and Kim, 2007). While this occurs in the
majority of intronic miRNAs, a subset (labeled "mirtrons") exist as a pre-miRNA intron whose
splicing produces the pre-miRNA hairpin (Berezikov et al., 2007; Okamura et al., 2007; Ruby et
al., 2007). Overall, in the nucleus, miRNA precursors are synthesized and undergo an initial
round of processing to produce pre-miRNAs.
After this initial processing, the pre-miRNA hairpin is subsequently exported from the
nucleus to the cytoplasm via Ran-GTP and Exportin-5 (Lund et al., 2004; Yi et al., 2003). After
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Figure 1.1 The miRNA processing pathway. MiRNAs are initially transcribed by either RNA
polymerase II or III to produce a primary miRNA transcript, or pri-miRNA. In the nucleus, the
pri-miRNA is converted by Drosha and DGCR8 into a pre-miRNA hairpin. This pre-miRNA
hairpin is exported from the nucleus via Exportin-5 and Ran-GTP to the cytoplasm, where it
undergoes a second round of processing by Dicer and TRBP into a miRNA duplex. This duplex
is then unwound, and the mature miRNA associates with the Argonaute family of proteins to
produce the RNA induced silencing complex, or RISC, where it engages in regulation of target
mRNA transcripts. Adapted from (Winter et al., 2009).
cytoplasmic export, the pre-miRNA undergoes a second round of processing by the complex of
Dicer and TRBP to produce the miRNA duplex (Chendrimada et al., 2005; Haase et al., 2005;
Hutvagner et al., 2001). This complex interacts with the Argonaute proteins to produce the
mature miRNA-Argonaute protein complex (with some evidence that Argonaute family
members themselves cleave the pre-miRNA to produce a second intermediate), which acts with
additional factors to produce the RNA-induced silencing complex, or RISC, and subsequently
regulate target mRNA expression (Diederichs and Haber, 2007; Gregory et al., 2005; Matranga
et al., 2005; Rand et al., 2005).
MiRNA function
Once miRNAs are loaded onto RISC, they can interact with target mRNAs and regulate
their expression in a specific way depending upon their base pairing. If a miRNA exhibits
complete sequence complementarity with a target mRNA, it will engage in mRNA degradation
due to specific endonucleolytic cleavage of the transcript by Argonaute-2 (Liu et al., 2004; Song
et al., 2004). This process was originally described by Andrew Fire, Craig Mello and colleagues
as dsRNA-mediated genetic interference in C. elegans and was labeled RNA interference
(RNAi) (Fire et al., 1998). This is the mechanism by which plant miRNAs regulate their target
transcripts (Bartel, 2004). In contrast, the preponderance of animal miRNAs function through
imperfect base pairing with a target transcripts to engage in translational repression and mRNA
turnover that does not require Argonaute-catalyzed cleavage (Valencia-Sanchez et al., 2006).
Frequently, this translational repression is coupled to turnover of the target transcript due to its
deadenylation/decapping and subsequent degradation (Bagga et al., 2005; Behm-Ansmant et al.,
2006). In fact, recent proteomics analyses of miRNAs and their targets suggest that targets
significantly repressed at the protein level largely undergo these effects at the level of mRNA
degradation (Baek et al., 2008; Selbach et al., 2008).
The mechanism of translational repression by miRNAs of target mRNAs remains
controversial. Initial studies suggested that miRNAs regulate translation at the level of initiation
(Humphreys et al., 2005; Pillai et al., 2005). These results were largely based upon two types of
experiments: the delivery of target mRNAs containing internal ribosome entry sites that bypass
distinct stages of translation initiation, and the tethering of RISC to target mRNAs via RNA stem
loop structures that would associate with Argonaute proteins fused to RNA binding proteins that
bound these stem loops. Using these techniques, both groups observed that bypassing the early
requirements of translational initiation, such as recognition of the 7-methylguanosine cap,
mitigates miRNA-mediated translational repression.
In contrast, other reports argued that miRNA-mediated translational repression occurs
post-initiation (Olsen and Ambros, 1999; Petersen et al., 2006; Seggerson et al., 2002). In these
studies, target mRNAs were examined via polysome analysis of either endogenous mRNAs or
expression of synthetic miRNA targets from DNA plasmids. Using these systems, they observed
association of target mRNAs with polysomes in both the presence and absence of miRNA, which
should not occur if miRNAs inhibited translation initiation. Through the application of nonsense
suppressor tRNAs, it was posited that miRNA-mediated translational repression occurs via early
ribosome drop-off during elongation. Due to the differences in the mRNA target delivery to cells
(transfection in the former set of experiments, expression from intracellular DNA in the latter), it
is difficult to directly compare the findings from these studies. Further complicating matters, a
controversial report suggested that miRNAs can actually promote target translation during
quiescence (Vasudevan et al., 2007). In sum, while it is clear that animal miRNAs can function
through translational repression of target transcripts, the mechanism behind this translational
repression is still contested.
A further wrinkle in the analysis of miRNA-mediated translational repression is found by
the effect of miRNAs on the association of mRNAs with intracellular RNA regulatory bodies
called processing bodies (P-bodies). These cytoplasmic foci are sites of storage for untranslated
mRNA and are believed to regulate gene expression. Interestingly, it has been observed that
RISC associates with mammalian P-bodies, mRNAs enter P-bodies in a miRNA-dependent
manner, and that P-body component GW 182 is an important regulator of miRNA function
(Jakymiw et al., 2005; Liu et al., 2005; Sen and Blau, 2005). In contrast to these findings, other
data shows RISC associating in conditions of cellular stress instead with a different class of
cytoplasmic RNA foci called stress granules, and that this association with stress granules, and
not P-bodies, occurs in a miRNA-dependent manner (Leung et al., 2006). Though distinct on the
contribution of different cytoplasmic RNA foci to miRNA-mediated repression, these findings
propose a role for altered cytoplasmic localization of target mRNAs in response to miRNA-
mediated repression.
While the above mechanistic studies of miRNA function leave many questions
unanswered, much is known about the cis elements of miRNAs and target mRNAs required for
translational repression. In particular, while imperfect base pairing is a hallmark of miRNA-
mediated translational repression, base pairing at specific sites appears vital for this repression.
This region, which encompasses nucleotides two through seven (and frequently nucleotide eight)
of the miRNA, has been termed the "seed" region, and mutation of this site within a target
largely abolishes miRNA-mediated repression (Doench and Sharp, 2004; Lewis et al., 2003).
Additionally, this seed sequence regulates both translational repression of target transcripts and
their turnover, as shown by ectopic expression of a miRNA leading to enrichment for mRNAs
containing the miRNA's seed sequence among the set of down-regulated transcripts; also, "off-
target" down-regulation of mRNAs in response to a given siRNA is believed to be due to this
seed sequence-mediated turnover (Birmingham et al., 2006; Lim et al., 2005).
Furthermore, additional predictive analysis of miRNA binding sites have created
additional rules for enhanced miRNA-mediated repression: AU sequence richness near the
miRNA binding site, closeness to other known miRNA binding sites to achieve cooperative
regulation, the ability of a site to base pair nucleotides thirteen through sixteen, location of the
site approximately fifteen nucleotides away from the stop codon, and location on either end of
long 3' UTRs (Grimson et al., 2007). Taken together, these observations provide a reasonable set
of rules for assessing a miRNA-mRNA target interaction. With similar rules in mind, along with
the original requirement for site conservation among related species, miRNA target-prediction
algorithms have been developed (Enright et al., 2003; Friedman et al., 2009; Grimson et al.,
2007; John et al., 2004; Kiriakidou et al., 2004; Lewis et al., 2005; Lewis et al., 2003; Rajewsky,
2006; Stark et al., 2003). Such approaches provide a powerful set of resources for predicting
germane miRNA-mRNA interactions. However, experimental validation of any individual
miRNA-mRNA target interaction is still necessary to establish a functional relationship, as
comprehensive functional assessment of the various approaches is still lacking.
To perform such functional validation of miRNA-mRNA interactions, several
technologies have been developed for the purpose of inhibiting miRNA function. An initial
approach was the development of modified oligonucleotides that could bind to miRNAs in order
to block miRNA-mRNA interactions in tissue culture (Meister et al., 2004). More recently,
further modifications have been generated to create "antagomiRs," which act both to inhibit and
turn over target miRNAs (Krutzfeldt et al., 2005). While the original modified oligonucleotides
could cause transient inhibition of miRNAs in cell culture, antagomiRs can be delivered to whole
animals and appear to be stable in tissues for several weeks. It is not, however, clear how
uniform antagomiR delivery is to individual cells and subsets of tissues in an animal.
Furthermore, as antagomiRs are broadly delivered throughout the animal, it is neither possible to
induce miRNA inhibition in different cell types, nor to track inhibition of a miRNA by the
antagomiR. Moreover, longer-term studies of miRNA inhibition would require repeated delivery
of the antagomiR, which is both costly and time-consuming.
As an alternative, a genetic approach to miRNA inhibition has been developed, termed
miRNA sponges (Ebert et al., 2007). These sponges work through expression from a plasmid of
a synthetic transcript containing many copies of an idealized miRNA binding site. With
sufficient expression of the sponge, the miRNA is "sopped up" by the synthetic target, leading to
subsequent derepression of endogenous targets. While this allows for both regulatable and stable
inhibition of an individual or family of miRNAs, it is still limited by not knowing the
completeness of miRNA inhibition in the animal. Considering that miRNAs, which require
stable association with a given transcript for repression, are concentration-dependent regulators,
complete inhibition of a miRNA may have distinct effects from incomplete inhibition. Thus,
traditional genetic strategies have provided crucial insights to the role of miRNAs in
development and disease.
MiRNA mammalian genetics-global consequences
To initially examine the global role of miRNAs in mammalian development, a germline
knockout of Dicerl was generated (Bernstein et al., 2003). These animals are embryonic lethal,
with failure to collect Dicerl-null progeny after embryonic day 6.5 (E6.5) because of a depletion
of stem cells. This stem cell failure was bolstered by the inability to generated Dicerl-null
embryonic stem (ES) cells. In fact, once Dicerl-null ES cells were generated by forced deletion
of a conditional allele of Dicerl, they underwent a sharp cell cycle arrest (Kanellopoulou et al.,
2005; Murchison et al., 2005). In cells that eventually bypassed this arrest, both self-renewal and
differentiation were severely compromised. This suggested that Dicerl was essential for ES cell
identity and function.
While these findings demonstrated that Dicer was required for early mammalian
development, it was unclear whether this requirement was due to Dicer's role in miRNA
biogenesis or its function in either alternative small RNA processing events or functions
unrelated to small RNA maturation. To assess further the contribution of miRNA biogenesis to
mammalian development, a similar knockout allele was generated for Dgcr8 (Wang et al., 2007).
While Dgcr8-null progeny are also inviable, they survive longer than Dicerl-null embryos.
Moreover, it was possible to generate Dgcr8-null ES cells; however, these cells also experience a
cell cycle block at the G1 phase of the cell cycle that is triggered by the embryonic miRNA
family miR-290 (Wang et al., 2008b). These Dgcr8-null ES cells, though experiencing impaired
self-renewal, were able to express both pluripotency and differentiation markers. Overall, these
observations suggested that there were important differences between mutations in different
components of the miRNA processing pathway, with the particular potential for miRNA-
independent functions for Dicerl. This idea has been further supported by small RNA cloning
and sequencing from Dicerl and Dgcr8-null ES cells, which has revealed several small RNA
species that are produced in a Dicerl-dependent, Dgcr8-independent manner (Babiarz et al.,
2008).
In addition to ES cells, mouse embryonic fibroblasts (MEFs) have been analyzed in the
context of depleted miRNA processing. In these studies, it was initially noted that Dicerl loss
triggered cell cycle defects similar to those in ES cells, with a particular increase in aneuploidy
due to extended chromosome bridges, which was in line with an earlier analysis of Dicer-
depleted chicken cells, which noted increases in chromosome segregation defects and changes in
centromeric heterochromatin structure (Fukagawa et al., 2004; Harfe et al., 2005). These findings
were followed by a more temporally regulated deletion of Dicerl in MEFs, which found its loss
induced cellular senescence via the pl9Arf-p53 pathway (Mudhasani et al., 2008). While the
trigger for pl 9Arf was not determined in this study, it further highlighted the cell cycle
consequences of miRNA processing ablation.
While these cellular studies have provided an important groundwork for examining the
loss of miRNA processing in development, more precise genetic studies have allowed for the
characterization of miRNAs in general on tissue-specific developmental pathways. Some of the
earliest examinations of Dicerl loss occurred in the lymphoid system, with deletion of Dicerl in
T cells. It was initially observed that loss of Dicerl caused aberrant lineage choice and
differentiation in tandem with significantly reduced survival (Cobb et al., 2005; Muljo et al.,
2005). Moreover, mutation of either Dicerl or Drosha in various subsets of T cells was shown to
cause specific depletion of regulatory T cells (T-regs) (Chong et al., 2008; Cobb et al., 2006;
Liston et al., 2008; Zhou et al., 2008). This loss of T-regs led to a robust autoimmune disorder in
the Dicerl-null animals, and this was a cell autonomous consequence of loss of miRNA
processing within the T-cell lineage. In sum, these data highlight a role for miRNA biogenesis in
T-cell lineage choice and a potential role for mutated miRNA processing factors in autoimmune
diseases.
Further examination of miRNAs in the lymphoid compartment occurred with mutation of
Dicerl in the B-cell lineage. In these animals, loss of miRNAs caused a potent block of
differentiation at the pro- to pre-B cell transition (Koralov et al., 2008). This was coupled to a
survival defect largely related to a specific miRNA cluster, miR-17-92. When survival was
sustained by expression of anti-apoptotic factors, Dicerl loss further altered V(D)J
recombination at stages downstream of gene rearrangements. These results further support the
idea of miRNAs regulating developmental choice, frequently through changes in cell survival.
Another tissue type exhibiting striking changes in response to abrogated small RNA
processing is the reproductive tract. A variety of studies have examined Dicerl loss in both the
male and female reproductive systems, along with loss in the gametes proper (Gonzalez and
Behringer, 2009; Hayashi et al., 2008; Hong et al., 2008; Maatouk et al., 2008; Murchison et al.,
2007; Nagaraja et al., 2008; Otsuka et al., 2008; Papaioannou et al., 2009; Tang et al., 2007). In
all cases, loss of Dicerl severely restricted both reproductive system development and gamete
maturation, causing near to complete sterility. Interestingly, small RNA cloning from mouse
oocytes revealed a novel class of endogenous siRNAs (endo-siRNAs) that, along with the
piRNAs mentioned above, appear to target transposons and related mobile genetic elements for
suppression (Tam et al., 2008; Watanabe et al., 2008). Notably, these endo-siRNAs are depleted
in the absence of Dicerl, suggesting their processing through at least the Dicerl step of small
RNA maturation. Overall, these studies demonstrate a required function for small RNA
processing in mammalian reproduction.
MiRNA processing has further been examined in the differentiation program of the skin,
where bulge stem cells regulate development of both skin cells and the hair follicle (Andl et al.,
2006; Yi et al., 2006; Yi et al., 2009; Yi et al., 2008). With loss of both Dicerl and Dgcr8,
embryonic skin morphogenesis is strikingly impaired. This impairment is largely due to failure to
produce the miRNA miR-203, whose repression of the stem-cell maintenance factor p63 is vital
for differentiation of both the skin and hair follicle compartments. Similar defects in proper
development in the absence of Dicerl have been seen in the kidney, where loss of Dicerl causes
glomerular disease related to tubular injury (Harvey et al., 2008; Shi et al., 2008). Moreover, loss
of Dicer] in the developing lung causes a similar morphogenetic defect in the lung epithelium,
arguably through altered FGF signaling between lung epithelial cells and the mesenchyme
(Harris et al., 2006). Similar failures in morphogenesis are further seen in the developing limb
bud and postnatal endothelium upon Dicerl deletion (Harfe et al., 2005; Suarez et al., 2008).
Overall, a role for the miRNA processing pathway in developmental morphogenesis and stem-
cell maintenance, particularly in epithelial tissues, has been firmly established.
Examination of Dicerl loss in a variety of mesenchymal tissues has further demonstrated
a role for miRNA processing in tissue remodeling (da Costa Martins et al., 2008; O'Rourke et al.,
2007). In developing skeletal muscle, loss of Dicerl caused a potent cell death response in
myoblasts, leading to significantly reduced skeletal muscle mass and abnormal myofiber
structure. Moreover, loss of Dicerl in adult cardiac muscle triggered a potent remodeling of the
cardiac myocardium, leading to atrial enlargement and eventual hypertrophy. Similar effects
were seen in Dicerl-null chondrocytes, where there was a concomitant reduction in proliferation
and enhancement of differentiation upon Dicerl mutation (da Costa Martins et al., 2008). In
total, these findings demonstrate that Dicerl regulates both differentiation and remodeling in
mesenchymal tissues.
Additional evidence for miRNA-mediated control of cell survival is seen in the
developing nervous system. In a variety of regions within the brain, including the cortex,
hippocampus, striatal neurons, and cerebellum, deletion of Dicerl causes defective
morphogenesis at both the cell and tissue level (Cuellar et al., 2008; Davis et al., 2008; De Pietri
Tonelli et al., 2008; Schaefer et al., 2007). Frequently, this morphogenetic failure induces
neurodegeneration; however, Dicerl loss can trigger neurological changes without
neurodegeneration. In addition, Dicerl mutation in the mouse retina causes a progressive
neurodegeneration, with animals unable to respond to light within weeks of Dicerl loss
(Damiani et al., 2008). Overall, these results suggest a broad role for miRNA biogenesis in the
nervous system.
A final tissue for which impaired miRNA maturation has been examined is the liver. Two
studies examined loss of Dicerl in the late embryo and adult liver (Hand et al., 2009; Sekine et
al., 2009). In both cases, loss of Dicerl led to a concomitant increase in both proliferation and
apoptosis in hepatocytes that frequently induced replacement of the organ with wild type cells.
Importantly, these changes were coupled to increases in inflammation and broad up-regulation of
genes expressed in the fetal liver. In one study, aged mice, though largely repopulated with
Dicerl wild type hepatocytes, developed hepatocellular carcinomas that exhibited some level of
Dicerl recombination. Overall, these studies provide important evidence for the loss of miRNA
processing altering not only tissue regeneration, but also proliferative and apoptotic programs
that can promote oncogenic transformation.
MiRNA mammalian genetics-miRNAs and miRNA clusters
While the above methods of globally inhibiting miRNA biogenesis have provided
valuable insights into the broad role of small RNAs in a variety of tissues, they face two
important limitations. First, due to the clear necessity of some small RNAs for cellular viability,
both germline and conditional loss of miRNA processing components causes early lethality.
Second, while these studies demonstrate a role for small RNAs in general within a given tissue,
they do not allow for simple examination of the particular miRNAs important within a given cell
or tissue type. In order to examine particular small RNAs, targeted deletion of individual
miRNAs, miRNA families, and miRNA clusters has been performed.
Some of the earliest examinations of particular miRNAs in mammalian development
have occurred in the muscle, where highly expressed miRNAs have been identified. An initial
study was performed on the muscle-specific miRNA miR-1-2 (Zhao et al., 2007). Comparable to
Dicerl deletion in the heart, mutation of miR- 1-2 caused defects in morphogenesis and function
of cardiomyocytes, particularly through difficulties in electrical conduction. In addition to miR-
1, a loss-of-function allele has been generated for miR-208, an intronic miRNA within the alpha-
myosin heavy chain (a-MHC) gene (van Rooij et al., 2007). Its deletion, without changing a-
MHC expression, caused pronounced defects in cardiac hypertrophy and fibrosis, along with
effects on expression of other MHC members. Beyond the muscle, deletion of an endothelial-
specific miRNA, miR-126, caused specific defects in vascular development and angiogenesis,
which was more pronounced during vascular remodeling after myocardial infarction (Wang et
al., 2008a). Overall, these early knockout studies provided valuable evidence for individual
miRNAs regulating cardiac muscle and endothelial cell function.
While these studies develop a role for individual miRNAs in muscle and endothelial cell
development, the majority of analyses of loss-of-function for miRNAs and miRNA families have
occurred in the hematopoeitic system. In the myeloid compartment, the clearest example of
miRNA regulation has been shown in the granulocyte lineage by mutation of miR-223
(Johnnidis et al., 2008). In miR-223 mutant mice, there is a specific increase in the number and
proliferation of granulocyte progenitors. Strikingly, these consequences on differentiation are
largely regulated by a single target, the transcription factor Mef2c, whose additional mutation
reversed the effects of miR-223 loss. In the lymphoid lineage, a set of diverse phenotypes have
been explored by loss-of-function mutation. The earliest example of lymphoid consequences for
loss of a miRNA was miR-155, whose mutation led to defects in T helper cell differentiation and
function in antibody production, particularly through alterations in cytokine production
(Rodriguez et al., 2007; Xiao et al., 2007). Moreover, specific depletion of miR-155 in T-regs,
previously shown to be impaired by loss of Dicer], caused defects in proliferation and T-reg
number comparable to complete loss of miRNA processing (Lu et al., 2009). Overall, these
studies provide striking evidence for individual miRNAs in both myeloid and T cell
differentiation.
In the B lymphocyte lineage, several groups have reported mutations of miRNAs or
miRNA clusters that contribute to differentiation. For miR-150, mutation impacted the later
stages of B cell development, as it is most strongly expressed in mature B lymphocytes (Xiao et
al., 2007). As with miR-223, these effects appear to be largely controlled by a single miRNA
target, the transcription factor c-Myb, as deletion of c-Myb causes the opposite effect of miR-150
loss. Of note, the miR-150/c-Myb pathway has also been shown to be important in myeloid
differentiation, where altering miR-150 regulates the megakaryocyte versus erythroid transition
via c-Myb (Lu et al., 2008).
While the above studies have examined the role of individual miRNAs in developmental
decisions, as of now there is a single report of mutation of a miRNA cluster in the mouse
(Ventura et al., 2008). In this study, the miR-17-92 cluster (discussed in detail below) and its
paralogs were mutated. While the germline nulls of miR-17-92 die perinatally due to defects in
lung and vascular development, inactivation of the cluster in the adult caused a striking
developmental phenotype in B cells. In particular, miR-17-92-null B cells had a block in
differentiation specifically at the pro- to pre-B cell transition, likely through up-regulation of the
pro-apoptotic factor Bim due to loss of repression by several members of the cluster. This work
was complemented by work showing that the effects of Dicerl loss on B cell differentiation were
largely reversed via re-expression of mature miRNAs from the miR-17-92 cluster, again through
altered expression of Bim and its effects on apoptosis (Koralov et al., 2008). Taken together, this
collection of genetic analyses provides strong evidence for both individual miRNAs and miRNA
clusters in regulating important developmental transitions in mammals.
MiRNAs and cancer
Overview
Cancer is a multifactorial disease in which acquisition of either an individual change or a
series of changes promotes uncontrolled growth of a subset of cells within a tissue; in many
cases, these changes are DNA mutations. In oncogenes, these changes function by promoting the
activity of a target gene; in tumor suppressor genes, these changes function by inhibiting or
eliminating the activity of a target gene. Through these changes, tumor cells broadly acquire
several features requisite for development of cancer: self-sufficiency in growth signals,
insensitivity to anti-growth signals, escape from apoptosis, replicative immortality, sustained
angiogenesis, and tissue invasion and metastasis (Hanahan and Weinberg, 2000).
Based upon the known regulatory function of miRNAs, Ron Plasterk posited four ways
that miRNAs and their targets could be regulated in human disease: there could be a gain of
function mutation of a miRNA, there could be a loss-of-function mutation of a miRNA, there
could be a loss-of-function mutation in an target mRNA so that it avoids miRNA-mediated
repression, or there could be a gain of function mutation in a target mRNA so that it gains novel-
miRNA mediated repression (Plasterk, 2006). While the fourth possibility has not yet been
observed, there are several lines of evidence suggesting the first three types of changes occur in
many, if not all, cancers. Here I will describe the most important observations for miRNAs and
mRNA targets undergoing these classes of alterations in human cancers, and what insights they
can provide on the role of miRNAs in tumorigenesis.
Gain of function mutation of miRNAs
MiR-17-92
The earliest studies of miRNAs in tumorigenesis focused on the role of miRNAs as
oncogenes. These initial studies were largely led by examination of the miR-17-92 cluster. MiR-
17-92 are particularly important in the study of oncogenic miRNAs, as the cluster was the first
polycistronic miRNA shown to be altered in the disease. This cluster is position in 13q31.2,
which is frequently amplified in a wide collection of of B-cell lymphomas, including Burkitt's
lymphomas, Diffuse Large B-Cell Lymphomas, and Mantle Cell Lymphomas (He et al., 2005;
Lenz et al., 2008; Ota et al., 2004; Rinaldi et al., 2007; Tagawa et al., 2007; Tagawa and Seto,
2005). The cluster is also found overexpressed, and occasionally amplified, in a number of other
cancer types, including lung cancers, hepatocarcinomas, neuroblastomas, medulloblastomas, and
colorectal cancers (Connolly et al., 2008; Hayashita et al., 2005; He et al., 2005; Uziel et al.,
2009).
The argument that miR-1 7-92 is a bonafide oncogene is strengthened by the finding that
a truncated version of this cluster (miR-17-19b, lacking miR-92) greatly accelerates
tumorigenesis in a mouse model of B cell lymphoma in which the initiating oncogene is an Eg-
Myc transgene (Figure 1.2) (He et al., 2005). Interestingly, miR-17-92 not only cooperates with
the Myc oncogene but it is also one of its transcriptional targets (O'Donnell et al., 2005). A
molecular circuit has emerged, linking Myc, miR-17-92, and members of the E2F family of
transcription factors. According to this model, c-Myc can directly induce transcription of miR-
17-92, and two members of this cluster (miR-1 7 and miR-20), can in turn repress the translation
of E2F proteins (E2F1, E2F2 and E2F3). The circuitry is closed by E2F1-3 that can also induce
the transcription of miR- 17-92 (O'Donnell et al., 2005; Sylvestre et al., 2007; Woods et al.,
2007).
The significance of these findings with respect to the oncogenic properties of miR-1 7-92
is unclear. E2F proteins are key regulators of cell-cycle progression, but are also inducers of
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Figure 1.2 Overexpression of the mir-17-19b cluster accelerates c-myc-induced
lymphomagenesis in mice. a, Schematic representation of the adoptive transfer protocol using
Et-myc HSCs. b, Mice reconstituted with HSCs expressing mir-1 7-19b (MSCV mir-1 7-19b) or
infected with a control MSCV virus were monitored by blood smear analysis. The Kaplan-Meier
curves represent the percentage of leukemia-free survival or overall survival. c, External GFP
imaging of tumor-bearing mice shows the overall distribution of tumor cells. Adapted from (He
et al., 2005).
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apoptosis (laquinta and Lees, 2007). This latter function is likely mediated via activation of the
p l9-Arf/p53 pathway. It is tempting to speculate that the modulation of E2F 1-3 expression by
miR-1 7-92 may contribute to Myc-induced transformation by suppressing cell death. This would
be consistent with the observation, by He and colleagues, that in the Ejt-Myc model B cell
lymphomas over-expressing miR-1719b show greatly reduced spontaneous apoptosis compared
to controls (He et al., 2005). While repression of E2F 1-3 is likely to contribute to the oncogenic
activity of miR- 17-92, it does not explain it fully. Indeed, not only does deletion of E2fl not
accelerate Eji-Myc-induced lymphomagenesis, it actually suppresses it (Baudino et al., 2003).
Indeed a number of other targets of miR-1 7-92 have also been proposed to mediated its tumor
promoting activities, among them TGF- signaling pathway factors, PTEN, p21, AML1, Bim,
p107, TSP1, and CTGF (Dews et al., 2006; Fontana et al., 2008; Fontana et al., 2007; Lu et al.,
2007; Petrocca et al., 2008b). In particular, the finding of regulation by miR-17-92 of TSP1 and
CTGF, both regulators of angiogenesis, provide particular evidence for this miRNA cluster in
tumor progression (Dews et al., 2006).
The recent generation of loss-of-function and gain-of-function alleles of miR-1 7-92 in
the mouse has provided important insights into its role in tumorigenesis (Lu et al., 2007; Uziel et
al., 2009; Xiao et al., 2008). Transgenic mice overexpressing miR-17-92 in lymphocyte
progenitors develop a lymphoproliferative disorder affecting both B and T cells that eventually
results in autoimmunity (Xiao et al., 2008). Moreover, transgenic mice overexpressing miR-
17-92 in the lung epithelium undergo a potent increase in lung epithelial proliferation coupled to
defective differentiation of the proximal lung, with an expansion of the neuroendocrine cell
compartment; this effect could be at least partly mediated by inhibition of p107, a member of the
Rb family of cell cycle regulators (Lu et al., 2007). This lung hyper-proliferation is of particular
interest, as miR- 17-92 overexpression, frequently via amplification of the miR-17-92 locus, has
been reported in human lung cancers (Hayashita et al., 2005; Matsubara et al., 2007). Finally,
expression of the miR-17-92 cluster in cerebellar granule neuron progenitors from Ink4c- ;
Ptchl +/- but not Ink4c--; Trp53- - mice cooperated to promote development of medulloblastoma
in a mouse transplant model (Uziel et al., 2009). Taken together, these reports provide direct
evidence for this oncogenic miRNA cluster in the mouse.
These findings lend additional support to the hypothesis that one or more miRNAs
expressed from the miR-17-92 are critical regulators of cell survival in lymphocytes. While we
are far from a full identification of the key set of genes controlled by miR-1 7-92, the works of
Ventura and Xiao suggest that the effect on cell survival may be mediated, at least in part, by the
BH3-only protein Bim. Both authors have reported that the Bim 3' UTR contains multiple
binding sites for miRNAs expressed by miR- 7-92 and that the expression of this pro-apoptotic
gene is suppressed by this cluster (Koralov et al., 2008; Xiao et al., 2008). Bim is a crucial
regulator of cell survival in lymphocytes and a potent suppressor of Myc-induced B cell
lymphomagenesis (Bouillet et al., 1999; Bouillet et al., 2002; Egle et al., 2004; Hemann et al.,
2005).
Moreover, the tumor suppressor function of Bim is dosage-sensitive, as even deletion of a
single Bim allele accelerates lymphomagenesis in the Egt-Myc model without concomitant loss
of the remaining wild type allele (Bouillet et al., 1999; Bouillet et al., 2002; Egle et al., 2004;
Hemann et al., 2005). It is therefore likely that Bim suppression by miR-1 7-92 contributes to
both the tumor promoting activity of miR-1 7-92 overexpression and to its physiologic function
in regulating normal B cell development. In support of this hypothesis, Koralov and colleagues
have found that deletion of the miRNA processing enzyme Dicerl in B cell progenitors leads to
a drastic defect in B cell proliferation that is reminiscent of what was observed in miR- 17-92-
deficient mice (Koralov et al., 2008). This defect is accompanied by elevated expression of Bim
and, more importantly, can be partially rescued by Bim deletion.
A recurring theme with miRNAs is the frequent occurrence of multiple copies of the
same, or closely related, miRNAs at different loci. This fact raises the possibility of functional
overlap and compensation and significantly complicates the interpretation of loss-of-function
studies where only one member of a miRNA family is deleted. The miR-17-92 cluster is no
exception to this observation. Both the human and the mouse genomes contain two closely
related paralogs: miR-106a-363 (on the X chromosome), and miR-106b-25 (on chromosome 7
in humans and chromosome 5 in mice). These two paralogs express miRNAs that have the same
seed sequences as the miRNAs expressed from miR-17-92 and in some cases are absolutely
identical. While more work has been done to characterize miR-1 7-92, emerging evidence
suggest that miR-106a-363 and miR-106b-25 are also potential oncogenes. MiR-106b-25 is
overexpressed in gastric cancers, where it impairs signaling through the TGF-3 pathway, and
miR-106a-363 has been reported to be frequently activated by insertional mutagenesis in mouse
models of T cell leukemias and lymphomas (Landais et al., 2007; Lum et al., 2007; Petrocca et
al., 2008a; Uren et al., 2008).
To determine the extent of functional cooperation between these three highly related
miRNA clusters, Ventura and colleagues have generated mutant mice for each of these three
clusters, as well as compound mutants in which two or all three clusters were simultaneously
deleted. Their analysis shows that miR-17-92 alone is essential for mouse development, as even
double mutant mice simultaneously deficient for miR-106a-363 and miR-106b~25 develop
normally and are fertile. Interestingly, however, while deletion of miR-106b~25 does not result
in any obvious defect, simultaneous deletion of miR-106b-25 and miR-17-92 leads to embryonic
lethality at mid-gestation, with embryos showing more severe developmental defects and
increased apoptosis than for deletion of miR-1 7-92 alone (Ventura et al., 2008).
At the moment it is unclear why miR-106b-25 and miR-106a-363 are not essential genes
while miR-1 7-92 is. It must be noted, however, that miR-106a-363 is expressed at much lower
levels compared to miR-1 7-92 in most tissues and that the miR-106b-25 cluster does not contain
miRNAs of the miR-19 and miR- 18 family (which are present in the miR- 17-92 cluster). It is
likely that generation of more refined mutant mice, in which individual miRNAs belonging to
the miR-1 7-92 cluster are deleted or added back, will provide answers to these important
questions.
MiR-155
Mir-155 is a well established oncogenic miRNA that is frequently over-expressed in
human B cell malignancies, including Diffuse Large B Cell lymphomas, primary mediastinal B
cell lymphomas, and Hodgkin's lymphomas (Eis et al., 2005; Kluiver et al., 2006; Kluiver et al.,
2005; Kluiver et al., 2007; van den Berg et al., 2003). The history of miR-155 is particularly
instructive. In 1989, well before the discovery ofmiRNAs, Clurman and Hayward identified a
common proviral DNA insertion site in lymphomas induced by the avian leucosis virus and
named the corresponding gene BIC (Clurman and Hayward, 1989). Although it was noted that
the BIC RNA could form extensive secondary structures, and in particular a 145-nucleotide
stem-loop, the absence of an obvious open reading frame remained a puzzling feature, even after
it was conclusively shown that BIC could cooperate with Myc in lymphomagenesis and
erythroleukemogenesis (Tam, 2001; Tam et al., 1997; Tam et al., 2002).
The puzzle was solved when it became clear that the BIC gene hosts a microRNA-miR-
155--and that miR-155 overexpression in B cells is sufficient to induce polyclonal proliferation
of pre-B cells followed by full-blown B cell leukemia in a transgenic mouse model (Costinean et
al., 2006; Eis et al., 2005; Kluiver et al., 2005; Lagos-Quintana et al., 2002). A different and
complementary approach to investigate the function of miR-155 has been recently reported by
two groups. Rather than deleting the miR-155 gene, these authors have generated mice carrying a
mutation disrupting a miR- 155 binding site in the 3' UTR of a predicted miR- 155 target gene.
Both groups selected the Activation-Induced Cytidine Deaminase (AID) gene, which
allows immunoglobulin diversification by promoting somatic hypermutation (SHM) and class-
switch recombination (CSR) in B cells. The 3' UTR of this gene contains a single binding site
for miR-155 that confers sensitivity to miR-155-mediated repression in a reporter assay (Teng et
al., 2008). Interestingly, mutation of the miR-155 binding site on AID and deletion of miR-155
lead to a comparable increase in AID expression in activated B-cells, suggesting that AID is a
bona fide target of miR-155 (Dorsett et al., 2008; Teng et al., 2008).
While both approaches observed comparable changes in expression, the functional
consequences were significantly different in the two systems; while in miR-155 deficient B cells
CSR was reduced, it was increased in B cells carrying the mutant AID (Dorsett et al., 2008; Teng
et al., 2008; Thai et al., 2007; Vigorito et al., 2007). This contrast was observed with respect to
SHM, which is normal in miR-155-deficient B cells, but appears increased in B cells with the
mutant miR-155 binding site in the AID gene elegantly demonstrate how loss of miRNA-
mediated regulation of a single target gene can have profound physiologic effects, they also
serve as a reminder that the phenotypic consequences of loss of a miRNA are likely due to the
simultaneous deregulation of more than one gene.
MiR-372-373
MiR-373 was one of the earliest known miRNAs found as an oncogene. It was
discovered in a reverse-genetic screen, in which a library of known miRNAs and miRNA
clusters was expressed in fibroblasts and screened for their ability to bypass oncogene-induced
senescence (Voorhoeve et al., 2006). In this screen, two members of a miRNA cluster (miR-
372-373) were found to suppress p53-dependent cell cycle arrest in response to H-Ras 2V. In
this study, they observed that miR-373 was able to escape this cellular senescence via repression
of the LATS2 tumor suppressor, which subsequently activates the p53 effector, p21. Importantly,
miR-372 and miR-373 were observed to be frequently overexpressed in testicular cancer, a
disease noted for the dearth of mutations in TP53. In total, these findings provided strong
evidence for a role of this miRNA family in oncogenic transformation.
Additional data for the role of miR-373 orthologs has been found in examination of the
proliferation of ES cells. As mentioned above, it is possible to generate Dgcr8-null ES cells,
which, coincident with a block in miRNA biogenesis, undergo a potent block in the G1/S phase
of the cell cycle (Wang et al., 2008b). Importantly, expression of a pre-miRNA library in Dgcr8-
null ES cells revealed that numerous members of the miR-290 miRNA family (of which miR-
373 is a member) were able to rescue proliferation via suppression of a variety of predicted
mRNA targets involved in cell cycle regulation. In sum, these findings bolster the notion of the
greater miR-373 family regulating transformation through cell cycle control.
Beyond these effects on transformation, further data has suggested a role for miR-373 in
several steps of tumor progression, including invasion and metastasis (Huang et al., 2008). In this
study, they performed a reverse-genetic screen to identify miRNAs that promote cell migration
in vitro and validated the hits in vivo using breast cancer cell lines. Three miRNAs sharing the
same seed sequence (miR-373, miR-520c and miR-520e) scored positively in the assays. These
three miRNAs are expressed from a common region on human chromosome 19. While miR-373
has homologs in the mouse, dog, and rat genomes, miR-520c and miR-520e belong to a very
large family of miRNAs that have no homologs in non-primate genomes (Bentwich et al., 2005).
Importantly, the pro-metastatic activity of miR-373 appears to be independent from its
ability to suppress the p53 pathway, as RNAi-mediated depletion of neither p53 nor LATS2
conferred increased cell migration and invasion in vitro to non-metastatic breast cancer cells.
Rather, Huang and colleagues propose that miR-373 may promote metastasis by suppressing the
cell surface receptor CD44, since CD44 is a direct target of miR-373 and injection of MCF-7
cells stably expressing shRNAs against CD44 promoted the formation of distant metastases
(Huang et al., 2008). While they observed elevated expression of these miRNAs in metastatic
breast cancer patients, additional work will be required to determine the widespread relevance of
these results for human breast cancer patients and their treatment.
MiR-lOb
By performing miRNA expression profiling in primary human breast cancers and breast
cancer cell lines, Iorio and colleagues had identified a set of 29 miRNAs that were significantly
deregulated compared to normal breast tissues (lorio et al., 2005). To determine whether any of
these miRNAs contribute to metastasis, Ma and colleagues compared their expression in a set of
metastatic and non-metastatic human breast cancer cell lines. With this approach they identified
miR-10b as a miRNA whose expression was increased only in metastatic cell lines (Ma et al.,
2007). They also identified the mechanism underlying increased expression of miR-10 Ob, by
showing that it is a direct transcriptional target of TWIST 1, a master regulator of embryogenesis
and a powerful inducer of the Epithelial-Mesenchimal Transition (EMT) (Yang et al., 2004). Ma
and colleagues went on to demonstrate that ectopic expression of miR-10b was sufficient to
convert the non-metastatic cell lines into metastatic ones, as determined by in vitro invasion
assays and a xenograft mouse model (Ma et al., 2007). Importantly, miR-10 Ob overexpression
caused increased motility, invasion, and angiogenesis, but not increased proliferation, indicating
that miR-10 Ob specifically affects the metastatic process and not primary tumor formation (Figure
1.3). Consistent with this hypothesis, Ma and colleagues also showed that while miR-10b
expression is elevated in 50% of primary breast tumors from patients with metastasis (9 out of
18), it is low in primary tumors from metastasis-free women (5/5).
As for the mechanism by which miR-10 Ob exerts its pro-metastatic influence, Ma and
colleagues showed that it is at least in part mediated by the direct repression of HOXD 10, a
homeobox gene that is known to repress the transcription of several genes involved in cell
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Figure 1.3 MiR-10b induces distant metastasis. a, MECA-32- and Ki-67-stained sections of a
primary mammary tumor formed by miR-10b-transduced cells, at week 6 after orthotopic
transplantation. Arrows in panel a indicate tumor cells within a vessel, and arrows in panel d
indicate endothelial cells.b, H&E- and AE1/AE3-stained sections of lungs isolated from mice
that received miR-10 Ob-transduced or mock-infected cells, at week 9 after transplantation. Circles
indicate clusters of metastatic cells. The arrow indicates normal bronchial epithelium. Inset,
AE1/AE3 staining of a primary tumor. c, Numbers of lung micrometastases per section in
individual mice that received orthotopic injection of miR-10b-transduced or mock-infected
SUM149 cells, at week 9 (left panel) and week 11 (right panel) after transplantation,
respectively. d, Bright field, GFP imaging, and H&E staining of lungs isolated from mice that
received orthotopic injection of miR-10b-transduced or mock-infected cells, at week 11 after
transplantation. e, GFP imaging and H&E staining of a macroscopic peritoneal metastasis in a
mouse that received orthotopic injection of miR- 10 b-transduced cells, at week 11 after
transplantation. f, Incidence of lung metastasis and macroscopic peritoneal metastasis in mice
that received orthotopic injection of miR- 10b-transduced or mock-infected cells. Adapted from
(Ma et al., 2007).
migration and invasion. One of the genes repressed by HOXD 10 is the small GTPase RhoC, a
well characterized player in the metastatic process (Clark et al., 2000). Accordingly, expression
of a miR- 10 Ob-resistent HOXD 10 (missing the 3' UTR) or knockdown of RHOC largely
suppressed the miR-10b-induced cell migration and invasion phenotype. Thus, the work of Ma
and colleagues has defined a novel pathway that contributes to the metastatic phenotype of a
subset of human breast cancers and paves the way for additional studies aimed at determining the
general relevance of miR- 10b as a prognostic indicator and as a possible pharmacological target
in human breast cancer patients.
Loss-of-function mutation of miRNAs
Global down-regulation of miRNAs
One of the earliest indications that miRNAs may participate in tumorigenesis was the
finding that tumor cells display a global reduction in miRNA abundance compared to normal
tissue (Lu et al., 2005). This global examination of miRNAs occurred via bead-based miRNA
profiling, in which oligonucleotide-capture probes complementary to human and mouse miRNAs
are coupled to polystyrene beads impregnated with various mixtures of fluorescent dyes so that
each individual miRNA is represented by a distinct color. Following adaptor ligation, reverse-
transcribed miRNAs are amplified using a common primer, hybridized to the capture beads and
stained. Finally, the beads are analyzed on a high-speed flow cytometer capable of identifying
bead color and intensity. These data can be used to determine the abundance of individual
miRNA species. In addition to being sensitive and economic, the bead-based hybridization
approach described above appears to have a higher specificity compared to glass-hybridization
methods. Indeed, in a spiking experiment involving 11 closely related sequences, the bead
method was capable of efficiently discriminating between single base-pair mismatches.
This method was applied to profile the expression of 217 miRNAs in human tumors
compared to normal tissues, leading to the striking observation that tumor cells display a global
reduction in miRNA expression levels (Figure 1.4) (Lu et al., 2005). An analogous difference
was observed when normal lungs and lung tumors from K-Ras mutant mice were compared.
Although this finding does not prove that microRNAs play a functional role in tumorigenesis, the
observation that more differentiated cells express higher levels of miRNAs than do
undifferentiated or poorly differentiated cells suggests that miRNA might be involved in
determining and maintaining the differentiated state.
This global loss was not found in other large-scale studies of miRNA profiling (Volinia et
al., 2006). These differences were largely due to alternative means of normalization. While the
Golub group normalized against synthetic RNA spikes introduced before and after hybridization,
the Croce group normalized against the total small RNA content. Since the loss of miRNAs is so
broad, such a change would not be observed by the latter normalization scheme. Additionally,
the Golub group's miRNA profiles were shown to be an accurate predictor of both the
differentiation state and developmental origin of the tumor. Moreover, classifiers based on these
miRNA profiles were found to be more informative than mRNA profiles in classifying poorly
differentiated tumors. In total, these reports demonstrate that miRNA profiling is a powerful
method for cataloging the miRNA content in a given cell type, developmental stage, or disease
state.
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Figure 1.4. Comparison between normal and tumor samples reveals global changes in
miRNA expression. a, Markers were selected to correlate with the normal versus tumor
distinction. A heatmap of miRNA expression is shown. b, miRNA markers of normal versus
tumor distinction in human tissues from a, applied to normal lungs and lung adenocarcinomas of
Kras L1 mice. c, HL-60 cells were treated with all-trans retinoic acid (ATRA +) or vehicle (-) for
the indicated number of days. A heatmap of miRNA expression from a representative experiment
is shown. Adapted from (Lu et al., 2005).
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At first, the mechanism by which miRNAs are globally lost in mammalian cancers was
largely undefined. An initial observation, in which primary miRNA transcripts were analyzed in
the same samples profiled at the miRNA level, revealed that many pri-miRNAs were unchanged
in the same tumors that experienced down-regulation of the mature miRNA (Thomson et al.,
2006). This data indicated that the global loss of miRNAs occurred at the level of processing or
miRNA product stability. In contrast to this result, an analysis of Myc-regulated miRNAs
suggested a widespread silencing of miRNAs at the transcriptional level by c-Myc (Chang et al.,
2008). A series of recent findings has provided further evidence for miRNA down-regulation at
the level of miRNA processing. First, an analysis of mRNA expression for a series of miRNA
processing components in ovarian cancer revealed decreases in Dicerl and Drosha transcript
abundance in both ovarian cancer cell lines and in primary tumors, and that patients with reduced
expression of these components have a significant worsening of prognosis (Merritt et al., 2008).
Similar changes in Dicerl expression, and a subsequent worsening of prognosis, have been
observed in lung adenocarcinomas (Karube et al., 2005). Moreover, they discovered somatic
point mutations in DICER1 and RNASEN (the gene which encodes Drosha) within both ovarian
cancer cell lines and patient material.
Beyond this, a recent examination of mismatch-repair deficient cancers observed a
striking rate of frameshift mutations in TARBP2, the gene encoding TRBP (Melo et al., 2009).
These frameshifts led to premature stop codons in TARBP2 and subsequent decreases in TRBP
levels. This decrease in TRBP leads to reduced levels of Dicerl and reductions in miRNA
processing. Notably, overexpression of either wild type TARBP2 or wild type DICER1 in these
mutant cells, which restored miRNA processing to wild type levels, was sufficient to slow tumor
growth, suggesting that the defect in miRNA processing caused by these mutations altered the
tumor phenotype. This was in line with other work showing that impaired miRNA processing
enhances the tumorigenic potential of cancer cells (discussed in detail in Chapters 2 and 3 of this
thesis) (Kumar et al., 2007). In total, this collection of studies provides strong evidence for
abrogation of the miRNA processing machinery within human cancer.
MiR-34
A series of recent reports has explored the regulation of miRNAs by tumor suppressor
genes. These studies have focused on the miRNAs regulated by p53, a tumor suppressor gene
that is frequently inactivated in human cancers. This approach has lead to the identification of the
miR-34 family as being an important mediator of p53 activity (Bommer et al., 2007; Chang et
al., 2007; Cole et al., 2008; Corney et al., 2007; He et al., 2007; Raver-Shapira et al., 2007;
Tarasov et al., 2007; Tazawa et al., 2007; Welch et al., 2007). This family consists of three
highly related miRNAs expressed from two separate loci: miR-34a from chromosome lp36 and
miR-34b/miR-34c as a cluster from 1 lq23. The transcription of both loci appears to be directly
regulated by p53 via binding to conserved sites in the respective promoters.
TP53 is a very well characterized transcription factor and a potent tumor suppressor
whose activity is induced in response to a variety of stimuli, including DNA damage, oncogene
activation, hypoxia, and oxidative stress (Vogelstein and Kinzler, 1992). TP53 exerts its tumor
suppressive function by activating the promoters of a large number of genes whose function is to
act as cell-cycle inhibitors or pro-apoptotic factors. The result is, depending on the cellular
context, either cell death or growth arrest (in the form of cell cycle arrest or senescence).
Intriguingly, cellular senescence appears to function as a longer-term effector of p53 activation.
As such, regulation of the transcriptome by miRNAs would be an effective means of establishing
the p53 senescence response. Consistent with a role in the p53 pathway, ectopic miR-34
expression in cell culture systems leads to a partial arrest in the G phase of the cell cycle or to
increased cell death. From the studies published so far, it appears that the three members of the
miR-34 family are functionally equivalent. It must be noted, however, that while miR-34a is
predominantly expressed in the brain, miR-34b/c are reported to be present at high levels in the
lungs and are virtually undetectable in other tissues. It will be important to determine whether
stimuli that induce p53 activation also induce broad expression of miR-34 members in vivo and
whether miR-34 exerts p53-independent functions.
While there is consensus that miR-34 can mediate, at least in part, the p53 response, the
exact mechanism is still unclear. Microarray experiments reveal that ectopic miR-34 expression
results in a broad change in gene expression that resembles that induced by p53 activation, with
an enrichment for genes involved in controlling apoptosis, cell cycle progression, angiogenesis,
and DNA repair. Different groups have focused on different targets, including members of the
E2F family of transcription factors, the antiapoptotic protein BCL2, the NAD-dependent
deacetylase SIRT 1, cell cycle regulators CDK4, CDK6, Cyclin E2, and even a membrane
receptor (c-MET) (Bommer et al., 2007; He et al., 2007; Tazawa et al., 2007; Welch et al., 2007;
Yamakuchi et al., 2008). Although it is formally possible that further studies will show that one
of these genes is the critical target of miR-34, it is more likely that miR-34 acts by fine-tuning
the response to p53 activation via the modulation of a large array of genes.
Finally, it must be noted that while most experiments indicate that miR-34 is downstream
of p53, some data also suggest that miR-34 can act, at least in part, upstream of p53. In
particular, ectopic expression of miR-34a leads to increased p53 expression in colon carcinoma
cell lines and induces apoptosis less efficiently in p53-/- cells than in cells with functional p53.
The studies described above strongly suggest that members of the miR-34 family may act as
tumor suppressor genes. Consistent with this hypothesis, hemizygous deletion of the miR-34a
locus is a recurrent event in several human cancers (Bagchi and Mills, 2008). Furthermore,
deletion of miR-34a and low or undetectable expression of this miRNA has been reported in
neuroblastoma cell lines, where its reintroduction leads to apoptosis (Welch et al., 2007). Loss of
miR-34b and miR-34c has also been observed in breast and in non-small cell lung cancers, and
expression of these miRNAs is frequently reduced in non-small cell lung cancer cell lines
(Bommer et al., 2007; Calin et al., 2004).
While all these observations seem to indicate an important role of the miR-34 family in
tumorigenesis, determining whether loss of miR-34 expression can initiate or accelerate
tumorigenesis will require the generation of miR-34 knockout mice. Moreover, the possible role
of miR-34 in regulating cellular senescence in response to p53 activation provides an interesting
basis for understanding the effects of p53 on aging, a process which functions largely through
cellular senescence in tissues; these ideas are supported by the regulation of SIRT I1, an important
regulator of eukaryotic aging, by miR-34 (Serrano and Blasco, 2007; Yamakuchi et al., 2008).
Such investigations will almost certainly require the use of miR-34 deficient animals.
MiR-206 and miR-335
If the work on miR-10b shows miRNAs can act by promoting metastasis, the work on
miR-335 and miR-206 shows that other miRNAs have the opposite effect, acting as powerful
suppressors of the metastatic phenotype. To identify anti-metastatic miRNAs, Tavazoie and
colleagues also used breast cancer cell lines (Tavazoie et al., 2008). For their analysis, they
subjected the poorly metastatic human breast cancer cell line MDA-MB-231 and a set of highly
metastatic derivatives that preferentially colonize the bones or the lungs to miRNA expression
profiling. Of the six miRNAs whose expression was most consistently decreased in the
metastatic lines, three (miR-335, miR-126, and miR-206) were shown to actually suppress
metastasis formation when their expression was restored in the metastatic lines.
While miR-126 also negatively affected tumor cell proliferation, expression of miR-335
and miR-206 did not result in significant changes in either proliferation or apoptosis of the tumor
cells, indicating that these two miRNAs specifically affect the metastatic process. Indeed, by
performing in vitro assays, Tavazoie and colleagues demonstrated that these two miRNAs have a
profound effect on cell migration. As for the molecular mechanism, the authors provide an
interesting list of pro-metastasis genes whose expression is regulated by miR-335, and show that
knock down of two of them (SOX4 and TNC) can suppress the metastatic phenotype. Clearly,
additional studies are warranted to fully dissect the critical pathways that are physiologically
regulated by miR-335, miR-126, and miR-206, and to determine whether they can become useful
anticancer targets, but at a minimum these three miRNA are promising novel prognostic
indicators in breast cancer patients. Indeed, by analyzing a cohort of 20 primary breast cancers,
Tavazoie and colleague have found that low expression of miR-335 and miR-126 (and to a lesser
extent miR-206) correlates with very poor metastasis-free survival. In sum, this study provides
powerful evidence that this family of miRNAs suppresses breast cancer metastasis, and that these
miRNAs are relevant in clinical progression.
Let-7
Let- 7, one of the first miRNAs to be discovered, was initially identified in C elegans,
where it controls the timing of developmental events. In the nematode, loss of let- 7 prevents cell
cycle exit and terminal differentiation of a particular type of cells (seam cells) at the transition
from larval to adult life (Reinhart et al., 2000). Homologs of let- 7 have been identified in
mammals, and the human genome contains at least 12 members of the let-7 family, organized in
eight different loci (http://microrna.sanger.ac.uk).
Consistent with studies that show let-7's central role in controlling cell proliferation and
differentiation in vertebrates, a number of studies have provided evidence supporting a role for
let-7 in human cancer. First, various let-7 members are located at chromosomal sites frequently
deleted in a variety of human tumor types (Calin et al., 2004). In addition, reduced expression of
let-7 family members has been reported in a subset of non-small lung cancers, where it correlates
with poor prognosis and advanced staging of the disease (Takamizawa et al., 2004). Moreover,
expression of let-7 family members was part of a miRNA expression set which predicted for
poor prognosis in lung adenocarcinomas (Yanaihara et al., 2006).
Gene deletion is not the only mechanism through which expression of let-7 family
members is deregulated in human cancers. As discussed above, the c-Myc oncogene can
negatively regulate let-7, an ability that may very well contribute to its oncogenic potential
(Chang et al., 2008). Furthermore, recent work has shown that the Lin-28 protein binds to the
pre-miRNAs of let-7 family members preventing the processing of the mature miRNAs, a
finding that explains why some cell types and cancer cell lines have high levels of let-7
precursors, but undetectable mature let-7 (Heo et al., 2008; Newman et al., 2008; Rybak et al.,
2008; Viswanathan et al., 2008). Interestingly, recent data suggests that c-Myc's ability to
reduce let-7 levels is not due to transcriptional silencing, but to up-regulation of Lin-28, which
subsequently inhibits processing of let-7 family members (Chang et al., 2009).
An exciting initial explanation for the role of let-7 in tumor suppression was provided by
the Slack group, who showed that, in both the nematode and human cells, let-7 family members
can suppress expression of the Ras family of proto-oncogenes via their 3' UTRs (Johnson et al.,
2005). Beyond the Ras family, several other oncogenes have been described as targets of the let-
7 miRNA family. For example, the HMG-domain containing protein HMGA2 is strongly
repressed by let-7 (Lee and Dutta, 2007; Mayr et al., 2007; Park et al., 2007). The c-Myc
oncogene itself appears to be targeted by let-7 family members in Burkitt's lymphoma (Sampson
et al., 2007). Finally, a recent examination of gene expression in response to let-7 expression
observed direct and widespread regulation of several positive regulators of the cell cycle,
including CDC25A, CDK6, and Cyclin D2, by the let-7 family (Johnson et al., 2007). Overall,
these studies posit that loss of let-7 expression may promote tumorigenesis by simultaneously
leading to up-regulation of a wide network of oncogenes.
While a conclusive demonstration that loss of let-7 expression can initiate or promote
tumorigenesis in vivo will likely have to wait for generation of mice carrying loss-of-function
alleles of let-7 (a feat complicated by the presence of multiple let-7 members in mice), three
recent reports have shown that forced let-7 expression can suppress tumorigenesis. Yu and
colleagues found that the expression of let-7 family members is markedly lower in breast tumor-
initiating cells (BT-ICs) compared to non-BT-ICs derived from primary breast cancers (Yu et al.,
2007). Consistent with a role in regulating self renewal of breast cancer cells, overexpression of
let-7 in BT-ICs leads to reduced proliferation, increased differentiation, and suppression of tumor
formation in immuno-compromised mice. The authors also propose that the effects of let-7 on
self-renewal and differentiation are likely mediated by different targets; indeed, suppression of
HMGA2 promoted differentiation with little effect on self-renewal, while suppression of H-Ras
had a profound effect on self-renewal without promoting differentiation.
Beyond cancer stem cells, several reports have suggested a role for let-7 in normal stem
cell function. An early finding was provided by the Hannon group, in which let-7 expression was
strongly altered during differentiation in vitro in a mammary cell differentiation system (Ibarra et
al., 2007). Moreover, a study by the Morrison laboratory provided specific evidence for let-7 in
mediating stem cell self-renewal in young mice (Nishino et al., 2008). In both hematopoeitic and
neural stem cells, let-7 expression increased with age, leading to suppression of HMGA2 and
subsequent up-regulation of the Ink4a-Arf transcripts, which have been shown to regulate self-
renewal of stem cells. While this data conflicts with the work of Yu and colleagues suggesting
that HMGA2 suppression by let-7 changed differentiation but not self-renewal, it is possible that
these differences are due to distinctions in stem-cell function in normal and cancer stem cells.
While these studies provide significant evidence for let-7 in tumor development and stem
cell maintenance in the mammary, blood, and neural cell lineages, let-7 loss was initially
observed to be important particularly in non-small cell lung cancer. However, the functional
evidence for let-7 suppressing lung tumorigenesis has been relatively limited until two recent
studies. In one, let-7 was induced in lung cancer cells and ectopically expressed in autochthonous
lung tumors via lentiviral expression (discussed in detail in Chapter 4 of this thesis) (Kumar et
al., 2008). In another report, let-7 family members were delivered to lung cancer cells in vitro as
siRNAs and delivered in an autochthonous model of non-small cell lung cancer by adenovirus
(Esquela-Kerscher et al., 2008). Taken together, these studies provided an important
demonstration for let-7 suppressing the initiation of non-small cell lung cancer.
Loss-of-function mutation of miRNA binding sites
While the altered expression of miRNAs has been shown to control several processes
important to tumorigenesis, a small set of examples is being found in which target mRNAs
undergo changes to avoid miRNA-mediated regulation. The clearest example has been seen for
the HMG-domain containing protein HMGA2 (Mayr et al., 2007). As mentioned above, the
HMGA2 mRNA contains multiple sites for the let-7 miRNA within its 3' UTR. Moreover, it has
been known that HMGA2 translocations that occur and are important for the development of
human lipomas, though removing only a small fragment of the coding sequence of the mRNA,
cause a potent increase in its expression. Mayr and colleagues thus postulated that the
rearrangements seen in human lipomas were not selecting for loss of the coding sequence, but
instead loss of the 3' UTR and consequent miRNA regulation. In fact, point mutation of all of
the let-7 binding sites in the HMGA2 3' UTR recapitulated the translocation mRNA's ability to
transform cells (Figure 1.5). Overall, this study provided powerful evidence for genetic selection
of an oncogene to lose its miRNA regulation.
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Figure 1.5 Soft-agar assay for anchorage-independent growth. a, Hmga2 constructs used for
stable transfection b, Colony formation. For cells stably transfected with the indicated vector, the
percentage that yielded colonies is plotted. When compared with Hmga2-wt, a significantly
higher number of colonies was observed for Hmga2-tr. Hmga2-m7 showed significantly more
colonies than any of the other constructs tested. Adapted from (Mayr et al., 2007).
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While the above study suggested that 3' UTRs undergo mutagenic pressure in human
cancer, it was unclear whether there were global changes comparable to that of HMGA2. A
recent report has provided significant evidence for an epigenetic change of this kind (Sandberg et
al., 2008). In this study, it was noted that active proliferating cells have shorter 3' UTRs due to
upstream polyadenylation site usage. Notably, this alternative polyadenylation causes loss of
many miRNA binding sites. This has led to the idea that cancer cells, which undergo increased
proliferation relative to normal cells, might utilize such alternative polyadenylation to eliminate
miRNA-mediated repression of oncogenic targets. While mechanisms of both alternative
polyadenylation and oncogenic de-repression have yet to be determined, this observation has
provided a novel means by which cancers can escape miRNA-mediated regulation.
Conclusions
MiRNAs are a novel small RNA species whose regulation of target mRNAs alters many
processes germane to transformation and tumorigenesis. Taken together, the evidence for
changes in miRNAs broadly and specifically is robust. However, the functional validation of
these changes in models of cancer has been severely lacking. To better understand the role of
miRNAs in cancer, we have performed a series of studies comparing loss and gain of function of
miRNAs in mammalian cancer models. These studies provide important demonstrations of the
effects of miRNAs on cancer and suggest novel therapeutic targets for the disease.
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CHAPTER 2: Impaired microRNA
processing enhances cellular transformation
and tumorigenesis
The work presented in this chapter is largely taken from a paper published in Nature Genetics
(Kumar et al., 2007). I contributed all figures presented in this chapter. Jun Lu helped to design
the original pSuper oligonucleotides and performed miRNA profiling on samples. Kim L.
Mercer, independent of me, performed tumor grading analysis presented in Figure 2.9D.
MicroRNAs (miRNAs) are a novel class of small non-coding RNAs that post-
transcriptionally regulate the expression of target mRNA transcripts. Many of these target
mRNA transcripts are involved in proliferation, differentiation, and apoptosis (Bartel, 2004;
Gregory and Shiekhattar, 2005), processes commonly altered during tumorigenesis. Recent work
has shown a global decrease of mature miRNA expression in human cancers (Lu et al., 2005).
However, it is unclear whether this global repression of miRNAs is reflective of the
undifferentiated state of tumors or causally contributes to the transformed phenotype. Here we
show that global repression of miRNA maturation promotes cellular transformation and
tumorigenesis. Cancer cells expressing short hairpin RNAs (shRNAs) targeting three different
components of the miRNA processing machinery exhibited a significant decrease in steady-state
miRNA levels and displayed a more pronounced transformed phenotype. In animals, miRNA
processing-impaired cells (hereafter referred to as miR KD cells) formed tumors with accelerated
kinetics. These tumors were more invasive than controls, suggesting that global miRNA loss
enhances tumorigenesis. Furthermore, conditional deletion of Dicerl enhanced tumor
development in a K-Ras-induced mouse model of lung cancer. Overall, these studies indicate
that abrogation of global miRNA processing promotes tumorigenesis.
In order to examine the role of miRNA processing in tumorigenesis, we designed
shRNAs targeting the three established regulators of miRNA processing: Drosha, DGCR8, and
Dicerl. In murine lung adenocarcinoma (LKR13) cells (Johnson et al., 2001; Wislez et al.,
2006), these hairpins achieved robust knockdown of target mRNA levels (Figure 2.1 A) and
reduced steady-state miRNA levels (Figure 2.1 B). Of note, these shRNAs did not completely
eliminate mature miRNAs. For Dicerl in particular, we would expect incomplete knockdown, as
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Figure 2.1 Impaired miRNA processing promotes cellular transformation. (A) Quantitative
real-time polymerase chain reaction (Q-RT PCR) was performed with probes for DGCR8,
Drosha, or Dicerl in LKR13 cells infected with empty vector or shRNAs against DGCR8,
Drosha, or Dicerl (see Supplementary Methods for details). Expression levels were initially
normalized to TBP and subsequently normalized relative to DGCR8, Drosha, or Dicer 1 levels in
LKR13 cells infected with empty vector. Values are mean +/- s.d. (n=3) with propagated error.
(B) Small RNA Northern blotting was performed against let-7 and glutamine tRNA in LKR13
cells infected with empty vector, a control shRNA (see Supplementary Methods for details), or
shRNAs against DGCR8, Drosha, or Dicer1. (C) LKR13 cells infected with empty vector or
shRNAs against DGCR8, Drosha, or Dicerl were plated at low density (2500 cells per 10 cm
plate), grown for five days, and fixed and stained with crystal violet. (D) Small RNA Northern
blotting was performed as above in U20S cells infected with shRNAs against Renilla luciferase,
DGCR8, Drosha, or Dicerl (see Supplementary Methods for details). (E) U20S cells infected
with shRNAs against Renilla luciferase, DGCR8, Drosha, or Dicerl were plated at low density
as described above.
Dicerl is required for the generation of its target small interfering RNA. We then tested the
effect of impaired miRNA processing on the transformation properties of these cells. MiR KD
LKR13 cells formed significantly larger colonies than controls when plated at low density
(Figure 2. 1C) and had improved colony formation in soft agar (Figure 2.2A). Additionally, miR
KD cells formed more foci than control cells (Figure 2.2B). These enhanced transformation
properties appear to be a consequence of increased proliferation, as miR KD cells grew faster
than controls, exhibited a higher percentage of cells entering S phase, and reduced numbers of
Go/G 1 cells (Figure 2.2C-E). Thus, defective miRNA maturation (or some other unknown
function of these genes) alters the transformed state of mouse tumor cells, accompanied by
enhanced proliferative capacity.
To determine if impaired miRNA processing similarly affected murine and human cancer
cells, we designed additional short hairpin RNAs against the human miRNA processing
machinery. These hairpins also achieved knockdown of steady-state miRNA levels in three
independent human cancer cell lines as assessed by Northern blotting (Figure 2.1 D) and miRNA
profiling (data not shown). Similar to the results from LKR13 cells, impaired miRNA processing
enhanced both colony formation and growth in soft agar of human cancer cells (Figure 2. 1E and
Figure 2.2F). Importantly, this effect was independent of the tissue of origin; miR KD cells
derived from osteosarcomas (U20S), colorectal carcinomas (HCA7), and breast carcinomas
(MCF7) all exhibited enhanced transformation (Figure 2.1 E and Figure 2.2F-J). Overall, these
results suggest that global repression of miRNAs enhances transformation of cancer cells.
To determine if global repression of miRNAs enhances the tumorigenic potential of
cancer cells, we injected miR KD LKR13 cells subcutaneously into immune-compromised mice.
MiR KD cells formed tumors with accelerated kinetics, with tumor volumes that were at least an
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Figure 2.2. (A) LKR13 cells infected with empty vector or shRNAs against DGCR8, Drosha, or
Dicerl were plated at 50,000 cells per plate in semisolid media, grown for two weeks, and fixed
and stained with crystal violet. Colonies were counted from independent platings, with five
random fields per condition. Values are mean +/- s.d. Plate magnification X4. Inset
magnification, X20. (B) LKR13 cells infected with empty vector or shRNAs against DGCR8,
Drosha, or Dicer l were plated at low density (1000 cells per plate) along with wild type mouse
embryonic fibroblasts (3X105 cells per plate), grown for two weeks, and fixed and stained with
crystal violet. Colonies were counted from independent platings. Values are mean +/- s.d. (n=3).
(C) LKR13 cells infected with empty vector or shRNAs against DGCR8, Drosha, or Dicerl were
plated at 5000 cells per well. Cells were counted over time in triplicate. Values are mean +/-
s.e.m. (n=3). (D) LKR13 cells infected with empty vector or shRNAs against DGCR8, Drosha,
or Dicerl were plated at 105 cells per well in media with reduced serum. Cells were subsequently
pulse treated with BrdU, stained, and analyzed by flow cytometry (see Methods for details).
Representative histograms of LKR13 cells infected with empty vector or a shRNA against
Dicerl are shown. Graph values are mean +/- s.d. (n=3). (E) LKR13 cells infected with empty
vector or shRNAs against DGCR8, Drosha or Dicerl were plated at 105 cells per well in media
with reduced serum. Cells were subsequently stained with 7-AAD and analyzed by flow
cytometry (see Methods for details). Representative histograms of LKR13 cells infected with
empty vector or a shRNA against Dicerl are shown. Graph values are mean +/- s.d. (n=3). (F)
U20S cells infected with shRNAs against Renilla luciferase, DGCR8, Drosha, or Dicerl were
plated in semisolid media and colonies counted as described above. (G) HCA7 cells infected
with shRNAs against Renilla luciferase, DGCR8, Drosha, or Dicer 1 were plated at low density
as described above. (H) HCA7 cells infected with shRNAs against Renilla luciferase, DGCR8,
Drosha, or Dicerl were plated in semisolid media and colonies counted as described above. (I)
MCF7 cells infected with shRNAs against Renilla luciferase, DGCR8, Drosha, or Dicerl were
plated at low density as described above. (J) MCF7 cells infected with shRNAs against Renilla
luciferase, DGCR8, Drosha, or Dicer 1 were plated in semisolid media and colonies counted as
described above.
order of magnitude greater than controls (Figure 2.3A). Steady-state miRNA levels in miR KD
tumors were decreased compared to controls (Figure 2.4A). Earlier work suggested that the
global loss of miRNAs in human cancers corresponds to altered differentiation in tumors relative
to normal tissue (Lu et al., 2005). Thus, it was possible that miR KD tumors might be
histologically distinct from controls. Surprisingly, miR KD tumors were similar to controls by
histological analysis, all appearing moderately differentiated with the clear presence of glandular
structures (Figure 2.4B). Importantly, however, miR KD tumors commonly invaded the
surrounding normal tissue of the host, including skeletal muscle, adipose tissue, and nerve
sheaths (Figure 2.3B). Careful histological analysis of control tumors revealed no such invasion
(data not shown). Consistent with the invasive phenotype in miR KD tumors, miR KD cells
demonstrated enhanced migration through a collagen matrix in vitro, suggesting that repression
of miRNAs in cancer cells results in increased motility (Figure 2.3C).
Recent work with loss-of-function alleles of Dicerl in mammals has described defects in
processes potentially unrelated to miRNAs, such as silencing of heterochromatic regions and
chromosome segregation (Harfe et al., 2005; Kanellopoulou et al., 2005; Murchison et al., 2005).
We observed no changes in transcript levels from major satellite repeats (Figure 2.5A); in
addition, we noted similar levels of phosphorylated ribosomal S6 and eIF2a in miR KD and
control cells, suggesting that global translation is not altered (Figure 2.5B). However, it remained
possible that miR KD cells had undergone irreversible changes, independent of miRNAs, which
enhance transformation. To investigate this possibility, we generated a shRNA against Dicerl
flanked by loxP sites (pSicoR-shDicerl), allowing subsequent removal of the hairpin via Cre-
mediated recombination (Ventura et al., 2004). Upon delivery of adenoviral Cre to pSicoR -
shDicerl cells, we observed a concomitant restoration of miRNA processing (Supplementary
Figure 2.3
A
600
-- shDGCR8
-U-shDrosha
E t hDicerl
E -+-empty
- 400
0 5
shDGCR8
Time (days)
shDrosha
shDicerl
90001
60001
3000
OL, 0
Figure 2.3 Impaired miRNA processing promotes tumorigenesis in vivo. (A) LKR13 cells
infected with empty vector or shRNAs against DGCR8, Drosha, or Dicerl were injected
subcutaneously into immunocompromised mice (105 cells/injection) and tumor growth was
measured over time. Values are mean +/- s.e.m. (n=6). (B) Hematoxylin/eosin staining of
tumors. Examples of tumor cells surrounding nerve sheaths and infiltrating into host adipose
tissue and skeletal muscle of the host are shown. Original magnification, X40. N, nerve sheath.
A, adipose tissue. M, skeletal muscle. T, tumor cells. Arrows indicate infiltrating tumor cells.
Arrowheads indicate host tissue infiltrated by tumor cells. (C) In vitro migration assays using
LKR13 cells infected with empty vector or shRNAs against DGCR8, Drosha, or Dicerl were
performed (see Methods for details). Results are representative of three experimental repeats.
Values are mean +/- s.d. (n=3).
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Figure 2.4 (A) Small RNA Northern blotting was performed against miR-20, let-7, and
glutamine tRNA on tumor RNA from three separate tumors of LKR13 cells infected with empty
vector or shRNAs against DGCR8, Drosha, or Dicerl. (B) Hematoxylin/eosin staining of tumors.
Note the presence of glandular structures (arrows) representative of moderate differentiation in
all of the different tumors. Original magnification, X20.
Figure 2.5
A .
OL
pS6
empty
c
0
x4)
N
E
O
c
g . II1
S62alpha
pelF2alpha 4e
elF2alpha
shDGCR8 shDrosha shDicerl
Figure 2.5 (A) Quantitative real-time polymerase chain reaction (Q-RT PCR) was performed
with probes for the major satellite repeat transcript in LKR13 cells infected with empty vector or
shRNAs against DGCR8, Drosha, or Dicerl (see Supplementary Methods for details).
Expression levels were initially normalized to TBP and subsequently normalized relative to the
major satellite repeat transcript in LKR13 cells infected with empty vector. Values are mean +/-
s.d. (n=4) with propagated error. (B) Immunoblotting for the expression of total and
phosphorylated S6 and elF2a in LKR13 cells infected with empty vector or shRNAs against
DGCR8, Drosha, or Dicerl.
Figure 2.9a). MiRNA processing continued to be impaired in pSicoR-shDicerl cells infected with
a control adenovirus. Notably, adenoviral Cre-mediated removal of the Dicer 1 hairpin resulted in
reduced soft agar growth relative to control adenovirus-treated cells. This reversal was not
observed in pSicoR-shluc cells (Supplementary Figure 2.9b). Thus, the enhanced transformation
associated with impaired miRNA processing was reversible.
To determine if this enhanced transformation was specific to depletion of the miRNA
processing machinery, we attempted to overcome the effect through expression of human
cDNAs in miR KD LKR13 cells. As murine shRNAs do not demonstrate full sequence
complementarity with their human cDNA counterparts, the human cDNAs were expected to
retain expression. In this context, miRNA processing would be maintained while the shRNA was
expressed and functional. We observed a near complete restoration of miRNA expression in cells
containing the human cDNA in tandem with its target shRNA (Supplementary Figure 2.9c). Of
note, shRNA-expressing cells lacking their corresponding cDNA or expressing a cDNA against a
different miRNA processing component failed to restore mature miRNA levels, validating the
specificity of the effect. MiRNA processing-rescued cells showed reductions in both low density
colony formation and growth in soft agar compared to miR KD cells (Supplementary Figure
2.9d, e), demonstrating that protection against impaired miRNA processing was sufficient to
prevent the phenotype triggered by the shRNAs. Therefore, the enhanced transformation
corresponding to defective miRNA maturation was specific to the miRNA processing machinery
and not a non-specific effect of shRNA expression.
In order to test if impaired miRNA processing was sufficient to transform non-cancerous
cells, we expressed shRNAs against the miRNA processing machinery in K-RasGl 2D-expressing
murine embryonic fibroblasts (MEFs), which have been shown to be incompletely transformed
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Figure 2.6 (A) LKR13 cells were infected with shRNAs against Dicerl or Renilla luciferase
flanked by loxP sites. Cells were subsequently infected with adenovirus expressing eGFP or Cre,
resulting in removal of the shRNA. Small RNA Northern blotting was performed as above on
LKR13 cells infected with shRNAs against Dicerl or Renilla luciferase and subsequently
infected with adenovirus expressing eGFP or Cre. (B) LKR13 cells infected with shRNAs
against Dicer l or Renilla luciferase and subsequently infected with adenovirus expressing eGFP
or Cre were plated at 50,000 cells per plate in semisolid media, grown for two weeks, and fixed
and stained with crystal violet. Colonies were counted from independent platings, with five
random fields per condition. Values are mean +/- s.d. (C) LKR13 cells were stably transfected
with control vector or Flag-tagged human DGCR8, Drosha, or Dicerl cDNA. These cells were
subsequently infected with shRNAs against DGCR8, Drosha, or Dicerl. Small RNA Northern
blotting was performed as above in LKR13 cells containing the constructs described. (D) LKR13
cells containing the constructs described in c were plated at low density as described above. (E)
LKR13 cells containing the constructs described in c were plated in semisolid media and
colonies counted as described above. Inset magnification, X20.
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(Tuveson et al., 2004). Compared to control K-RasG12D MEFs, miR KD K-RasG12D MEFs had an
elevated growth rate (Figure 2.7A). However, impaired miRNA processing was not sufficient to
fully transform K-RasG12D MEFs, as evidenced by the inability of the cells to form colonies in
soft agar (data not shown). To further address the role of miRNA processing on proliferation, we
infected shRNAs against the miRNA processing machinery into wild-type MEFs and examined
long-term population growth. Interestingly, wild-type cells had a markedly reduced long-term
proliferative capacity compared to controls (Figure 2.7B), consistent with observations from
Dicerl-null MEFs and embryonic stem cells (Harfe et al., 2005; Kanellopoulou et al., 2005;
Murchison et al., 2005). Therefore, while defective miRNA biogenesis improves the
transformation of cancer cells, it is not sufficient to promote de novo transformation.
To begin to investigate the basis for the enhanced transformation associated with
repression of miRNAs, we measured the expression of several oncogenes in miR KD LKR13
cells. As shown in Figure 2.8A, significantly higher protein levels of the oncogenes c-Myc and
K-Ras were detected without changes in other known oncogenes like N-Ras, H-Ras, and E2F-1.
K-Ras mRNA levels were slightly elevated in miR KD cells, while c-Myc mRNA levels were
unchanged compared to controls (Figure 2.7C). As Ras family members have been shown to
stabilize the c-Myc protein post-translationally through activation of the MEK/ERK and Akt
signaling pathways (Adhikary and Eilers, 2005), we investigated whether these pathways were
altered in miR KD cells. Surprisingly, no consistent change in MEKl/2, ERK1/2, or Akt
phosphorylation was noted in response to impaired miRNA processing (Figure 2.7D). These data
suggest that miRNAs directly regulate c-Myc expression post-transcriptionally.
To examine potential miRNA-mediated regulation, we used the miRNA target prediction
program miRanda (John et al., 2004) and observed that the 3' UTRs of murine K-Ras and c-Myc
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Figure 2.7 (A) K-RasG 12D murine embryonic fibroblasts (MEFs) infected with empty vector or
shRNAs against DGCR8, Drosha, or Dicerl were plated at 5000 cells per well. Cells were
counted over time in triplicate. Values are mean +/- s.e.m. (n=3). (B) Wild type MEFs infected
with empty vector or shRNAs against DGCR8, Drosha, or Dicerl were plated at 3X105 cells and
serially passaged and counted, with total population doublings measured over time. (C) Q-RT
PCR was performed with probes for K-Ras and c-Myc in LKR13 cells infected with empty
vector or shRNAs against DGCR8, Drosha, or Dicerl. Normalization was performed as
described. (D) Immunoblotting for the expression of total and phosphorylated Akt, MEK1/2, and
ERK1/2 in LKR13 cells infected with empty vector or shRNAs against DGCR8, Drosha, or
Dicerl. (E) small RNA Northern blotting was performed as above in 293T cells transfected with
empty vectors or vectors expressing a seed mutant let-7e (control miRNA) or wild type let-7g.
(F) Luciferase assays were performed in 293T cells co-transfected with 2'-O-methyl
oligonucleotides complementary to either miR- 181 a or let-7g and pRL-TK containing bulged
siCXCR4 binding sites, or murine K-Ras and c-Myc 3' UTRs. Firefly luciferase (pGL3) was
used as a transfection control. Expression was normalized to pGL3 levels and subsequently
normalized relative to pRL-CXCR4 expression. Values are mean +/- s.d. (n=6) with propagated
error. (G) Luciferase assays were performed in 293T cells transfected with pRL-TK containing
either wild type murine K-Ras and c-Myc 3' UTRs or murine K-Ras and c-Myc 3' UTRs
containing point mutations in their let-7 miRNA binding sites. K-Ras (EMBL accession no.
BC004642) mutations correspond to a series of point mutations ("ACAGTGGAAACC" to
"TGAGCGGCCAGG") from positions 157 to 168 of the 3' UTR. C-Myc (EMBL accession no.
X01023) mutations correspond to a G to A point mutation at position 165 of the 3' UTR.
Expression was normalized to pGL3 levels and subsequently normalized relative to
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corresponding wild type 3' UTR expression. Values are mean +/- s.d. (n=6) with propagated
error. (H) LKR13 cells infected with shRNAs against DGCR8, Drosha, or Dicer were
transfected with empty vector or with a vector overexpressing let-7g. Cells were then plated at
low density as described in the text.
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Figure 2.8 Impaired miRNA processing increases expression of specific oncogenes. (A)
Immunoblotting for K-Ras, c-Myc, a-tubulin, N-Ras, H-Ras, and E2F-1 in LKR13 cells infected
with empty vector or shRNAs against DGCR8, Drosha, or Dicerl. (B) Luciferase assays were
performed in 293T cells transfected with pRL-TK containing bulged siCXCR4 binding sites
(Doench et al., 2003) or murine K-Ras and c-Myc 3' UTRs. Firefly luciferase (pGL3) was used
as a transfection control. Expression was normalized to pGL3 levels and subsequently
normalized relative to pRL-CXCR4 expression. Values are mean +/- s.d. (n=6) with propagated
error. (C) LKR13 cells were transfected with 2'-O-methyl oligonucleotides complementary to
either miR- 181 a or let-7g and then plated at 5000 cells per well. Cells were counted over time in
triplicate. Values are mean +/- s.e.m (n=3).
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were both targets of the let-7 family of miRNAs. To evaluate whether elevated K-Ras and c-Myc
protein levels were due to let-7 mediated derepression, we selectively overexpressed let-7g and
measured the effects on luciferase-based reporter constructs carrying the 3' UTRs of K-Ras and
c-Myc (Figure 2.7E). Consistent with previous studies (Johnson et al., 2005), we observed robust
repression of the K-Ras 3' UTR with let-7 overexpression (Figure 2.8B). In addition, the c-Myc
3' UTR was also repressed in this setting, suggesting that both oncogenes are let-7 targets.
Conversely, 2'-O-methyl oligonucleotides complementary to let-7g caused derepression of the 3'
UTRs of K-Ras and c-Myc (Figure 2.7F). Moreover, both oncogenes are direct let-7 targets, as
mutation of the let-7 binding sites in the K-Ras and c-Myc 3' UTRs caused derepression
comparable to let-7 inhibition (Figure 2.7G). To examine the role of let-7 family members in
transformation, LKR13 cells were transfected with 2'-O-methyl oligonucleotides complementary
to let-7g. We observed an elevation in growth rate with let-7 inhibition (Figure 2.8C). Moreover,
overexpression of let-7g in miR KD LKR13 cells led to significant reduction in low-density
colony-forming ability (Figure 2.7H). Finally, in miR KD human cancer cells, we noted an
enrichment of let-7 family members among the miRNAs whose repression correlates best with
heightened transformation (data not shown). However, it is also possible that other miRNAs
whose repression correlates with enhanced transformation might function in a similar way.
To understand the significance of these findings in vivo, we assessed the role of impaired
miRNA processing in a mouse model of lung tumorigenesis, using the conditional, activatable
allele of K-Ras, LSL-K-RasG12D (Tuveson et al., 2004). Intranasal infection of LSL-K-RasG12D
mice with adenovirus expressing Cre has been shown to induce non-small cell lung cancer in
these mice with complete penetrance and a defined time course (Jackson et al., 2001). By
crossing LSL-K-RasG12D mice with mice conditional knock-out allele of Dicerl (Harfe et al.,
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2005), we generated LSL-K-Ras G12D mice that were wild type, heterozygous, or homozygous for
the conditional allele for Dicerl (hereafter referred to as "KD +/+," "KD flox/+," and "KD
flox/flox," respectively).
When this cohort of mice was compared twelve weeks after infection with adenovirus
expressing Cre, we observed a significant increase in tumor burden in the KD flox/+ and KD
flox/flox mice compared to KD +/+ mice. This tumor burden was reflected in significant
increases in tumor/lung area ratio (Figure 2.9A), tumor size (Figure 2.9B), and tumor number
(Figure 2.9C). We also performed histological grading analysis of tumors from KD +/+, KD
flox/+, and KD flox/flox mice. Overall, we noted a slight shift in grade in the Dicerl mutant
mice, with the highest-grade lesions only present in the KD flox/+ and KD flox/flox mice
(Figure 2.9D). These lesions displayed areas of nuclear pleomorphism, prominent nucleoli, and
significant vacuolation (Figure 2.9E). In addition, the KD flox/+ and KD flox/flox mice
exhibited more extensive bronchiolar hyperplasia than KD +/+ mice (Figure 2.9F), further
demonstrating the enhanced tumor burden in Dicerl mutant mice. In total, these results suggest
that impaired miRNA processing can enhance tumorigenesis in vivo through an enhanced tumor
burden.
These studies demonstrate that impaired miRNA biogenesis accelerates oncogenic
transformation through the deregulation of target oncogenes. Previous work has shown that both
human and murine cancers exhibit a global reduction of mature miRNA levels when compared to
normal tissues (Lu et al., 2005). Our work demonstrates that this reduced mature miRNA
expression can promote tumorigenesis. Importantly, the loss of miRNA processing, though
incomplete, causes a dramatic change in the transformed phenotype of cancer cells. Furthermore,
our results are consistent with observations correlating reduced Dicerl expression in a subset of
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Figure 2.9 Impaired miRNA processing enhances the in vivo tumor burden in a mouse
model of lung cancer. (A) LSL-K-RasGl2D mice either wild type, heterozygous, or homozygous
conditional for Dicerl (KD +/+, KD flox/+, and KD flox/flox, respectively) were intranasally
infected with adenovirus expressing Cre. Twelve weeks post-infection, animals were sacrificed
and tumor and lung areas were quantified with Bioquant software. (B) Tumor sizes were
quantified for the animals described above with Bioquant software. (C) Tumor numbers were
quantified for the animals described above with Bioquant software. Values are mean +/- s.e.m.
(n= 11 for KD +/+, n=15 for KD flox/+, and n=10 for KD flox/flox). *: p<5x10-5, **: p<0.05;
***: p<0.005. (D) Tumors from animals of the genotypes described above were scored for
histological grade using a grading scheme described previously (see Methods for details). Values
are mean +/- s.e.m. (n=5 for each genotype). (E) Hematoxylin/eosin staining of a Grade III tumor
from a KD flox/+ animal. Original magnification, 20X. Filled arrows indicate areas of nuclear
pleomorphism. Arrowheads indicate areas with prominent nucleoli. Empty arrows indicate areas
of vacuolation. (F) Hematoxylin/eosin staining of bronchiolar hyperplasia from a KD flox/flox
animal. Original magnification, 20X.
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non-small cell lung cancers with poor prognosis (Karube et al., 2005). These findings are also
consistent with work showing the let-7 family as a negative regulator of the Ras family of
oncogenes (Johnson et al., 2005), while extending its role in oncogenic transformation to c-Myc.
Of note, previous studies have implicated specific miRNAs as oncogenes, as their
overexpression accelerates tumorigenesis (Hayashita et al., 2005; He et al., 2005; O'Donnell et
al., 2005; Ota et al., 2004; Volinia et al., 2006). Our study does not directly contradict these
findings, but suggests that overall repression of miRNAs can enhance tumorigenesis. Recent
work has also shown that the global repression of miRNAs in human cancers does not coincide
with reductions in the primary miRNA transcripts, suggesting that altered regulation of the
miRNA processing machinery occurs in human cancers (Thomson et al., 2006). Taken as a
whole, these investigations highlight a functional role for miRNA biogenesis in tumorigenesis.
Materials and Methods
Cell culture. Human cancer cell lines (HCA7, MCF7, U20S) were originally obtained from
ATCC. LKR13 cells were generated from a murine lung adenocarcinoma (Johnson et al., 2001;
Wislez et al., 2006). Wild type and LSL-K-RasG12 D MEFs were generated as described previously
(Tuveson et al., 2004). Cells were maintained using standard conditions.
Transformation, immortalization, growth, and tumorigenesis assays. Transformation,
immortalization, growth, and tumorigenesis assays were performed essentially as described
(Sage et al., 2000).
BrdU and cell cycle profile analysis. Anti-BrdU and 7-AAD staining were analyzed by flow
cytometry as per manufacturer's instructions (BD Biosciences).
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Invasion assays. Invasion assays were performed using a 24-well collagen-based cell invasion
assay as per manufacturer's instructions (Chemicon).
shRNA design and infection. shRNAs were designed, cloned, and infected into cells as
described previously (Brummelkamp et al., 2002; Ventura et al., 2004). Subsequent adenovirus
infection of shRNA-expressing cells was performed as described (Ventura et al., 2004).
Northern blotting. Small RNA Northern blotting was performed as described (Ventura et al.,
2004).
Immunoblotting assays. Immunoblotting was performed as described (Sage et al., 2000).
Quantitative reverse transcription (Q-RT) PCR. Q-RT PCR of murine DGCR8, Drosha,
Dicerl, K-Ras, and c-Myc was performed as before (Sweet-Cordero et al., 2005). Q-RT PCR of
satellite repeat transcripts was performed as described (Martens et al., 2005).
miRNA overexpression and repression assays. miRNAs let-7g and seed mutant let-7e with
approximately 500 basepairs of flanking sequence were cloned into MSCV-neo (Clontech). 2'-
O-methyl (2'-O-Me) oligonucleotides complementary to let-7g and miR-181 a were synthesized
commercially (Integrated DNA Technologies). Overexpression vectors and 2'-O-Me
oligonucleotides were transfected into cells using described methods (Hutvagner et al., 2004;
Meister et al., 2004).
Luciferase assays. Murine K-Ras (EMBL accession no. BC004642) and c-Myc (EMBL
accession no. X01023) 3' UTRs were cloned into Renilla luciferase vectors described previously
and luciferase assays were performed as before (Doench et al., 2003).
miRNA expression analysis. miRNA expression profiling was performed using a bead-based
miRNA detection platform as described with modifications (Lu et al., 2005).
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Mice. LSL-K-Ras G12D mice (Tuveson et al., 2004) were crossbred to Dicer fl x/flox mice (Harfe et
al., 2005) to generate LSL-K-RasG12D; Dicerlflx/+mice, which were subsequently interbred to
produce the experimental cohort.
Intranasal infection and tumor analysis. Mice were infected intranasally with adenovirus
expressing Cre as described (Jackson et al., 2001). Twelve weeks after infection, mice were
sacrificed and lungs were collected, fixed in formalin, and stained for histology as described
previously (Jackson et al., 2001). Lung and tumor areas were determined using Bioquant Image
Analysis software as described previously (Jackson et al., 2005).
Tumor grading analysis. Tumor grading was done without knowledge of genotype as described
previously (Jackson et al., 2005). Each tumor was given a score of I to 3 based on predetermined
criteria.
shRNA design. shRNAs against murine DGCR8, Drosha, and Dicerl were cloned into
pSuper.RETRO.puro (Oligoengine) with the following oligonucleotides:
control shRNA: 5'-CTTACAATCAGACTGGCGA-3'
shDGCR8: 5'-CCAATGATGACCAAGATTA-3'
shDrosha: 5'-CAACAGTCATAGAATATGA-3'
shDicerl: 5'-GCATGGTGGTGTCGATATT-3'
shRNAs against firefly luciferase, murine Dicerl, and human DGCR8, Drosha, and Dicerl were
cloned into pSicoR.pgk.puro with the following oligonucleotides:
shluc: 5'-GAGCTGTTTCTGAGGAGCC-3'
murine shDicerl: 5'-GCATGGTGGTGTCGATATT-3'
human shDGCR8 A: 5'-GAAGCTCATTACTTTATCA-3'
human shDGCR8 B: 5'-GAAAGAGTTTGTTATTAAC-3'
human shDrosha A: 5'-GAAGCTCTTTGGTGAATAA-3'
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human shDrosha B: 5'-GAATTCGGCAGCCCAAATA-3'
human shDicerl A: 5'-GCAGCTCTGGATCATAATA-3'
human shDicerl B: 5'-GGAAGAGGCTGACTATGAA-3'
BrdU and cell cycle profile analysis. LKR13 cells were grown overnight in media containing
reduced serum (1%) and treated with BrdU for 2 hours before preparation for staining and flow
cytometry.
Quantitative reverse transcription (Q-RT) PCR. Taqman probes (Applied Biosystems) were
as follows: DGCR8 (Mm00473695_sl), Drosha (Mm01310009_ml), Dicerl
(Mm00521734_gl), K-Ras (Mm00517494_ml), c-Myc (Mm00487804_ml), TBP
(Mm0044697 l_ml).
Immunoblotting assays. Primary antibodies used were as follows: K-Ras, N-Ras, H-Ras, E2F-
1, c-Myc, P-tubulin (Santa Cruz); phospho- and total ERK1/2, phospho- and total MEK1/2,
phospho- and total Akt, phospho- and total eIF2a, phospho- and total ribosomal S6 (Cell
Signaling Technology); M2 anti-Flag (Sigma-Aldrich).
cDNA rescue. cDNAs containing Flag-tagged Dicerl, Drosha, and DGCR8 were co-transfected
with MSCV-neo into LKR13 cells, selected, and subcloned for uniform cDNA expression. Cells
expressing cDNAs were subsequently infected with shRNAs as above.
miRNA overexpression. miRNAs of the following mature sequences, with approximately 500
basepairs of flanking sequence, were cloned into MSCV-neo:
let-7g: 5'-UGAGGUAGUAGUUUGUACAGU-3'
seed mutant let-7e: 5'-UCUGGACGGAGGUUGUAUAGU-3'
miRNA expression analysis. Samples were subjected to total RNA preparation using TRIzol
(Invitrogen). Two pg of total RNA from each sample, together with two pre-labeling control
119
synthetic RNA oligonucleotides (60 fmoles of 5'-pGACCUCCAUGUAAACGUACAA-3' and
10 fmoles of 5'-pUUGCAGAUAACUGGUACAAG-3') were labeled, through adaptor-ligation-
mediated amplification. Six mock labeling reactions, in which water was used as the starting
material, were also performed for background calculation. Labeled materials were mixed with
biotinylated post-labeling control oligonucleotides and were hybridized to miRNA-detection-
probes conjugated to colored xMap beads (Luminex Corp.), stained with streptavidin-
phycoerythrin, and detected on a Luminex 100S flow cytometer.
Median fluorescence intensity readings from Luminex data collector software were used in
subsequent analyses. To eliminate the background signal from each miRNA-detection-probe,
average readings from the six mock labeling reactions were subtracted from the sample readings.
Data were further normalized following a two -tep procedure, as described. First, data for the
same sample were linearly scaled between different bead sets, based on the sum of the two post-
labeling control readings. Second, data were further scaled to reflect the amount of miRNA per
amount of total RNA. To this end, the sum of both pre-labeling controls from all bead sets for the
same sample was used to eliminate weakly labeled outliers (using a cutoff of 3000) and to
linearly normalize data (so that the sum becomes 9000 for each sample). Data were then
thresholded at 0.1 and control features were removed. To aid further analysis, a new feature
(termed TFI) was added to the dataset representing the sum of all miRNA readings from each
sample.
For each of the three cell lines (HCA7, MCF7, U20S), data were thresholded to eliminate
features whose maximum expression in all samples of that particular cell line does not exceed
64. The remaining features were used to calculate Pearson correlation between miRNA
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expression and soft-agar colony formation. Nominal P-values were calculated after 10000
permutations on the construct labels in the soft-agar colony formation data.
Tumor grading. The criteria for each grade are as follows: Grade 1 tumors have uniform nuclei
showing no nuclear atypia. Grade 2 tumors contain cells with uniform but slightly enlarged
nuclei that exhibit prominent nucleoli. Grade 3 tumors have cells with enlarged, pleomorphic
nuclei showing prominent nucleoli and nuclear molding and/or vacuolation within the tumor.
121
References
Adhikary, S., and Eilers, M. (2005). Transcriptional regulation and transformation by Myc
proteins. Nat Rev Mol Cell Biol 6, 635-645.
Bartel, D. P. (2004). MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 116,
281-297.
Brummelkamp, T. R., Bernards, R., and Agami, R. (2002). A system for stable expression of
short interfering RNAs in mammalian cells. Science 296, 550-553.
Doench, J. G., Petersen, C. P., and Sharp, P. A. (2003). siRNAs can function as miRNAs. Genes
Dev 17, 438-442.
Gregory, R. I., and Shiekhattar, R. (2005). MicroRNA biogenesis and cancer. Cancer Res 65,
3509-3512.
Harfe, B. D., McManus, M. T., Mansfield, J. H., Hornstein, E., and Tabin, C. J. (2005). The
RNaseIII enzyme Dicer is required for morphogenesis but not patterning of the vertebrate limb.
Proc Natl Acad Sci U S A 102, 10898-10903.
Hayashita, Y., Osada, H., Tatematsu, Y., Yamada, H., Yanagisawa, K., Tomida, S., Yatabe, Y.,
Kawahara, K., Sekido, Y., and Takahashi, T. (2005). A polycistronic microRNA cluster, miR-
17-92, is overexpressed in human lung cancers and enhances cell proliferation. Cancer Res 65,
9628-9632.
He, L., Thomson, J. M., Hemann, M. T., Hernando-Monge, E., Mu, D., Goodson, S., Powers, S.,
Cordon-Cardo, C., Lowe, S. W., Hannon, G. J., and Hammond, S. M. (2005). A microRNA
polycistron as a potential human oncogene. Nature 435, 828-833.
Hutvagner, G., Simard, M. J., Mello, C. C., and Zamore, P. D. (2004). Sequence-specific
inhibition of small RNA function. PLoS Biol 2, E98.
Jackson, E. L., Olive, K. P., Tuveson, D. A., Bronson, R., Crowley, D., Brown, M., and Jacks, T.
(2005). The differential effects of mutant p53 alleles on advanced murine lung cancer. Cancer
Res 65, 10280-10288.
Jackson, E. L., Willis, N., Mercer, K., Bronson, R. T., Crowley, D., Montoya, R., Jacks, T., and
Tuveson, D. A. (2001). Analysis of lung tumor initiation and progression using conditional
expression of oncogenic K-ras. Genes Dev 15, 3243-3248.
John, B., Enright, A. J., Aravin, A., Tuschl, T., Sander, C., and Marks, D. S. (2004). Human
MicroRNA targets. PLoS Biol 2, e363.
122
Johnson, L., Mercer, K., Greenbaum, D., Bronson, R. T., Crowley, D., Tuveson, D. A., and
Jacks, T. (2001). Somatic activation of the K-ras oncogene causes early onset lung cancer in
mice. Nature 410, 1111-1116.
Johnson, S. M., Grosshans, H., Shingara, J., Byrom, M., Jarvis, R., Cheng, A., Labourier, E.,
Reinert, K. L., Brown, D., and Slack, F. J. (2005). RAS is regulated by the let-7 microRNA
family. Cell 120, 635-647.
Kanellopoulou, C., Muljo, S. A., Kung, A. L., Ganesan, S., Drapkin, R., Jenuwein, T.,
Livingston, D. M., and Rajewsky, K. (2005). Dicer-deficient mouse embryonic stem cells are
defective in differentiation and centromeric silencing. Genes Dev 19, 489-501.
Karube, Y., Tanaka, H., Osada, H., Tomida, S., Tatematsu, Y., Yanagisawa, K., Yatabe, Y.,
Takamizawa, J., Miyoshi, S., Mitsudomi, T., and Takahashi, T. (2005). Reduced expression of
Dicer associated with poor prognosis in lung cancer patients. Cancer Sci 96, 111-115.
Kumar, M. S., Lu, J., Mercer, K. L., Golub, T. R., and Jacks, T. (2007). Impaired microRNA
processing enhances cellular transformation and tumorigenesis. Nat Genet 39, 673-677.
Lu, J., Getz, G., Miska, E. A., Alvarez-Saavedra, E., Lamb, J., Peck, D., Sweet-Cordero, A.,
Ebert, B. L., Mak, R. H., Ferrando, A. A., et al. (2005). MicroRNA expression profiles classify
human cancers. Nature 435, 834-838.
Martens, J. H., O'Sullivan, R. J., Braunschweig, U., Opravil, S., Radolf, M., Steinlein, P., and
Jenuwein, T. (2005). The profile of repeat-associated histone lysine methylation states in the
mouse epigenome. Embo J 24, 800-812.
Meister, G., Landthaler, M., Dorsett, Y., and Tuschl, T. (2004). Sequence-specific inhibition of
microRNA- and siRNA-induced RNA silencing. Rna 10, 544-550.
Murchison, E. P., Partridge, J. F., Tam, O. H., Cheloufi, S., and Hannon, G. J. (2005).
Characterization of Dicer-deficient murine embryonic stem cells. Proc Natl Acad Sci U S A 102,
12135-12140.
O'Donnell, K. A., Wentzel, E. A., Zeller, K. I., Dang, C. V., and Mendell, J. T. (2005). c-Myc-
regulated microRNAs modulate E2F1 expression. Nature 435, 839-843.
Ota, A., Tagawa, H., Karnan, S., Tsuzuki, S., Karpas, A., Kira, S., Yoshida, Y., and Seto, M.
(2004). Identification and characterization of a novel gene, C13orf25, as a target for 13q31-q32
amplification in malignant lymphoma. Cancer Res 64, 3087-3095.
Sage, J., Mulligan, G. J., Attardi, L. D., Miller, A., Chen, S., Williams, B., Theodorou, E., and
Jacks, T. (2000). Targeted disruption of the three Rb-related genes leads to loss of G(1) control
and immortalization. Genes Dev 14, 3037-3050.
Sweet-Cordero, A., Mukherjee, S., Subramanian, A., You, H., Roix, J. J., Ladd-Acosta, C.,
Mesirov, J., Golub, T. R., and Jacks, T. (2005). An oncogenic KRAS2 expression signature
identified by cross-species gene-expression analysis. Nat Genet 37, 48-55.
123
Thomson, J. M., Newman, M., Parker, J. S., Morin-Kensicki, E. M., Wright, T., and Hammond,
S. M. (2006). Extensive post-transcriptional regulation of microRNAs and its implications for
cancer. Genes Dev 20, 2202-2207.
Tuveson, D. A., Shaw, A. T., Willis, N. A., Silver, D. P., Jackson, E. L., Chang, S., Mercer, K.
L., Grochow, R., Hock, H., Crowley, D., et al. (2004). Endogenous oncogenic K-ras(G12D)
stimulates proliferation and widespread neoplastic and developmental defects. Cancer Cell 5,
375-387.
Ventura, A., Meissner, A., Dillon, C. P., McManus, M., Sharp, P. A., Van Parijs, L., Jaenisch,
R., and Jacks, T. (2004). Cre-lox-regulated conditional RNA interference from transgenes. Proc
Natl Acad Sci U S A 101, 10380-10385.
Volinia, S., Calin, G. A., Liu, C. G., Ambs, S., Cimmino, A., Petrocca, F., Visone, R., Iorio, M.,
Roldo, C., Ferracin, M., et al. (2006). A microRNA expression signature of human solid tumors
defines cancer gene targets. Proc Natl Acad Sci U S A 103, 2257-2261.
Wislez, M., Fujimoto, N., Izzo, J. G., Hanna, A. E., Cody, D. D., Langley, R. R., Tang, H.,
Burdick, M. D., Sato, M., Minna, J. D., et al. (2006). High expression of ligands for chemokine
receptor CXCR2 in alveolar epithelial neoplasia induced by oncogenic kras. Cancer Res 66,
4198-4207.
124
CHAPTER 3: Dicerl functions as a
haploinsufficient tumor suppressor
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Abstract
While the global down-regulation of microRNAs (miRNAs) is a common feature of
human tumors, its genetic basis is largely undefined. To address this, we analyzed the
consequences of conditional Dicerl mutation (Dicerl "floxed" or Dicerlf ) on several mouse
models of cancer. Here we show that Dicerl functions as a haploinsufficient tumor suppressor.
Tumors from Dicerl' animals, though exhibiting reduced miRNA processing, maintain the wild
type allele, while tumors from Dicerlf y animals undergo incomplete recombination. When
complete loss of Dicerl is forced, tumorigenesis is abrogated. In line with these models, genome
copy number analysis shows frequent deletion of DICER1 in human cancer; importantly,
DICER] never undergoes homozygous deletion, suggesting that DICER1 is haploinsufficient in
human cancer. These findings suggest that haploinsufficient tumor suppressors like Dicerl,
which are frequently missed by traditional genetic analyses, play an important role in
oncogenesis.
127
Introduction
MicroRNAs (miRNAs) are short, non-coding RNAs that function to suppress post-
transcriptionally the expression of target mRNAs, predominately via inhibition of translation.
Such translational inhibition relies upon imperfect base pairing between the miRNA and the
target transcript, with the interaction at nucleotides 2-8, or the seed region, of the miRNA being
required for translational repression. Computational prediction of miRNA targets based upon
seed regions and sequence conservation has revealed a widespread potential for miRNA-
mediated transcript regulation, with hundreds of putative mRNA targets for an individual
miRNA (Bartel, 2004).
In line with this potential, it has been speculated that miRNAs could function as
oncogenes or tumor suppressor genes based upon their inhibition of a variety of tumor
suppressive and oncogenic mRNAs, respectively (Plasterk, 2006; Ventura and Jacks, 2009). In
particular, three distinct mechanisms have been posited. First, oncogenic miRNAs can undergo
gain of function in tumors. This has been most clearly demonstrated for the miR-17-92 cluster,
whose amplification in B-cell lymphomas promotes their development, potentially through its
control of B-cell differentiation (He et al., 2005; Koralov et al., 2008; Ventura et al., 2008). In
contrast, tumor suppressive miRNAs can experience loss of function in tumors. This has been
shown for the let-7 family, whose expression inhibits lung tumorigenesis by inhibition of
oncogenes like the Ras family and HMGA2 (Esquela-Kerscher et al., 2008; Kumar et al., 2008).
In particular, let-7 family members are in sites of frequent deletion in human tumors and their
processing is inhibited by the oncogenic Lin-28 proteins (Chang et al., 2009; Heo et al., 2008;
Newman et al., 2008; Viswanathan et al., 2008). Finally, oncogenes can acquire mutations to
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remove miRNA binding sites in tumors. This has been described for HMGA2, whose
translocation promotes lipoma development by releasing the transcript from let-7 mediated
tumor suppression (Mayr et al., 2007).
Early studies observed a global down-regulation of miRNAs in human cancer (Lu et al.,
2005). It was unclear whether this widespread loss of miRNAs was merely a consequence of
tumor development or was functionally related to tumorigenesis. We have demonstrated
previously that this global loss of miRNAs was functionally relevant to oncogenesis, as
impairment of miRNA maturation enhanced transformation both in cancer cells and a K-Ras-
driven model of lung cancer (Kumar et al., 2007). While these studies provide a functional basis
for inhibition of miRNA biogenesis in cancer, the genetic basis of impaired miRNA processing
in human cancer has been largely undefined. For a subset of miRNAs, widespread silencing
occurs at the transcriptional level via the c-Myc oncogene (Chang et al., 2008). Yet it has also
been shown that such broad reductions in miRNAs can occur post-transcriptionally, since
changes in miRNA levels frequently occur without changes in the levels of the primary miRNA
transcript (Thomson et al., 2006). Recently, it was shown that mutations in the miRNA
processing component TARBP2 occur frequently in mismatch repair-deficient colon cancer and
that these mutations promote tumorigenesis by impaired processing of miRNAs (Melo et al.,
2009). However, these limited cases do not resolve the common global reduction of miRNAs in
human cancers. Moreover, the precise genetics of such changes in tumors is poorly defined,
especially as no components of the miRNA processing pathway have been reported to be
completely deleted in human tumors. This is not surprising, since it has been shown that
germline deletion of miRNA processing components Dicerl and Dgcr8 in mice fails to produce
viable progeny (Bernstein et al., 2003; Wang et al., 2007). Thus, conditional deletion of miRNA
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processing components provides a powerful means of examining the role of miRNAs in
tumorigenesis.
Results and Discussion
We have previously shown that KrasLSL-GI2D mice either heterozygous or homozygous
conditional for Dicerl (hereafter referred to as KD f/+ and KD f/f), after intranasal infection with
adenovirus expressing Cre (Adeno-Cre), experienced a significant increase in lung tumor burden
compared to KrasLL -Gl2D mice wild type for Dicerl (hereafter referred to KD +/+) (Kumar et al.,
2007). To extend these observations of Dicerl-mediated tumor suppression, we characterized
survival of KD +/+, f/+, and f/f animals after intranasal Adeno-Cre infection. Both KD f/+ and f/f
animals experienced a significant reduction in survival relative to KD +/+ mice (Figure 3.1).
Surprisingly, we found that the KD f/+ cohort had a significant reduction in survival when
compared to KD f/f animals. To extend these findings to additional cancer types, we utilized a
mouse model of soft-tissue sarcoma generated through intramuscular infection with Adeno-Cre
of KrasLSL-Gl2D; Trp53f' mice (Kirsch et al., 2007). When we compared survival of KrasLSL-GI
2 D
Trp53f mice either wild type, heterozygous, or homozygous conditional for Dicerl (hereafter
referred to as KPD +/+, f/+, and f/f) intramuscularly infected with Adeno-Cre, we observed a
reduction in survival only in the KPD f/+ cohort (Figure 3.2). Overall, these results indicate that
tumors generated from animals heterozygous conditional for Dicerl specifically impact survival.
These findings stand in opposition to traditional tumor suppressors, in which
homozygous mutation provides a direct advantage to tumor cells while heterozygous mutation
promotes tumorigenesis only after subsequent mutation or inactivation of the remaining wild
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Figure 3.1. Dicerl mutation reduces post-infection survival in a genetically engineered mouse
model of K-Ras driven lung cancer. KrasL L-Gl 2D mice either wild type, heterozygous, or
homozygous conditional for Dicerl (KD +/+, KD f/+, and KD f/f, respectively) were intranasally
infected with adenovirus expressing Cre and survival was assessed. Statistical significance was
assessed by the log-rank test.
132
Figure 3.2
75 150
Post-infection survival (days)
100
75
GENOTYPE
- KPD +/+ (n=23)
----- KPD fI+ (n=33)
.......... KPD f/f (n=15)
225
133
Figure 3.2. Dicerl mutation reduces post-infection survival in a genetically engineered mouse
model of K-Ras, p53-driven soft-tissue sarcoma. KraLS-G 2D; Trp53'mice either wild type,
heterozygous, or homozygous conditional for Dicerl (KPD +/+, KPD f/+, and KPD f/f,
respectively) were intramuscularly infected with adenovirus expressing Cre and survival was
assessed. Statistical significance was assessed by the log-rank test.
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type allele. To characterize precisely the mutation status of Dicerl conditional tumors, we
generated lung cancer cell lines from KPD f/+ animals and examined the Dicerl locus for further
deletion. We observed recombination of the conditional allele of Dicerl and retention of the wild
type allele, generating KPD +/- lung cancer cells (Figure 3.3A); similar maintenance of the wild
type allele was found in sarcoma cell lines from KPD f/+ mice (Figure 3.4). We further
examined Dicerl recombination in lung cancer cell lines from KPD f/f animals. In these cells,
we again found recombination of the conditional allele. However, recombination was
incomplete, generating KPD f/- lung cancer cells (Figure 3.3B); this incomplete loss of Dicerl
was also observed in sarcoma cell lines from KPD f/f mice (Figure 3.4). In sum, this data
indicates that only partial loss of Dicerl occurs in our genetically engineered mouse models
during tumorigenesis.
Based upon the hemizygous mutation of Dicerl in our tumors, we wanted to assess the
consequence of partial loss of Dicerl on the global miRNA profile. When we broadly compared
miRNAs in Dicerl wild type and heterozygous lung cancer cells, there was a global decrease in
steady-state miRNA levels in KPD +/- cells (Figure 3.5A and data not shown). Small RNA
Northern analysis verified these reductions in miRNA levels (Figure 3.5B). Taken together, the
miRNA profile ofDicerl heterozygous lung cancer cells suggests that Dicerl loss, even when
incomplete, functionally affects miRNA processing in tumors.
While the genetic analysis of the Dicerl locus in our mouse cancer models suggests that
Dicerl-mediated tumor suppression is haploinsufficient, it was still formally possible that Dicerl
mutant tumors eventually undergo complete inactivation of Dicer l via an alternative mechanism
like epigenetic silencing. Thus, we assessed the consequences of complete loss of Dicerl in our
genetically engineered mouse models. First, to promote complete loss of Dicerl in the lung, we
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Figure 3.3. Dicerl undergoes hemizygous loss in lung tumors. (A) DNA was prepared from
KrasLS L-G I2D mouse embryonic fibroblasts (MEFs) either heterozygous conditional or mutant for
Dicerl (KD f/+ and KD +/-) and lung cancer cell lines from KPD f/+ mice and the Dicerl locus
was examined by PCR. (B) DNA was prepared from KraSLSL-G12D MEFs either homozygous
conditional or heterozygous mutant for Dicerl (KD f/f and KD +/-) and lung cancer cell lines
from KPD f/f mice and the Dicerl locus was examined by PCR.
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Figure 3.4. Dicerl undergoes hemizygous loss in soft-tissue sarcoma. DNA was prepared from
KraLSL -G12D MEFs either heterozygous conditional or mutant for Dicerl (KD f/+ And KD +/-)
and sarcoma cell lines from KPD f/+ And f/f mice. The Dicerl locus was examined by PCR.
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Figure 3.5. Hemizygous deletion of Dicerl causes a global reduction in steady-state miRNA
levels. (A) MiRNA profiling and hierarchical clustering were performed on lung cancer cell lines
either wild type or heterozygous for Dicerl (KPD +/+ and KPD +/- respectively). (B) Small
RNA Northern blotting analysis of miRNAs and Glutamine tRNA was performed on KPD +/+
and KPD +/- lung cancer cell lines.
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infected KD f/+ and f/f mice with a lentivirus expressing Cre (Lenti-Cre). In contrast to
adenovirus, which transiently expresses Cre in the lung epithelium, lentiviral integration should
allow for stable, longer-term expression of Cre, allowing for likelier complete recombination at
the Dicerl locus. When we compared mice infected with Lenti-Cre, we observed a striking
decrease in tumor burden in KD f/f compared to KD f/+ mice (Figure 3.6A-C); this result
contrasts sharply with previous studies in which KD f/+ and f/f mice created a similar tumor
burden after Adeno-Cre infection. Notably, when we isolated tumors from KD f/f mice and
assessed Dicerl loss, we found all tumors had incomplete recombination, suggesting that there is
active selection against total Dicerl loss in lung tumors (Figure 3.6D).
To further examine the effects of complete Dicerl loss, we transduced a set of sarcoma
cell lines with CreERT2 to allow for tamoxifen-dependent Cre activity. Treatment with 4-
hydroxytamoxifen (4-OHT) led to efficient deletion of Dicerl in vitro (Figure 3.7A). To assess
the effect of this recombination on tumorigenesis, we transplanted untreated KPD f/- sarcoma
cells expressing CreERT2 into immune competent hosts and recombination was induced by
systemic tamoxifen administration. Compared to control treatments, tamoxifen delivery
substantially slowed tumor growth in KPD f/- sarcomas (Figure 3.7B). Of note, this system
allowed for Cre-mediated deletion of Dicerl, as the tumors that developed in tamoxifen-treated
animals had extensive Dicerl recombination (Figure 3.7C). Importantly, this tumor suppression
was not merely an effect of tamoxifen- or Cre-mediated toxicity, as tamoxifen treatment of
animals injected with KPD +/+ sarcoma cells expressing CreERT2 did not impair tumor growth
(Figure 3.8). In total, these studies demonstrate that complete deletion of Dicerl is deleterious,
strongly suggesting that Dicerl is a haploinsufficient tumor suppressor.
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Figure 3.6. Complete deletion of Dicerl in murine lung cancers inhibits tumor growth. (A) KD
f/+ and f/f mice were intratracheally infected with lentivirus expressing Cre. Twelve weeks post-
infection, animals were sacrificed and tumor and lung areas were quantified with Bioquant
software. (B) Tumor sizes were quantified for the animals described above. (C) Tumor numbers
were quantified for the animals described above. Values are mean +/- s.e.m. (n=7 for KD f/+ and
n=8 for KD f/f). *: p<0.005, #: p<0.05. (D) DNA was prepared from KrasLSL -G2D MEFs infected
with adenovirus expressing eGFP (K Ad-eGFP) or adenovirus expressing Cre (K Ad-Cre); KPD
f/- sarcoma cell lines infected with MSCV.CreER T2 .puro in the presence or absence of 4-OHT
(KPD f/- CreERT 2 -/+ tam); and thymus and lung tumors from KD f/f mice infected with Lenti-
Cre (KD f/f N 1-2 and T 1-4, respectively). The Dicerl locus was examined by PCR, while the
Kras locus was examined by PCR to assess tumor purity.
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Figure 3.7 continued
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Figure 3.7. Complete deletion of Dicerl inhibits sarcoma development. (A) KPD f/+ and f/-
sarcoma cell lines were infected with MSCV.CreERT 2.puro. Cre-mediated recombination was
induced by treatment with 4-OHT for defined time points. DNA was prepared and recombination
of the Dicerl locus was assessed by PCR. (B) Two independent KPD f/- sarcoma cell lines
infected with MSCV.CreERT2.puro were injected subcutaneously into C57B16/129SV Fl
animals. Animals were treated with or without tamoxifen by intraperitoneal injection and tumor
growth was measured over time. Values are mean +/- s.e.m. (n=8 each). (C) Tumors were
isolated from KPD f/- sarcoma cell line transplants treated with or without tamoxifen. DNA was
prepared and recombination of the Dicerl locus was assessed by PCR. Asterisk corresponds to
the wild type Dicerl locus from the C57B16/129SV Fl host animals.
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Figure 3.8. Tamoxifen treatment of KPD +/+ sarcoma cells expressing CreERT2 does not impair
tumor growth. KPD +/+ sarcoma cell lines infected with MSCV.CreERT2.puro were injected
subcutaneously into C57B16/129SV F1 animals. Animals were treated with or without tamoxifen
by intraperitoneal injection and tumor growth was measured over time. Values are mean +/-
s.e.m. (n=7 each).
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While these findings indicate that partial loss of Dicerl promotes tumor development, it
was not clear whether comparable deletions are seen in human cancer. To explore this, we
assessed DICER1 copy number data from the Cancer Genome Project at the Sanger Institute
(Forbes et al., 2008). In their data sets, there was frequent loss of one allele of DICER] in several
different tumor types (Table 3.1). Of note, there were never high-level amplifications of the
DICER] locus in these tumor sets, suggesting these losses were not due to random genome
instability. More importantly, homozygous deletion of DICER] was never observed, in line with
our findings of Dicerl functioning as a haploinsufficient tumor suppressor. When combined with
the promotion of tumorigenesis by frequent heterozygous point mutation of TARBP2 (which
promotes miRNA processing by stabilizing Dicerl) in mismatch-repair deficient colon cancer,
the DICER1 hemizygous loss observed here provides one reasonable mechanism by which
miRNA processing becomes impaired in human cancer (Melo et al., 2009).
The findings presented here provide substantial evidence for Dicerl as a
haploinsufficient tumor suppressor. These findings are in line with earlier observations of global
down-regulation of miRNAs in human cancer and the functional relevance of this down-
regulation in tumorigenesis (Kumar et al., 2007; Lu et al., 2005). These results further clarify the
genetic basis for this global loss of miRNAs, via partial loss of function of the miRNA
processing machinery in human tumors. Although the frequent DICER1 single-copy deletion
noted in human cancers provides a relevant mechanism of impairing miRNA biogenesis,
additional mechanisms may occur. In particular, in light of the frequent mutation of TARBP2 in
mismatch-repair deficient colon cancer, it is possible that point mutation of other components of
the miRNA processing machinery can occur, as has been described for DICER] and DROSHA in
a small number of ovarian cancer cell lines (Merritt et al., 2008).
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Table 3.1. DICER1 is frequently deleted in various human cancers.
Tumor Type Fraction of Tumors with DICER1 hemizygous loss
Breast 17/45
Kidney 13/21
Large Intestine 14/39
Liver 3/9
Lung 37/149
Ovary 6/22
Pancreas 6/16
Stomach 9/21
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Beyond such mutational analyses, these results represent an expansion of the list of
haploinsufficient tumor suppressors to include components of the miRNA processing machinery.
The breadth of tumor suppressor genes that function via haploinsufficiency is only beginning to
be appreciated (Santarosa and Ashworth, 2004). In fact, the traditional reliance on complete loss
of tumor suppressor genes by heterozygous mutation and subsequent LOH is likely to miss
factors whose effects do not require complete loss like p2 7Ki pl and Dmp 1. Moreover, such
analyses are certain to ignore genes whose partial loss is tumor suppressive while their complete
loss is deleterious to tumor growth, such as Dicerl. As genome-wide studies begin to explore the
functional role of chromosomal deletions in human cancer, it will be important to consider
haploinsufficiency of deleted genes in such contexts.
Materials and Methods
Mice. KraLSL-Gl2D; Dicerl +/f/+'f/fanimals were generated as described previously (Kumar et al.,
2007). KrasLSL-G12D; Trp53' animals were bred with KrasLSL-G12D; Dicerlf animals to produce
KraLSL-G12D; Trp53/+; Dicerf/+ animals. These animals were backcrossed to KrasLSL-G12D
Trp53f f animals to produce KrasLSL-GI2D; Trp53'- Dicerlf/+ animals, which were interbred to
produce the experimental cohort.
Intranasal, intratracheal, and intramuscular infection. Mice were infected intranasally,
intratracheally, and intramuscularly with adenovirus and lentivirus expressing Cre as described
(Jackson et al., 2001; Kirsch et al., 2007; Kumar et al., 2008). Lung and tumor areas were
determined using Bioquant Image Analysis software as described previously (Kumar et al.,
2007).
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Cell line injection and tamoxifen treatment. C57B16/129SV Fl animals were subcutaneously
injected with 2.5* 104 sarcoma cells. Mice were subsequently treated with corn oil with and
without tamoxifen as described previously (Ventura et al., 2007). Tumors were measured as
described (Kumar et al., 2007).
Cell culture. Primary sarcoma and lung cancer cell lines were generated by dissection of tumors
from mice infected with adenovirus expressing Cre, digestion with trypsin and plating and
propagation in serum-containing media. KraLSL-G2; Dicerlfffmouse embryonic fibroblasts
were generated as described (Tuveson et al., 2004). Sarcoma cell lines were infected with
MSCV.CreERT2.puro and treated with 4-OHT for defined time points as described (Ventura et
al., 2007). Cells were maintained using standard conditions.
Recombination analysis. DNA was prepared from MEFs, tumors, and cancer cell lines. Dicerl
recombination was assessed by PCR using previously described primers (Harfe et al., 2005).
Kras recombination primer information is provided below.
Northern blotting. Small RNA Northern blotting was performed as described (Ventura et al.,
2004). Probe information is provided in Supplemental Materials and Methods.
miRNA expression analysis. miRNA expression profiling was performed using a bead-based
miRNA detection platform as described with modifications (Lu et al., 2005).
PCR genotyping. PCR genotyping of Dicerl was performed as described previously (Harfe et
al., 2005). PCR genotyping of Kras was performed using standard conditions with the following
primers:
Forward #1: 5'-GTC TTT CCC CAG CAC AGT GC-3'
Reverse #1: 5'-CTC TTG CCT ACG CCA CCA GCT C-3'
Reverse #2: 5'-AGC TAG CCA CCA TGG CTT GAG TAA GTC TGC A-3'
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Northern blotting. Small RNA Northern blotting was performed using the following probes (all
5' to 3'):
miR-29: AYCGATTTCARATGGTGCTA
miR-26: CCTATCCTGRATTACTTGAA
miR-30: AGTSDRGGATGTTTACA
let-7 (combined at an even stoichiometric ratio): AACTATACAACCTACTACCTCA,
AACTATACAATCTACTACCTCA, AACTATGCAACCTACTACCTCT,
AACCATACAACCTACTACCTCA, ACTGTACAAACTACTACCTCA
miR- 15b: TGTAAACCATGATGTGCTGCTA
miR-7: ACAACAAAATCACWAGTCTTCCA
Glutamine tRNA (Gln tRNA): TGGAGGTTCCACCGAGAT
MSCV.CreERT2.puro. CreER T2 was generated from the Rosa26-CreER2 targeting vector
described previously (Ventura et al., 2007). CreERT2 was amplified with the primers 5'-GCA
GTC GAC ACC ATG TCC AAT TTA CTG ACC-3' And 5'-GAA GAA TTC TCA AGC TGT
GGC AGG GAA ACC-3'. The PCR product was digested with SalI and EcoRI and ligated to
Xhol/EcoRI-cut MSCV.puro (from Clontech).
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CHAPTER 4: Suppression of non-small cell
lung tumor development by the let-7
microRNA family
159
The work presented in this chapter is largely taken from a paper published in The Proceedings of
the National Academy of Sciences (Kumar et al., 2008). I contributed to Figures 4.3, 4.4, 4.7,
4.8A, 4.9-4.13. Stefan J. Erkeland contributed Figures 4.1A and B, 4.2, 4.5, 4.6, and 4.8B. Ryan
E. Pester and Cindy Y. Chen assisted in the experiments presented in 4.3, 4.4, 4.7, 4.8A, 4.9-
4.13. Margaret S. Ebert contributed Figure 4. 1C.
160
Abstract
Many microRNAs (miRNAs) target mRNAs involved in processes aberrant in
tumorigenesis, such as proliferation, survival, and differentiation. In particular, the let-7 miRNA
family has been proposed to function in tumor suppression, as reduced expression of let-7 family
members is common in non-small cell lung cancer (NSCLC). Here we show that let-7
functionally inhibits non-small cell tumor development. Ectopic expression of let-7g in K-
RasG 2D-expressing murine lung cancer cells induced both cell-cycle arrest and cell death. In
tumor xenografts, we observed significant growth reduction of both murine and human non-
small cell lung tumors when overexpression of let-7g was induced from lentiviral vectors. In let-
7g expressing tumors, reductions in Ras family and HMGA2 protein levels were detected.
Importantly, let-7g-mediated tumor suppression was more potent in lung cancer cell lines
harboring oncogenic K-Ras mutations than in lines with other mutations. Ectopic expression of
K-RasGl 2D largely rescued let-7g mediated tumor suppression, while ectopic expression of
HMGA2 was less effective. Finally, in an autochthonous model of NSCLC in the mouse, let-7g
expression substantially reduced lung tumor burden.
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Introduction
MicroRNAs (miRNAs) are a class of short, highly conserved, noncoding RNAs known to
play important roles in numerous developmental processes. MiRNAs are initially transcribed as
longer primary transcripts that undergo sequential processing by the RNase Ill-like enzymes
Drosha and Dicer (Bartel, 2004). After maturation, miRNAs regulate gene expression through
incomplete basepairing to a complementary sequence in the 3' untranslated region (UTR) of a
target mRNA. The miRNA-mRNA interaction results in translational repression and accelerated
turnover of the target transcript (Valencia-Sanchez et al., 2006). Computational analyses predict
that mammalian miRNAs regulate approximately 30% of all protein-coding genes, as an
individual miRNA can target many different mRNAs and an individual mRNA can be regulated
by several different miRNAs (Lewis et al., 2005; Lewis et al., 2003).
Numerous findings suggest that miRNAs undergo aberrant regulation during
tumorigenesis. MicroRNA genes are frequently located in genomic regions gained and lost in
mammalian cancers (Calin et al., 2004; Sevignani et al., 2007). Functionally, several miRNAs
have been described as oncogenes. For example, the miRNA cluster miR-17-92 is amplified in
human B-cell lymphomas and was found to cooperate with c-Myc to accelerate
lymphomagenesis in the mouse (He et al., 2005). The BIC transcript, which was isolated from a
common retroviral insertion site that cooperates with c-Myc in lymphomagenesis and is highly
upregulated in Burkitt's lymphoma, encodes a primary miRNA transcript for miR-155 (Lagos-
Quintana et al., 2002; Metzler et al., 2004). Moreover, miR-372 and miR-373 were shown to be
oncogenic in an expression screen and were implicated in testicular cancer through inactivation
of the p53 pathway (Voorhoeve et al., 2006). Other miRNAs have been described as tumor
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suppressors. Intriguingly, miRNA expression profiling has shown that miRNAs are globally
downregulated in tumors relative to normal tissue (Lu et al., 2005). Recent work from our group
demonstrated that global downregulation can promote tumorigenesis (Kumar et al., 2007). MiR-
15 and miR-16 are located in chromosome 13ql4, a region frequently deleted in chronic
lymphocytic leukemia (CLL) (Cimmino et al., 2005). Furthermore, recent studies have shown
that p53 transcriptional activation targets the miR-34 family in a step important for cell cycle
control (Chang et al., 2007; He et al., 2007; Raver-Shapira et al., 2007). In total, these findings
provide several lines of evidence for the importance of miRNA in tumorigenesis.
Let- 7 was originally identified in C. elegans as a regulator of developmental timing and
cellular proliferation (Reinhart et al., 2000). The discovery of mammalian let-7 family members
prompted speculation that these miRNAs might be tumor suppressors (Pasquinelli et al., 2000).
There are at least nine individual members of the let-7 family in mammals, and several let-7
genes are located in regions frequently deleted in human cancer (Calin et al., 2004). Moreover,
let-7 expression is reduced in a subset of non-small cell lung cancer (NSCLC) patients, and this
reduction is correlated with poor prognosis (Takamizawa et al., 2004; Yanaihara et al., 2006).
When ectopically expressed in cancer cell lines, let-7 miRNA can repress cellular proliferation
(Johnson et al., 2007; Lee and Dutta, 2007). Finally, let-7 family members functionally inhibit
the mRNAs of well characterized oncogenes, such as the Ras family (Johnson et al., 2005),
HMGA2 (Hebert et al., 2007; Lee and Dutta, 2007; Mayr et al., 2007; Wang et al., 2007), c-Myc
(Koscianska et al., 2007; Kumar et al., 2007), and cell-cycle regulators like CDC25A, CDK6,
and Cyclin D2 (Johnson et al., 2007).
The two best-characterized let-7 targets are the Ras family and HMGA2. Activating
mutations in Ras family members (H-ras, K-ras and N-ras) are found in many human tumors
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including -30% of NSCLCs (Bos, 1989). The let-7 family has been shown to regulate both N-
Ras and K-Ras mRNAs via their 3' UTRs (Johnson et al., 2005). Notably, all previous studies
reporting let-7-mediated repression of proliferation have been performed in cells expressing
mutant forms of N- and K-Ras (Johnson et al., 2007; Lee and Dutta, 2007). The high mobility
group A (HMGA) proteins are major nonhistone chromosomal proteins involved in
transcriptional regulation controlling proliferation and differentiation. HMGA2 is implicated in
tumorigenesis via chromosomal translocations and transcriptional upregulation in several tumor
types, although the function of this upregulation in tumorigenesis is unclear (Meyer et al., 2007;
Sarhadi et al., 2006; Young and Narita, 2007). The HMGA2 3' UTR contains seven let-7 target
sites and disruption of these sites enhances oncogenic transformation (Mayr et al., 2007). Finally,
let-7 expression is inversely correlated with expression of HMGA2 in NSCLC and ectopic
overexpression of HMGA2 promotes cellular proliferation in the presence of let-7 (Lee and
Dutta, 2007).
The above findings suggest that the let-7 miRNA family functions in tumor suppression.
However, studies to date have not demonstrated that let-7 miRNA can suppress tumorigenesis in
vivo. Moreover, there is a lack of functional data related to the regulation of individual let-7
targets on tumorigenesis in vivo. Finally, no studies to date have examined let-7 function in
autochthonous tumors, which allows the evaluation of the roles of let-7 in tumor initiation and
progression. Here we have used constitutive and inducible expression of let-7 to examine its
effect on tumor development.
Results
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Let-7g Impairs Tumor Cell Proliferation and Promotes Tumor Cell Death in vitro. To
assess the roles of the let-7 miRNA on cell cycle control and cell death, we transfected a let-7g
miRNA duplex into murine K-RasGl 2 D-expressing lung adenocarcinoma cells (LKR13).
Consistent with previous studies (Johnson et al., 2007; Lee and Dutta, 2007), transfected let-7g
triggered a significant shift in the cell-cycle distribution, with an accumulation of Go/G - and
G2/M-phase cells and a corresponding reduction of S-phase cells (Figure 4.1A). In addition,
transfection of let-7g caused significant cell death in LKR13 cells (Figure 4. 1B). To extend these
findings, we developed a doxycycline (dox)-regulated expression system to induce miRNA
expression in cell lines. Using the inducible vector system, we observed a substantial
(approximately five-fold) induction of let-7g in the presence of dox (Figure 4.2B). Furthermore,
induction of let-7g in LKR13 cells caused a robust decrease in cell density (Figure 4.2A).
Overall, these results indicate that let-7g can restrict cellular proliferation and induce cell death.
Let-7g Suppresses Tumorigenesis in vivo. The LKR13 cells with inducible let-7g were
transplanted into immune-compromised mice to which dox was administered in the drinking
water. Using this system, we observed a substantial reduction in tumor growth in mice following
induction of let-7g compared to controls; induction of miR-15b, though putatively described as a
tumor suppressor in CLL (Cimmino et al., 2005), did not alter tumor growth in this system
(Figure 4.3A). Importantly, this reduction in tumor growth was dependent upon induction of let-
7g, as transplantation of the same cells into animals without dox treatment led to rapid tumor
development (Figure 4.3B). Interestingly, tumors with ectopic let-7g expression, although
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Figure 4.1 Let-7 activity impairs proliferation and enhances cell death in vitro. (A-B)
LKR13 cells were transfected with duplex small RNA corresponding to controls or mmu-let-7g
(see Supporting Information for details), fixed and stained with 7-AAD (A) or the ApoptestT -
FITC kit (B), and analyzed by flow cytometry. Values are mean +/- s.d. *: p<0.0005, **:
p<5x10-5; #: p<0.01; ##: p<0.05. (C) LKR13 cells were transfected with miRNA sponges
corresponding to no sites (empty), miR-16, or the let-7 family. Cells were then fixed and stained
with propidium iodide and analyzed by flow cytometry. Values are mean +/- s.d.
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Figure 4.2
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Figure 4.2 Let-7g impairs proliferation and enhances cell death. (A) LKR13-Tet-On-KRAB-
TE-empty and -let-7g cells were plated (5x 105 cells/plate). Twelve hours later, cells were placed
in the presence/absence of 5 tg/ml doxycycline. Forty-eight hours later, images were taken by
phase contrast microscopy. (B) Small RNA Northern blotting was performed against let-7g and
Glutamine tRNA in LKR13-Tet-On-KRAB-TE-empty, -miR-15b, and -let-7g (see Supporting
Information for details) cells in the presence/absence of 5 tg/mL doxycycline.
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Figure 4.3 Let-7g suppresses tumorigenesis in vivo. (A) LKR13 cells with Tet-On-KRAB-TE-
empty, -miR-15b, and -let-7g cells were plated in the presence of 5 gg/ml doxycycline. Twenty-
four hours later, cells were sorted and injected subcutaneously into immune-compromised mice
(2.5x 1 04 cells/injection). Two days later, mice were treated with drinking water containing
doxycycline (2 mg/mL) and sucrose (4% w/v) and tumor values were measured over time.
Values are mean +/- s.e.m. (n=6). (B) LKR13-Tet-On-KRAB-TE-let-7g cells were treated with
doxycycline, sorted, and injected as described above. Two days later, mice were treated with
either drinking water containing doxycycline (2 mg/mL) and sucrose (4% w/v) or drinking water
containing sucrose alone. Tumor values were measured over time. Values are mean +/- s.e.m.
(n=6). (C-E) Tet-On-KRAB-TE-let-7g cells were generated in A549 (C), Calu-1 (D), and H1650
(E) cells. Cells were prepared and injected (106 cells/injection) into immune-compromised mice.
Mice were treated and tumors were measured as above. Values are mean +/- s.e.m. (n=6).
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smaller in size, were more advanced than controls, demonstrating widespread invasion into
surrounding muscle (Figure 4.4). The steady-state levels of let-7g and miR-15b miRNAs were
substantially induced in tumors grown in the presence of dox (Figure 4.5A and Figure 4.6). This
induction was correlated with a decrease in Ras family members and HMGA2, previously
characterized targets of the let-7 family (Figure 4.5B) (Johnson et al., 2005; Lee and Dutta, 2007;
Mayr et al., 2007).
While let-7g induction suppressed tumor growth, tumors did eventually form in
the presence of dox. In order to assess the growth of let-7g-expressing tumors, we explanted
tumors and tested them in secondary transplants. Secondary transplants of let-7g tumors that
developed in the presence of dox grew at a similar rate as controls (Figure 4.7A). These tumors
generally had significant levels of let-7g, though the degree of induction varied (Figure 4.7B).
These results demonstrate that while let-7g expression suppresses tumor growth, tumors can
form in the presence of high levels of let-7g. Furthermore, the tumors eventually propagate
similarly to controls, suggesting that cancer cells may become resistant to the tumor suppressive
functions of let-7g.
We then examined the effect of let-7g induction on established tumors. Tumors were
allowed to grow to 30 mm 3 prior to addition of dox. This treatment led to a slight reduction in
tumor growth rate but did not cause tumor regression (Figure 4.8A). As expected, there was a
substantial induction of the corresponding miRNAs in these tumors, suggesting that the absence
of tumor regression was not due to the failure to induce let-7g (Figure 4.8B).
Let-7g Potently Suppresses Mutant K-Ras-Driven Non-Small Cell Lung Tumorigenesis in
vivo. To extend let-7g-mediated tumor suppression to human cells, we introduced the dox-
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Figure 4.4
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Figure 4.4 Let-7g does not alter tumor invasion. Hematoxylin/eosin staining of LKR13-Tet-
On-KRAB-TE-empty, -miR-15b, and -let-7g tumors treated with doxycycline in the drinking
water as described in Figure 4.3A. Original magnification, 20X. M, skeletal muscle. T, tumor
cells.
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Figure 4.5 Let-7g induced tumors maintain overexpression and target suppression. (A)
Small RNA Northern blotting was performed against let-7g and Glutamine tRNA in LKR13-Tet-
On-KRAB-TE-empty and -let-7g tumors generated from mice treated with or without
doxycycline in the drinking water as described above. (B) Western blotting was performed in
LKR13-Tet-On-KRAB-TE-empty and -let-7g tumors generated from mice treated with
doxycycline in the drinking water as described above.
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Figure 4.6 Induced tumors maintain miRNA overexpression. Small RNA Northern blotting
was performed against let-7g, miR-15b, and Glutamine tRNA in LKR1 3-Tet-On-KRAB-TE-
miR-15b and -let-7g tumors generated from mice treated with doxycycline in the drinking water
as described in Figure 4.3A.
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Figure 4.7 Let-7g does not suppress growth of induced tumors in secondary transplants.
(A) Mice were injected (2.5x10 4 cells/injection) with LKR13 cells with Tet-On-KRAB-TE-miR-
15b and -let-7g cells, and treated with doxycycline in the drinking water as previously described.
Tumors were then explanted, re-treated for 24 hours with doxycycline (5 gg/mL), sorted, and
injected (2.5x10 4 cells/injection) and mice were treated with doxycycline in the drinking water as
previously described. Tumors were then measured over time. Values are mean +/- s.e.m. (n=6).
(B) Small RNA Northern blotting was performed against let-7g, miR-15b and Glutamine tRNA
in LKR13-Tet-On-KRAB-TE-miR-15b and -let-7g tumors generated as described above.
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Figure 4.8 Let-7g expression in established tumors slows tumor growth without regression.
(A) Mice were injected with LKR13-Tet-On-KRAB-TE-empty, -miR-15b, and -let-7g cells
(2.5x 104 cells/injection) and monitored for tumors. Once tumors were greater that 2 mm in
diameter, mice were intraperitoneally injected with doxycycline (40 mg/kg) and tumors were
measured over time. Values are mean +/- s.e.m. (n=6). (B) Small RNA Northern blotting was
performed against let-7g, miR-15b and Glutamine tRNA in LKR13 cells with Tet-On-KRAB-
TE-empty, -miR-15b, and -let-7g tumors generated from mice treated with doxycycline in the
drinking water as described above.
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inducible miRNA system in a series of human NSCLC lines. Two of the NSCLC lines contain
activating mutations in K-Ras (A549 and Calu-1), while one does not (H1650). In all three
NSCLC lines, control miRNA induction had no effect on tumor growth (Figure 4.9). In the K-
Ras mutant NSCLC lines, let-7g induction triggered near-complete suppression of tumor
formation (Figure 4.3C and D). In contrast, let-7g induction caused only a partial reduction in the
rate of tumor growth in the non K-Ras mutant NSCLC line (Figure 4.3E). This indicates that
tumor suppression is somewhat mutation-specific, as the let-7g-mediated reduction in tumor
growth is stronger in tumors driven by mutant K-Ras than those containing wild-type K-Ras.
Let-7g-Mediated Tumor Suppression is Rescued Substantially by Mutant K-Ras. In order to
determine which mRNA targets of let-7 are germane to its ability to suppress non-small cell lung
tumorigenesis, we ectopically expressed mutant K-Ras (K-RasG12 D) and HMGA2 in LKR13 cells
containing the dox-inducible miRNA system (Figure 4.10A). Of note, each protein was
upregulated modestly in the presence of enhanced expression of the other protein, suggesting
mutual activation of these let-7 targets. Importantly, the expression vectors for K-RasGl 2D and
HMGA2 lack their corresponding 3' UTRs, uncoupling the mRNA targets from direct let-7-
mediated repression.
When these cells were transplanted into immune compromised mice, we observed potent
let-7g-mediated tumor suppression in controls (Figure 4.11A). As shown in Figure 4.10B,
ectopic K-RasG12D led to substantial, though not complete, rescue of tumor growth in the face of
increased let-7g levels. In cells expressing ectopic HMGA2, there was a less robust rescue of
tumor growth (Figure 4. 10C). There were also no changes in tumor growth rate in cells over-
expressing miR- 15b upon ectopic expression of activated K-Ras or HMGA2 (Figures 4.11B and
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Figure 4.9 MiR-15b does not suppress non-small cell lung tumorigenesis. (A-C) Tet-On-
KRAB-TE-miR-15b cells were generated in A549 (A), Calu-1 (B), and H1650 (C) cells. Cells
were prepared and injected (106 cells/injection) into immune compromised mice. Mice were
treated and tumors were measured as above. Values are mean +/- s.e.m. (n=6).
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Figure 4.10 K-RasCG 2D substantially rescues let-7g mediated tumor suppression. (A)
LKR13-Tet-On-KRAB-TE-miR- 15b and -let-7g cells were infected with pBabe.Zeo.empty, K-
RasG12D, and HMGA2 and Western blotting was performed. (B-C) LKR13-Tet-On-KRAB-TE-
let-7g cells infected with pBabe.Zeo.K-RasGl2D (B) or HMGA2 (C) were prepared and injected
(106 cells/injection) into immune-compromised mice. Mice were treated and tumors were
measured as above. Values are mean +/- s.e.m. (n=6).
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Figure 4.11 K-RasCG 2D does not alter miR-15b mediated tumor growth. (A) LKR13-Tet-On-
KRAB-TE-let-7g cells infected with pBabe.Zeo.empty were prepared and injected (106
cells/injection) into immune-compromised mice. Mice were treated and tumors were measured
as above. Values are mean +/- s.e.m. (n=6). (B-C) LKR13-Tet-On-KRAB-TE-miR-15b cells
were infected with pBabe.Zeo.empty (B), K-RasGl2 D (B), or HMGA2 (C). Cells were prepared
and injected (106 cells/injection) into immune-compromised mice. Mice were treated and tumors
were measured as above. Values are mean +/- s.e.m. (n=6).
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C). Overall, these results suggest that mutant K-Ras plays a key role in let-7g--mediated tumor
suppression. However, the rescue of tumor growth was incomplete, suggesting that other let-7
targets, likely including HMGA2, are also relevant for let-7g-mediated tumor suppression.
Let-7g Suppresses Tumor Initiation in an Autochthonous NSCLC Model. We next
examined the tumor suppressive effect of let-7g in naturally arising lung tumors in the mouse.
When infected with Cre-expressing virus in the lung epithelium, KrasLSL-GI 2D; Trp53floxflx mice
develop highly aggressive NSCLC following a well-defined time course (Jackson et al., 2005).
These lesions recapitulate advanced human lung adenocarcinoma in many ways, including
stromal desmoplasia. To deliver let-7g to the lung epithelium, we generated a lentiviral vector
co-expressing let-7g or a seed-mutant version of let-7g (let-7g sm) with Cre using a dual-
expression system (Figure 4.12A). This vector generated substantial expression of let-7g and let-
7g sm relative to controls in cultured cells (Figure 4.12B). In addition, let-7g expressed from this
vector caused robust repression of a reporter through the K-Ras 3' UTR, which was not observed
with the seed mutant of let-7g (Figure 4.13).
KrasLSL-G12D; Trp53ox/flox mice were infected with let-7g- and let-7g sm-containing
lentiviruses, and effects on tumor development were determined by visual inspection and
histological analysis. We observed a significant reduction in both lung tumor number and tumor
area following infection with the vector expressing let-7g versus controls (Figure 4.12C and D).
In addition, there was a slight decrease in average tumor size in let-7g expressing mice (Figure
4.12E). The levels of let-7g and let-7g sm expression in these tumors were determined by
Northern blotting. Consistent with findings in xenograft tumors, there was sustained
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Figure 4.12 Let-7g suppresses tumor initiation in an autochthonous NSCLC model. (A)
Diagram of the Puro.Cre lentiviral vector for co-expression of let-7g/let-7g sm with Cre
recombinase. (B) Small RNA Northern blotting was performed against let-7g (both wild type and
seed mutant), miR-17 and Glutamine tRNA in HEK293 cells infected with Puro.Cre (empty),
Puro.let7gsm.Cre (let-7g sm), and Puro.let7g.Cre (let-7g). (C-E) KrasLSL-12D; Trp5flr /fox mice
were intratracheally infected with the Puro.Cre lentiviral vectors described above. Twelve weeks
post-infection, animals were sacrificed and tumor number (C), tumor and lung area (D), and
tumor size (E) were quantified with Bioquant software. Values are mean +/- s.e.m. (n=9 for
empty, n=l 1 for let-7g, and n=l 1 for let-7g sm). *: p<0.0005, #: p<0.01; ###: p<O.1. (F) Small
RNA Northern blotting was performed against let-7g (both wild type and seed mutant) and
Glutamine tRNA on lung tumors generated from KrasLSL-Gl2D; Trp53floX/flox mice infected with
Puro.Cre (empty), Puro.let7g.Cre (let-7g), and Puro.let7gsm.Cre (let-7g sm). (G) Western
blotting was performed on lung tumors generated from KrasLS G12D; Trp53f/ox/lox mice infected
with Puro.Cre (empty), Puro.let7g.Cre (let-7g), and Puro.let7gsm.Cre (let-7g sm).
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Figure 4.13 Let-7g-expressing lentiviral vectors functionally repress the K-Ras 3' UTR.
Luciferase assays were performed in HEK293 cells transfected with Puro.Cre (empty),
Puro.let7g.Cre (let-7g), and Puro.let7gsm.Cre (let-7g sm) and pRL-TK containing bulged
siCXCR4 binding sites (CXCR4), a wild-type murine K-Ras 3' UTR (K-Ras), or a murine K-Ras
3' UTR with mutations in the let-7 binding site (K-Ras let-7 mutant) (Kumar et al., 2007).
Firefly luciferase (pGL3) was used as a transfection control. Expression was normalized to pGL3
levels and subsequently normalized relative to CXCR4 and empty expression. Values are mean
+/- s.d. (n=6) with propagated error.
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overexpression of let-7g and let-7g sm in tumors from mice infected with the corresponding
lentiviruses (Figure 4.12F). Moreover, these let-7g overexpressing tumors have reduced protein
levels of N-Ras, K-Ras, and HMGA2, indicating functional repression of known let-7 targets
(Figure 4.12G). In total, these findings suggest that let-7g effectively suppresses tumor initiation
in an autochthonous mouse model of mutant K-Ras--driven NSCLC. However, the tumors that
do form continue to express let-7g and suppress known targets, supporting the conclusion that
naturally arising tumors may gain resistance to let-7g.
Discussion
In this study we investigated the functional consequence of let-7g expression on non-small cell
lung tumorigenesis. Utilizing both inducible and constitutive expression systems, we observed
substantial tumor suppression by let-7g both in xenografts and in a mouse lung tumor model.
Two lines of evidence suggest that let-7g-mediated tumor suppression is representative of the
let-7 family. First, transfection of other let-7 family members caused comparable induction of
cell death to let-7g (data not shown). Second, transfection of a miRNA sponge (Ebert et al.,
2007) targeting the entire let-7 family shifted the cell cycle distribution opposite to let-7g
overexpression, with a significant reduction of Go/GI-phase cells and a corresponding increase in
S- and G2/M-phase cells (Figure 4. 1C).
Previous studies of the effect of let-7 on cellular proliferation have used cells containing
activating mutations in K-Ras (A549) and N-Ras (H1299 and HepG2) (Johnson et al., 2007; Lee
and Dutta, 2007). As both K-Ras and N-Ras are previously characterized targets of the let-7
family, it was possible that the effects of let-7 on proliferation in these cell lines were due largely
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to downregulation of the Ras family. In the present study, we determined that K-RasG l 2D_
mediated rescue of tumor growth was not complete, suggesting that other let-7 targets are also
relevant to tumor suppression. In sum, these findings suggest that let-7-mediated tumor
suppression occurs largely, though not completely, through regulation of the Ras family.
While let-7g expression potently suppressed non-small cell lung tumorigenesis, tumors
inevitably formed in the presence of sustained let-7g induction. Notably, these tumors continued
to express let-7g and actively repressed let-7 targets, suggesting the tumors that form do not
propagate because of silencing of the let-7g vector. Moreover, this continued let-7g expression
occurred both in xenograft models and autochthonous lung tumors expressing let-7g. This
apparent resistance to let-7 was not observed in previous studies (Johnson et al., 2007; Lee and
Dutta, 2007), as they relied upon transient delivery of let-7 family members. This distinction
highlights the importance of stable induction of let-7 when analyzing its role in tumorigenesis,
since transient expression of let-7 does not recapitulate the long-term effects of let-7 on
tumorigenesis in vivo.
While we cannot exclude the possibility that the let-7g target repression observed here
was insufficient to suppress tumorigenesis, the apparent resistance to let-7g expression has
significant implications for the use of let-7 miRNAs as a therapeutic agent. Our data indicate that
sustained let-7 delivery might lead to initial suppression of tumor growth but that let-7-resistant
tumors might eventually emerge. Using the systems described here, one could probe downstream
pathways from let-7 targets, including Ras, HMGA2, and others, to assess their roles in let-7-
resistant tumors. Additionally, expression analysis of sensitive and resistant tumors might reveal
novel pathways functionally related to let-7 resistance.
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Here we describe one of the first cases of a miRNA family functioning as a tumor
suppressor in vivo. Our findings make clinically relevant predictions related to the use of let-7-
based therapeutic agents in NSCLC. The systems outlined in this study provide insight into let-
7-mediated tumor suppression and also establish unique tools for understanding the basis for
resistance of cancer cells to miRNA-mediated control of tumorigenesis. Moreover, the
doxycycline-based and lentiviral systems described could be applied to examine other small
RNAs suggested to function in tumorigenesis.
Materials and Methods
Cell Culture. Human cell lines (HEK293, A549, Calu-1, and H1650) were originally obtained
from ATCC. 3TZ cells were described previously (Psarras et al., 2004). LKR13 cells have been
described previously (Wislez et al., 2006). Cells were grown under standard conditions. After
introduction of pTE vectors, cells were maintained under standard conditions in Tet-Free Serum
per manufacturer's instructions (Clontech).
Cell Cycle and Cell Death Analysis. MicroRNA duplex sequences were transfected in triplicate
into LKR13 cells with DharmaFECT- 1 (Dharmacon) according to manufacturer's protocol. Cells
were harvested after 48 and 72 hours and either fixed in methanol and stained with 7-AAD
(Stem-Kit reagent, Beckman Coulter, Miami, FL) or stained using the ApoptestT M-FITC kit
(Nexins Research, Kattendijke, Netherlands) and analyzed by flow cytometry.
Lentivirus Production and Infection. Lentivirus production was performed as described
(Rubinson et al., 2003).
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Allograft/Xenograft Studies. Tet-On-KRAB-TE cells were treated for 24 hours with
doxycycline (5 [tg/mL) and sorted by flow cytometry. BalbC/Nu males (Taconic) were injected
with cells as described (Sage et al., 2000). Two days after injection, mice were treated with
drinking water containing doxycycline (2 mg/mL) and sucrose (4% w/v). Tumor sizes were
measured every two days. After indicated days, mice were sacrificed and tumors were isolated
for histology, Western and Northern blot analysis.
Intervention Studies. Mice were injected with LKR13-Tet-On-KRAB-TE cells and monitored
for tumors. Once tumors were greater that 2 mm in diameter, mice were intraperitoneally
injected with doxycycline (40 mg/kg) and tumors were measured as above.
Secondary Transplant Studies. Mice were injected with LKR13-Tet-On-KRAB-TE cells and
treated with doxycycline in the drinking water as above. Tumors were then explanted, re-treated
for 24 hours with doxycycline (5 [g/mL), and sorted by flow cytometry. Cells were then injected
and mice were treated with doxycycline in the drinking water as above. Tumor sizes were
measured every two days. After indicated days, mice were sacrificed and tumors were isolated
for Northern blot analysis.
Genetically Engineered Mice. KrasL SL -G I2D; Trp5 sfoox mice were generated as described
previously (Jackson et al., 2005).
Intratracheal Infection and Tumor Analysis. KrasSL-12D; Trp5 fl x/f  mice were infected
intratracheally with Puro.Cre lentivirus essentially as described (Murphy et al., 2006). Tumor
analysis was performed as described (Kumar et al., 2007).
Cell-Cycle and Cell Death Analysis. MicroRNA duplex sequences were designed for mmu-let-
7g (miRBase); the siGLO Cyclophilin B siRNA; and the miRIDIAN mimic control microRNA
#1 (Dharmacon, Perbio Science, Erembodegem, Belgium).
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Sponge treatment and Cell-Cycle Analysis. One day after plating in 24-well dishes, LKR-13
cells were transfected in triplicate with MSCV-puro empty vector, miR-16 sponge, or let-7
sponge using Lipofectamine2000. The next day the samples were enriched for transfected cells
by treatment with 5 gg/ml puromycin for 32 hours. The samples were placed in DMEM without
puromycin for 16 hours and harvested for fixation with Triton X-100 and staining with
propidium iodide at 72 hours post-transfection. Stained samples were analysed by flow
cytometry. Cell cycle profiles were analysed with ModFit software. The experiment was
performed three independent times.
Western Blotting. Tumor cell extracts were fractionated on 4%-20% SDS-polyacrylamide
gradient gels (Biorad) and transferred to Hybond-C membranes (Amersham). Membranes were
blocked with 5% milk in PBS and then incubated with the indicated antibody. Antibodies K-Ras
(sc30), N-Ras (sc31) from Santa Cruz Biotechnology, Pan-Ras (Upstate), HMGA2 (kind gift of
Dr. M. Narita), and f3-Actin (A5441) from Sigma were detected using HRP-conjugated antisera
(Amersham) and chemiluminescence.
Northern Blotting. Total RNA was extracted using TRIZOL reagent (Invitrogen, Carlsbad, CA)
according to manufacturer's protocol. Samples containing 20 gg total RNA and diluted in Gel
loading buffer II (Ambion, Applied Biosystems, Austin, TX) were loaded on a 15% denaturing
polyacrylamide gel (National Diagnostics) and separated at 35 Watt for 2 h. RNA was semi-dry
blotted using Brightstar Plus positively charged nylon membranes (Ambion, Applied
Biosystems, Austin, TX) at 350 mA for 2 hours. The blots were UV cross-linked and hybridized
with 5'-end y-radiolabeled antisense probes to let-7g (5'-ACTGTACAAACTACTACCTCA-3'),
let-7g sm (5'-ACTGTACAAACTACTAGGTCA-3'), miR-15b (5'-TGTAAACCATGA-
TGTGCTGCTA-3'), miR-17 (5'-CTACCTGCACTGTAAGCACTTTG-3'), and Glutamine
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tRNA (5'-TGGAGGTTCCACCGAGAT-3') at 370 C in ULTRAhyb®-Oligohybridization buffer
(Ambion, Applied Biosystems, Austin, TX) according to the manufacturer's protocol. All
Northern blots involving let-7g with Puro.Cre lentiviruses used let-7g sm probe mixed equally
with let-7g probe. Signals were visualized on a Phospho-Imager.
Lentivirus Production and Infection. Lentiviral pTE-empty, pTE-miR-15b, pTE-let-7g,
Puro.Cre, Puro.let-7g.Cre, and Puro.let-7gsm.Cre vectors were co-transfected with packaging
vectors into HEK293 cells with Fugene-6 transfection reagent (Roche Applied Sciences,
Indianapolis, IN). Virus was concentrated as described (Kissler et al., 2006). For pTE vectors,
virus was diluted in media containing polybrene (10 gg/mL) and added to Tet-On-KRAB cells.
Tet-On-KRAB cells were selected on puromycin to generate Tet-On-KRAB-TE-empty, Tet-On-
KRAB-TE-miR-15b, and Tet-On-KRAB-TE-let-7g cells. For Puro.Cre vectors, virus was
resuspended in HBSS and titrated by infection onto 3TZ cells and subsequent LacZ staining as
described previously (Psarras et al., 2004). Puro.Cre viral titers were normalized before
intratracheal delivery.
Luciferase Assays. Luciferase assays were performed as described previously (Doench et al.,
2003).
Tet-On-KRAB Cells. Retrovirus was produced as previously described (Cherry et al., 2000).
LKR13, A549, Calu-1, and H1650 cells were infected with pRevTet-On (BD Biosciences
Clontech, Carlsbad, CA) virus and selected on 500 .tg/mL G418 to generate Tet-On cells. Tet-
On cells were infected with pBABE-CMVtetRKRAB virus and selected on 100 tg/mL
hygromycin to generate Tet-On-KRAB cells.
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Tet-On-KRAB-TE-Zeo Cells. pBabe.Zeo.empty, K-RasGl 2D, and HMGA2 retroviruses were
produced and infected into LKR13-Tet-On-KRAB-TE-miR-15b and -let-7g cells and selected on
500pg/mL zeocin to generate Tet-On-KRAB-TE-Zeo cells.
Construct Design
Sponge vectors. Sponge MicroRNA binding sites for miR-16 or let-7 were cloned into MSCV-
puro with XhoI and Hpal as described previously (Ebert et al., 2007). The miR-16 sponge
contains nine bulged sites of sequence CGCCAAUAUUCUAUGCUGCUA; the let-7 family
sponge contains six bulged sites with alternating sequences AACUAUACAAGGACUACCUCA
and AACUAUACAAUGACUACCUCA.
pBabe-CMVtetRKRAB. The CMVtetRKRAB vector (Deuschle et al., 1995) was cut with
EcoRI and HpaI and the insert fragment was blunted by Klenow and cloned in the Snabl-site of
pBabe-Hygro generating pBabe-CMVtetRKRAB.
pTE-miR. PGK-PURO was amplified from pSM2C (Paddison et al., 2004) with pgkpuro-f (5'-
AGCGGCCGCAATTCTACCGGGTAGGGGA-3') and pgkpuro-r (5'-
ACAATTGTCAGGCACCGGGCTTGC-3'), cut with NotI and Mfel and cloned in the Notl-
MfeI fragment of the PUV1 lentiviral vector (courtesy of Dr. P. Stern). EGFP was amplified with
EGFPSallkozak: 5'-AGTCGACGCCACCATGGTGAGCAAGGGCGAGGA-3' and
EGFPBXM-linker: 5'-TTCAATTGTGTGCTCGAGTGTGGGATCCTTACTTGTACAGCTCG-
TCCATGCCG-3' and cloned in pCR2. 1-TOPO vector (Invitrogen, Carlsbad, CA). PCR2. 1-
TOPO-EGFP was cut with EcoRV and Spel, and the EGFP-fragment was cloned in Smal-Nhel
sites of pTRE-tight (BD Biosciences Clontech, Carlsbad, CA). pTRE-tight-EGFP was cut with
SSP1, blunted by Klenow and digested with NotI. This fragment was cloned in the blunted
BamHI-site and NotI sites of PUV 1-Puro resulting in pTE-EGFP. MicroRNA sequences were
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amplified with Let-7gF (5'-CACACTCGAGCAATTCTCCAAATATGGTAAAGATGAGGC-
3'), Let-7gR (5'-CACAGAATTCAAACGGTTTATCTGAACAACTCCAAGC-3') and miR-
15bF (5'-CACACTCGAGGGAGATGATTACGAAGTCCTTCCTAACA-3'), miR- 15bR (5'-
CACAGA-ATTCCCCTGTCACACTAAAGCAGCACAAT-3'), cut with EcoRI and XhoI and
cloned in equivalent sites of pTE-EGFP.
pBabe.Zeo.K-RasGl2D/HMGA2. The ORF of murine K-Ras4BGI 2D was amplified from a
luciferase fusion expression vector (courtesy of P. Sandy) using K-RasF (5'-
GACGGATCCATGACTGAGTATAAACTTGTG-3') and K-RasR (5'-
GAAGAATTCTCACATAACTGTACACCTTGTCC-3'). The ORF of human HMGA2 was
amplified from a pcDNA expression vector provided by C. Mayr (Mayr et al., 2007) using
HMGA2F (5'-TAAGGATCCATGAGCGCACGCGGTGAG-3') and HMGA2R (5'-
GCGGAATTCCTAATCCTCCTCTGCGGACTCTTG-3'). Both products were cut with BamHI
and EcoRI and cloned into pBabe.Zeo (Addgene).
Puro.Cre. Puro.Cre was initially generated by amplification of PuroR from MSCV.Puro
(Clontech) with PuroF (5'-CGCTGCGCCGAATTCATGACCGAGTACAAGCCCACG-3') and
PuroR (5'-TAAGCGGCCGCTCGAGTCAGGCACCGGGCTTGCGGGTC-3'), digestion with
EcoRI and NotI and cloning into UbC.Luciferase.PGK.Cre (courtesy of M. Dupage) to generate
Puro.Cre. Let-7g was amplified from murine genomic DNA with purolet7gF (5'-
GTGGCGCTCGAGAATATATATAAATGACTGGTGTATTTC-3') and purolet7gR (5'-
TAGCGGCCGCGAACCCTTCTATATATTCTG-3'), digested with Xhol and NotI and cloned
into Puro.Cre to generate Puro.let7g.Cre. Puro.let7gsm.Cre was generated by two rounds of site-
directed mutagenesis of Puro.let7g.Cre with mutlF (5'-
GATTCCAGGCTGACCTAGTAGTTTGTACAGTTTGAGGGTCTATGATAC-3'), mutl R (5'-
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GTATCATAGACCCTCAAACTGTACAAACTACTAGGTCAGCCTGGAATC-3'), mut2F
(5'-CAGGAGATAACTGTACAGGCCACTGGGTTGCCAGGAAC-3'), and mut2R (5'-
GTTCCTGGCAACCCAGTGGCCTGTACAGTTATCTCCTG-3').
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CHAPTER 5: Discussion
216
Overview
Here I have described a series of observations on the widespread and specific role of
microRNAs (miRNAs) in cancer. First, we found that the global loss of miRNAs in mammalian
cancers is not merely a consequence of altered differentiation, but that this global loss of
miRNAs functionally enhances cellular transformation and tumorigenesis. Second, one putative
mechanism by which this loss of miRNAs occurs is incomplete loss of Dicer], as it functions as
a haploinsufficient tumor suppressor in mammalian cancers. Finally, a specific miRNA family
called let-7 plays an important role in the development of non-small cell lung cancer by
suppressing a wide collection of mRNA targets, including K-Ras and HMGA2. Overall, these
data suggest that miRNAs have the potent capacity to inhibit tumorigenesis, and that individual
miRNA families can act specific tumor suppressors via suppression of discrete sets of
oncogenes. Moreover, they suggest that enhancing either the miRNA processing pathway or
ectopic expression of known tumor suppressive miRNAs might provide a novel therapeutic
avenue.
Global loss of miRNAs in cancer
Using a bead-based miRNA profiling strategy, it was shown that, when compared to
normal tissues, the steady-state levels of many miRNAs were reduced in human cancers (Lu et
al., 2005). Moreover, this global down-regulation of miRNAs in tumors also occurred in a mouse
model of mutant K-Ras--driven lung cancer, suggesting that this effect was generally relevant to
mammalian cancer. Initially, this widespread loss of miRNAs was believed to be a mere
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consequence of altered differentiation in cancer cells. This possibility was based upon changes in
miRNA abundance being reversible in response to differentiation in vitro. Notably, this
reversibility suggests that the loss of miRNAs could not be due to a complete loss of miRNA
biogenesis in tumors, as this miRNA production could be induced. In total, these findings led to
the idea that the loss of miRNAs in cancer was only an effect of transformation and not
functionally important for the disease.
In Chapter 2, I have shown that the global loss of miRNAs does play a functionally
relevant role in oncogenesis, as impaired processing of miRNAs enhanced cellular
transformation and tumorigenesis (Kumar et al., 2007). This was a general phenomenon of
mammalian cancers, as it occurred in both mouse and human cancer cells exhibiting a variety of
genetic changes. Moreover, it appeared to be an effect of the miRNA processing pathway and
'not simply individual genes, as depletion of three distinct components of the pathway (Dicerl,
Drosha, and DGCR8) produced comparable effects on transformation. Notably, impaired
processing of miRNAs only cooperated with cells that were fully transformed; partially
transformed cells received no benefit from impaired miRNA processing. In fact, untransformed
cells actually exhibited proliferative defects in response to inhibited miRNA maturation. This
likely explains why germline heterozygous mutations of miRNA processing components are
neither tumor prone in animal models nor observed in human cancer predisposition syndromes,
since mutation of these components as an initiating event would likely be deleterious to tumors.
The enhanced transformation seen with impaired miRNA maturation led to
overexpression of several oncogenes, including K-Ras and c-Myc, known to be regulated by
miRNAs like let-7. While several miRNAs were shown to be specifically down-regulated in cells
depleted for processing, it was unclear which miRNAs contribute to the tumor suppressive effect
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observed. Most likely, the combined loss of multiple miRNA families plays a role in the
enhanced tumorigenesis observed, complicating traditional loss of function genetic analyses.
Beyond this, it was found that inhibiting miRNA biogenesis caused an increased tumor
burden in an autochthonous model of K-Ras driven lung cancer, as KrasLSL-G12D mice either
heterozygous or homozygous conditional for Dicerl had an elevated tumor area as a fraction of
total lung compared to KrasLSL-G12D mice wild type for Dicer]. This increased tumor burden was
largely due to increases in tumor number in Dicerl mutant animals, suggesting that Dicerl
mutation, when combined with known oncogenes, promotes tumor initiation. Notably, while
Dicerl mutant animals had a modest increase in average tumor grade, this was likely due to the
increased number of lung tumors. Overall, these data provide important support for the role of
miRNA processing in suppressing tumor development in naturally arising tumors.
One concern about these findings is the series of observed miRNAs which appear to
function as oncogenes (He et al., 2005; Ma et al., 2007; Tam et al., 2002; Voorhoeve et al.,
2006). The results presented do not conflict with these reports, as not all miRNAs exhibit
comparable reductions with impaired processing. Moreover, none of the miRNAs described as
oncogenes were significantly repressed with inhibition of miRNA processing. It is intriguing to
speculate that oncogenic miRNAs might actually be up-regulated in tumors with impaired
miRNA processing, as reduced miRNA biogenesis might lead to more efficient processing of
oncogenic pre-miRNAs. However, the data presented in Chapter 3 suggests that there is not such
up-regulation of these oncogenic miRNAs with impaired processing. Overall, these results
indicate that, while some miRNAs likely function as oncogenes, the widespread loss of miRNAs
in cancer is tumor suppressive.
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Dicerl haploinsufficiency
As described above, it was previously shown that the global loss of miRNAs in human
cancer is not merely a consequence of tumorigenesis, but in fact functionally promotes
oncogenic transformation. However, in Chapter 3, I examined survival in K-Ras--driven lung
tumor-bearing mice either wild type, heterozygous, or homozygous conditional for Dicerl and
made a surprising observation. While both heterozygous and homozygous Dicerl conditional
mice exhibited reduced survival compared to wild type mice, animals heterozygous for
conditional Dicerl had a further reduction in survival compared to homozygous conditional
animals. This was notable, as traditional tumor suppressor genes work via inactivation of both
gene copies, leading to complete loss of function. In this situation, it appeared that such complete
loss of function was actually being selected against, since animals that should produce tumors
with partial loss of Dicerl fared worse than those animals that should produce tumors with
complete loss of Dicerl. In total, these results suggested that Dicerl, unlike traditional tumor
suppressor genes, inhibited tumorigenesis via haploinsufficiency.
This haploinsufficiency was verified by genetic analysis of both lung tumor and sarcoma
cell lines. In these cells, tumors from Dicerl conditional heterozygous animals failed to lose the
wild type allele and tumors from Dicerl conditional homozygous animals underwent only partial
deletion of Dicerl. Moreover, we found that heterozygosity was necessary for Dicerl to function
as a tumor suppressor, since forced homozygous deletion of Dicerl was deleterious to tumor
growth. Finally, the haploinsufficiency of Dicerl found in genetically engineered mouse models
of cancer was in line with human cancer genome analyses, in which DICER1 undergoes frequent
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hemizygous deletion in a variety of tumor types but never undergoes homozygous loss. Thus,
DICER] functions as a haploinsufficient tumor suppressor gene.
While hemizygous deletion of DICER1 provides one mechanism by which miRNA
processing is impaired during tumorigenesis, several other possible mechanisms exist. First,
there might be comparable hemizygous deletions of additional members of the miRNA
processing pathway. Unfortunately, the deletions seen for DICER] are usually extremely large
(>1 megabase) and include several genes, making it difficult to ascribe functional importance to
loss of an individual gene's deletion. One way to show the specific contribution of a gene to
tumor suppression is evidence for specific mutations within the gene in cancers. This has been
shown for both DICER] and RNASEN (the gene encoding Drosha) in a limited number of human
ovarian cancers (Merritt et al., 2008). A more interesting example was seen in mismatch-repair
deficient colon cancers, in which TARBP2 (the gene encoding TRBP) frequently contains
heterozygous frameshift mutations (Melo et al., 2009). These mutations create premature stop
codons and cause a loss of TRBP function. Importantly, this loss of TRBP specifically promotes
tumorigenesis via loss of miRNA processing caused by destabilization of the Dicerl protein.
Beyond mutations, these components could undergo epigenetic changes within human
tumors, such as silencing via DNA methylation. Furthermore, inhibition of many miRNAs can
occur at the level of transcription. For example, the oncogenic transcription factor c-Myc was
shown to inhibit a variety of miRNAs by silencing of the promoter (Chang et al., 2008).
However, it must be noted that many miRNAs down-regulated in cancer do so without changes
to the levels of their primary miRNA transcripts, indicating changes in miRNA processing or
stability in human cancers (Thomson et al., 2006). Moreover, the miRNA processing pathway
could be inhibited post-transcriptionally, such as the mutual regulation of Drosha and DGCR8
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gene expression and the inhibition of Argonaute by prolyl hydroxylation (Han et al., 2009; Qi et
al., 2008). In the future, robust resequencing and copy-number analysis of miRNA maturation
pathway components will be necessary to establish firmly the mechanisms of global miRNA loss
in human cancers; however, studies should also be done to look at alternative means of inhibiting
miRNA processing in cancer as well.
In addition to understanding the mechanism of miRNA loss in human tumors, these
studies suggest a novel therapeutic target in human cancer. Specifically, activators of miRNA
processing have the potential to act as robust anti-cancer agents. In particular, since such
compounds would only target cells with inhibited miRNA processing, which has been shown to
occur in cancer cells relative to normal tissue, they would likely be well-tolerated and of limited
toxicity. One limitation to such small molecule screens is that many compounds able to activate
miRNA processing in a given cell type will do so only indirectly, via induction of differentiation;
thus, screening in a variety of cell types will be necessary. With that noted, a recent study has
discovered a small molecule that is able to activate the processing of small RNAs (Shan et al.,
2008). In this study, they found that the compound enoxacin promotes both siRNA-mediated
degradation of target mRNAs and endogenous miRNA maturation. Importantly, the compound
works via interaction with TRBP, demonstrating activation of the miRNA processing pathway,
and not simply cell type-specific differentiation. Overall, this compound indicates that it is
possible to find chemical enhancers of miRNA processing. Future studies should both perform
additional screening for small molecule miRNA processing activators and test these molecules in
cancer cells for the ability to inhibit transformation.
Let-7 and non-small cell lung cancer
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As one of the initially discovered miRNAs, let-7 was shown to regulate proliferation of
seam cells in the developing C. elegans embryo (Pasquinelli et al., 2000; Reinhart et al., 2000).
When orthologs of let-7 were discovered in mammals, it was posited that they could play an
important role in cancer development. In support of this, several let-7 family members were
shown to be down-regulated in a subset of non-small lung cancers, and it was shown that this
reduced let-7 expression correlated with a worse prognosis (Takamizawa et al., 2004; Yanaihara
et al., 2006). This notion was strengthened by results showing that let-7 regulates a variety of
oncogenes, including the Ras family, HMGA2, c-Myc, and numerous cell-cycle regulators
(Johnson et al., 2007; Johnson et al., 2005; Lee and Dutta, 2007; Mayr et al., 2007; Sampson et
al., 2007). However, there was a dearth of functional data showing that the let-7 family
suppressed tumorigenesis. This is largely due to the nature of the let-7 gene family in mammals,
of which there are twelve different let-7 family members at eight different locations in the
genome; this makes loss of function genetics practically impossible.
In Chapter 4 (with additional data in Appendix 1), I demonstrated that induced
overexpression of one of the let-7 family members, let-7g, potently suppressed tumor growth in
xenografts generated from several non-small cell lung cancer cell lines (Kumar et al., 2008).
Similar results were obtained by others using siRNA mediated delivery of let-7 to non-small cell
lung cancer cells (Esquela-Kerscher et al., 2008). In both studies, let-7 overexpression was
additionally able to suppress tumorigenesis in an autochthonous mouse model of K-Ras driven
lung cancer.
Notably, the findings in Chapter 4 indicate that let-7 mediated tumor suppression is
significantly more robust in non-small lung cancer cells driven by oncogenic K-Ras, suggesting
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the potential for genotype specificity. This idea is in line with the notion of oncogene addiction,
in which tumors require the function of a driving oncogenic lesion not only for tumor
development but for sustained tumor maintenance (Sharma and Settleman, 2007). In contrast,
while expression of an oncogenic K-Ras unable to be suppressed by let-7 partially rescued tumor
growth in response to let-7, it was not complete, and additional targets, like HMGA2, also
provide an incomplete rescue. Overall, this indicates that while mutant K-Ras is necessary for
potent let-7-mediated tumor suppression, it is not sufficient to bypass said tumor suppression.
Though the above studies indicate that let-7 overexpression can suppress tumorigenesis
in xenografts and tumor initiation in a genetically engineered mouse model of lung cancer, it was
not clear whether let-7 induction in established, naturally arising lung tumors would be able to
suppress tumor growth. To address this, I used a lentiviral vector to induce let-7 with
doxycycline in the above autochthonous lung cancer model (see Appendix 1). Using this system,
I observed potent tumor suppression at all time points after tumor initiation. Surprisingly, there
was a comparable degree of tumor suppression at all time points, but the form of tumor
suppression depended on the time of induction. Overall, these studies indicate that let-7 can
inhibit the growth of established lung cancers in vivo.
These findings provide significant evidence for let-7 functioning as a tumor suppressor in
non-small cell lung cancer. However, several important questions remain. First, the precise
mechanism by which let-7 becomes inhibited in cancer has not been determined. It has been
shown that let-7 family members are frequently in sites of deletion in human cancer, suggesting
the mechanism of DNA loss in tumorigenesis (Calin et al., 2004). In addition, c-Myc has been
shown down-regulate several let-7 family members (Chang et al., 2008). Interestingly, this Myc-
mediated repression of let-7 sets up a positive feedback loop, as let-7 has been shown to inhibit
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c-Myc. Finally, a series of reports has shown that the let-7 family is regulated at the level of pre-
miRNA processing by the Lin-28 family of oncogenic proteins (Heo et al., 2008; Newman et al.,
2008; Viswanathan et al., 2008). In fact, recent data suggests that Myc-mediated repression of
let-7 is in fact due to Myc-mediate up-regulation of Lin-28, which subsequently blocks let-7
processing (Chang et al., 2009). Taken together, these findings provide several ways by which
let-7 can be inhibited during tumorigenesis.
Beyond the mechanism of let-7 loss, it will be important to examine the loss of function
of let-7 in cancer models. As mentioned above, there are twelve let-7 family members within
eight gene loci in mammals. Thus, traditional gene targeting approaches appear impractical
towards the assessment of loss of function. An alternative approach to examining let-7 loss of
function is that of miRNA sponges, in which a synthetic miRNA binding site is overexpressed in
cells (Ebert et al., 2007). By binding endogenous miRNAs to the synthetic target, endogenous
mRNAs are released from miRNA-mediated repression, recapitulating loss of miRNA function.
Future studies should work towards development of let-7 family consensus sponges in order to
examine loss of let-7 function in development and tumorigenesis.
While such studies will provide insights into the role of let-7 in tumor development, the
described results make clear the potential for let-7 to be used as a therapeutic, as let-7 delivery to
established tumors is clearly able to cause suppression of tumorigenesis. In this therapeutic
context, miRNAs like the let-7 family have several distinct advantages. First, their synthesis is
relatively standardized and is comparable for any potential miRNA. Second, unlike many small
molecules, miRNAs have a clearly demonstrated mechanism of action. Third, unlike many small
molecules, a given miRNA has a computationally predictable set of predicted targets, even if the
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relevant targets may not be obvious. Finally, the capacity of a miRNA to suppress multiple
targets makes resistance at the level of individual targets significantly less likely.
MiRNA therapeutics in general, and let-7 in particular, also suffer a set of disadvantages.
First, there is the fundamental challenge of delivering small RNAs to certain tissues and tumors,
which has not yet been resolved. Second, if targeted delivery of a miRNA to a tumor is
impossible, it is not clear what the systemic consequence of miRNA overexpression will be in
normal tissues. Finally, in Chapter 4 and Appendix 1, I have shown that while let-7 suppresses
tumor growth, tumors do eventually form and that these tumors exhibit resistance to further let-
7-mediated target suppression. Thus, there are both advantages and disadvantages to the
development of miRNA therapeutics.
Future studies can address many of these disadvantages. First, technological and
chemical development should aid our ability to deliver small RNAs, including miRNAs, to
defined tissues and tumors. Second, the development of transgenic mice (ideally in a
doxycycline-regulatable system) will allow one to examine the consequences of systemic
induction of let-7 in tumor-bearing animals. Third, the use of existing and transgenic let-7
induction systems should ideally allow for a closer examination of the resistance to let-7
induction and the mechanisms which underlie it. Overall, such studies provide for the exciting
possibility of translating our knowledge of miRNAs and cancer into novel therapeutic agents.
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APPENDIX 1: Induction of let-7g in
established non-small cell lung cancer
suppresses tumorigenesis
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Introduction
As a microRNA (miRNA) shown to regulate proliferation in C. elegans, orthologs of the
let-7 miRNA family in mammals have been shown to be differentially expressed in lung cancers.
In particular, several let-7 members have been shown to be down-regulated in a subset of non-
small cell lung cancers (NSCLCs) and this down-regulation correlates with a poorer prognosis
(Takamizawa et al., 2004; Yanaihara et al., 2006). Of note, let-7 has been shown to suppress a
variety of oncogenes, including the Ras family, HMGA2, c-Myc, and numerous cell-cycle
regulators (Johnson et al., 2007; Johnson et al., 2005; Lee and Dutta, 2007; Mayr et al., 2007;
Sampson et al., 2007).
There was, however, a dearth of functional data demonstrating that the let-7 family
functionally altered tumorigenesis. In two recent reports (one of which is described in detail in
Chapter 4), it was shown that let-7, when overexpressed in lung cancer cell lines, potently
suppressed tumor development (Esquela-Kerscher et al., 2008; Kumar et al., 2008). Furthermore,
this suppression was more robust in lung cancer cells driven by oncogenic mutations in K-Ras,
suggesting some degree of genotype specificity. However, oncogenic K-Ras expression was not
sufficient to rescue cancer cells overexpressing let-7, indicating the role of multiple let-7 targets
in tumor suppression. Finally, in two related genetically engineered mouse models of oncogenic
K-Ras driven NSCLC, expression of let-7 family members in the lung potently inhibited tumor
initiation. Taken together, these studies provided definitive evidence that the let-7 miRNA family
could functionally suppress NSCLC development.
While these reports supported a role for let-7 in lung tumor development, the contribution
of let-7 to inhibition of tumor initiation versus tumor maintenance was unclear. In particular, if
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let-7 family members were to be developed as therapeutic agents, it would be necessary to
establish a role for let-7 in suppressing the growth of established tumors. Moreover, genetically
engineered mouse models of NSCLC provide a powerful tool for examining the effect of let-7
induction in established cancers.
Therefore, to induce let-7 specifically within established lung tumors, it would be
necessary to generate a system for expression of a miRNA in a regulatable manner, such that let-
7 can be induced at a defined time after tumors have initiated. Here we describe such a system
and show that expression of let-7g inhibits tumor growth in both human NSCLC xenografts and
in an autochthonous mouse model of NSCLC. Surprisingly, induction of let-7g at different times
after tumor initiation caused a comparable reduction in tumor burden; this reduced tumor burden,
however, is caused by distinct effects of let-7g on tumors at different time points. Overall, these
results indicate that let-7 delivery to established lung tumors could serve as an effective
therapeutic approach.
Results and Discussion
To examine the role of let-7 in tumor maintenance, we first applied the dox-regulatable
miRNA system used previously (see Chapter 4 for details) within a human NSCLC cell line
(Kumar et al., 2008). When these cells are both transplanted and induced to express either let-7g
or miR- 15b in tumor xenografts, we observed robust suppression of tumor growth. To measure
the effect of these miRNAs in established tumors, we first transplanted the dox-regulatable cells
and only induced the miRNA after tumors had formed. Upon let-7g expression, we observed a
strong slowing of tumor growth relative to induction of miR-15b (Figure Al.1). However, while
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Figure A1.1. Let-7g expression in established tumors slows tumor growth without
regression. Mice were injected with either A549-Tet-On-KRAB-TE-miR-15b or A549-Tet-On-
KRAB-TE-let-7g cells (106 cells/injection) and monitored for tumors. Once tumors were greater
that 2 mm in diameter, mice were intraperitoneally injected with PBS with and without
doxycycline (40 mg/kg) and tumors were measured over time. Values are mean +/- s.e.m. (n=6).
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tumor growth did slow with let-7g expression, these tumors did not exhibit regression. In total,
these results suggest that let-7g expression can alter the growth of established lung tumors.
To examine further the role of let-7 in established lung tumors, we developed a
bifunctional lentiviral vector (Figure A1.2A). In this system, Cre recombinase, which is essential
for tumor development in KrasLSL-GJ2D-driven cancers, is expressed from a constitutive promoter
(Jackson et al., 2001). To express let-7 in an inducible manner, we placed both mCherry, a RFP
analog, and let-7g behind a doxycycline-regulatable promoter similar to the one used in lung
cancer cell lines (Kumar et al., 2008). To induce let-7g in the genetically engineered mouse
model, we combined the KrasLSL-GI2D; Trp53NSCLC model used previously with the CCSP-
rtTa transgenic mouse, which can induce gene expression in response to doxycycline throughout
the lung epithelium (Perl et al., 2002). These compound mutant animals will hereafter be referred
to as "KPR" mice. Using this system, we were able to achieve potent and specific induction of
let-7g in established lung tumors from animals treated with doxycycline (Figure A1.2B).
Moreover, in lung tumors induced to express let-7g, there was substantial suppression of known
let-7 targets like K-Ras, HMGA2, and c-Myc (Figure Al.2C). Thus, this system provides a
useful means of inducing let-7g in lung tumors initiated by Cre activity.
Using this system, we devised an experimental scheme for induction of let-7g at different
time points after tumor initiation. In this approach, we either never induced let-7g or induced let-
7g four, eight, or twelve weeks after lentiviral infection of KPR mice. When we examined tumor
burden in these same groups, we observed a robust decrease in tumor area as a fraction of lung
area in all sets of induced animals (Figure Al.3A). Surprisingly, this decrease in total tumor area
was similar in all sets of induced animals, suggesting that let-7-mediated tumor suppression
was equally efficacious over all durations of induction. As we further examined tumor burden in
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Figure A1.2. Generation of a bifunctional, doxycycline-inducible let-7g lentiviral vector. (A)
Diagram of the lentiviral vector for doxycycline-regulatable expression of let-7g with
constitutive expression of Cre recombinase. (B) KPR mice were infected with TRE.mCherry.let-
7g.PGK.Cre. Twelve weeks post-infection, animals were given feed containing or lacking
doxycycline for three days. Animals were sacrificed, tumors were collected and small RNA
Northern blotting was performed against let-7g, miR-15b, miR-17-5p, and Glutamine tRNA. (C)
KPR mice were infected with TRE.mCherry.let-7g.PGK.Cre. Twelve weeks post-infection, mice
were given feed containing doxycycline for either zero, four, or seven days. Animals were
sacrificed, tumors were collected, and Western blotting was performed against K-Ras, HMGA2,
c-Myc, and actin.
238
Figure A1.3
A
0.75
0.5
0.25
no dox 4off/120n 8off/on 12off4on
50
z
E
25
0
2
E 1.5
0.5
0
0
no dox 4off/12on Soff/on 12off/4on
no dox 4offtl2on 8off/8on 12off/4on
239
Figure A1.3. Let-7g induction suppresses tumorigenesis in an autochthonous NSCLC
model. KPR mice were intratracheally infected with TRE.mCherry.let-7g.PGK.Cre. Animals
were either given feed lacking doxycycline or were switched to feed containing doxycycline
four, eight, or twelve weeks post-infection. Sixteen weeks post-infection, animals were sacrificed
and lungs were examined by histology. (A-C) Tumor burden, measured by tumor area as a
fraction of total lung area (A), tumor number (B), and average tumor size (C) was quantified by
Bioquant software. Values are mean +/- s.e.m. (n=10 for each group).
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these animals, distinctions between these groups emerge. First, induction of let-7g at twelve
weeks post-infection caused a more substantial decrease in tumor number than induction at eight
or four weeks (Figure A1.3B). In contrast, induction of let-7g at four weeks post-infection led to
a greater reduction in average tumor size than induction at eight or twelve weeks (Figure A1.3C).
Taken together, these results suggest that delivery of let-7g in established tumors can suppress
tumor growth. Furthermore, the effects of suppression depend upon the time of delivery relative
to tumor initiation.
Overall, these findings provide important support for the development of let-7 family
members as therapeutic agents. In both human NSCLC xenografts and in an autochthonous
mouse model of NSCLC, let-7g induction in fully formed tumors was able to suppress
tumorigenesis. However, while induction of let-7g in the xenograft model merely slowed the
growth of tumors, let-7g overexpression in naturally arising tumors actually triggered regression
of tumors, as evinced by the substantial reduction in tumor number in animals induced at later
time points. In addition, an intriguing finding from these studies was the distinctive effect of let-
7g induction at different times after tumor initiation. While let-7g induction caused greater
decreases in average tumor size when induced early after tumor initiation, it caused a more
potent decline in tumor number when induced late. It is unclear whether these effects are caused
by differences in the duration of let-7g induction or in the stages of tumor development at these
time points. Moreover, this potent reduction in tumor number at late time points allows for the
characterization of let-7 mediated tumor clearance. A more detailed time course of let-7g
induction at later time points should allow for some insight into this process. Additionally,
examination of survival in tumor-bearing animals induced at different time points will allow for
better understanding of let-7g delivery and its potential in cancer therapy.
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Materials and Methods
Cell culture. A549-Tet-On-KRAB-TE-let-7g and A549-Tet-On-KRAB-TE-miR-15b cells were
described previously (Kumar et al., 2008). Cells were grown under standard conditions in Tet-
Free Serum as per manufacturer's instructions (Clontech).
Tumor xenografts. Tumor xenografts of A549 cells were performed as described (Kumar et al.,
2008). In short, mice were injected with A549-Tet-On-KRAB-TE-let-7g and A549-Tet-On-
KRAB-TE-miR-15b cells and monitored for tumors. Once tumors were greater that 2 mm in
diameter, mice were intraperitoneally injected with PBS with and without doxycycline (40
mg/kg), and tumors were measured.
Mice. KrasSL-G12D; Trp53 f animals were bred with CCSP-rtTA animals to produce KraLSL-G12D
Trp53f+; CCSP-rtTA animals. These animals were backcrossed to KrasLSL-GI2D; Trp53f f animals
to produce KrasLSL-G12 D; Trp53f CCSP-rtTA animals, which were interbred to produce the
experimental cohort of KrasSL-G2 D ; Trp53'- CCSP-rtTA animals.
Construction of TRE.mCherry.let-7g.PGK.Cre. TRE.Puro.let-7g.PGK.Cre was initially
generated by amplification of TRE from pTRE-Tight (Clontech) with 5'-
GACTCTAGACACGAGGCCCTTTCGTCTTCACACGAG-3' and 5'-
GAAGCTAGCTTCTCCAGGCGATCTGACGGTTCACTAAAC-3', digestion with XbaI and
NheI and cloning into UbC.Puro.let-7g.PGK.Cre to generate TRE.Puro.let-7g.PGK.Cre.
TRE.mCherry.let-7g.PGK.Cre was initially generated by amplification of mCherry from
UbC.mCherry.PGK.Cre (a kind gift of M. Winslow) with 5'-
CAAGAATTCACCATGGTGAGCAAGGGCGAG-3' and 5'-
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GGACTCGAGTTACTTGTACAGCTCGTCCATGC-3', digestion with EcoRI and XhoI and
cloning into TRE.Puro.let-7g.PGK.Cre to generate TRE.mCherry.let-7g.PGK.Cre.
Lentivirus Production and Infection. Lentivirus production was performed as described
(Rubinson et al., 2003).
Intratracheal Infection and Tumor Analysis. KrasLSL-G2 D; Trp53f -CCSP-rtTA mice were
infected intratracheally with TRE.mCherry.let-7g.PGK.Cre lentivirus essentially as described
(Murphy et al., 2006). Doxycycline treatment was performed via doxycycline-impregnated food
pellets as described previously (Politi et al., 2006). Tumor analysis was performed as described
(Kumar et al., 2007).
Western Blotting. Western blotting was performed as described previously (Kumar et al., 2008;
Kumar et al., 2007).
Small RNA Northern Blotting. Small RNA Northern blotting was performed as described
previously (Kumar et al., 2008).
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APPENDIX 2: Coordinate loss of miR-145
and RPS14 contribute to the pathogenesis of
5q- syndrome
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Introduction
Changes in copy number for whole chromosomes or chromosomal regions can cause
substantial changes in gene expression that contribute to the pathogenesis of many diseases,
including cancer. An interesting example is 5q- syndrome, a clinical subtype of myelodysplastic
syndrome (MDS) typified by a combination of impaired erythroid production and frequent
elevation of platelet counts, suggesting an imbalance in the erythroid-megakaryocytic lineage
pathway (Giagounidis et al., 2006; Heaney and Golde, 1999; Van den Berghe et al., 1974). We
have recently described an RNA interference screen in which we knocked down all protein-
coding genes within the common deletion region of 5q- syndrome (Boultwood et al., 2002). In
this screen, we found that partial knockdown of the ribosomal protein S 14 (RPS 14) strongly
recapitulated the defects in erythroid differentiation seen in 5q- syndrome (Ebert et al., 2008).
While hemizygous loss of RPS 14 clearly plays an important role in the erythroid differentiation
problems exhibited in 5q- syndrome, other features of the disease, such as increased platelet
production, are not affected by RPS14 loss.
MicroRNAs (miRNAs) are a novel class of small, non-coding RNAs that regulate target
mRNAs via imperfect base pairing and consequent inhibition of translation (Bartel, 2004).
Computational prediction of miRNA targets has predicted that the majority of protein-coding
genes might be regulated by miRNAs (Bartel, 2009). Moreover, a series of genetic analyses has
revealed that specific miRNAs play an important role in hematopoeitic development (Johnnidis
et al., 2008; Koralov et al., 2008; Rodriguez et al., 2007; Thai et al., 2007; Ventura et al., 2008;
Vigorito et al., 2007; Xiao et al., 2007). In particular, certain miRNAs shown to be regulated
during myeloid development play an important role in the normal erythroid-megakaryocyte
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lineage decision (Lu et al., 2008). Taken together, these findings indicate that miRNAs have the
potential to regulate target mRNAs important for hematopoeitic lineage choice.
A recent study examining miRNAs differentially expressed in response to specific
oncogenes revealed potent silencing of two adjacent miRNAs, miR-143 and miR-145, in cells
expressing the E1A oncoprotein (He et al., 2007). Moreover, these miRNAs are both down-
regulated in a variety of tumor types (Akao et al., 2007; Michael et al., 2003; Wang et al., 2008).
Furthermore, both miR-143 and miR-145 are overexpressed in polycythemia vera, a hematologic
disorder characterized by over-production of erythroid cells (Bruchova et al., 2008). Of note,
both miR-143 and miR-145 are within the common deletion region for 5q- syndrome. Thus, we
were interested in the possibility that loss of these miRNAs might, in combination with partial
loss of RPS14, contribute to the pathogenesis of 5q- syndrome.
Results and Discussion
To initially examine the role of miR- 143 and miR- 145 in the development of 5q-
syndrome, we generated lentiviral vectors for their overexpression (Figure A2. 1). When
introduced into human CD34+ hematopoeitic stem cells (HSCs) and triggered to undergo
differentiation, overexpression of miR-145, but not miR-143, led to a significant decrease in the
ratio of megakaryocyte to erythroid cells (Figure A2.2A). Since 5q- syndrome manifests in an
increase in the ratio of megakaryocyte to erythroid cells, one would expect factors that suppress
5q- pathogenesis to act in the manner of miR-145 overexpression. Thus, we focused our efforts
on miR-145.
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Figure A2.1. Overexpression of miR-143 and miR-145. HEL cells were infected with control
lentiviruses or lentiviruses overexpressing miR-143 or miR-145. Quantitative real-time
polymerase chain reaction (Q-RT PCR) was performed with probes for miR-143 and miR-145.
Expression levels were initially normalized to snoRNA-142 and subsequently normalized
relative to the HEL cells infected with the control lentivirus. Values are mean +/- s.d. (n=4) with
propagated error.
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Figure A2.2. MiR-145 regulates the megakaryocyte-erythroid lineage decision. (A) Relative
to an shRNA targeting Renilla luciferase (shluc), overexpression of miR-145, but not
overexpression of miR-143, promotes erythroid relative to megakaryocytic differentiation in
CD34+ HSCs. The ratios of cells from the megakaryocytic and erythroid lineages, indicated on
the y-axis, were assessed by flow cytometry with antibodies against CD41 and GlyA,
respectively. Values are mean +/- s.e.m. with propagated error. #: p<0.01. (B) Relative to an
shRNA targeting Renilla luciferase (shluc), expression of a miRNA sponge targeting miR-145,
promotes megakaryocytic relative to erythroid differentiation in CD34+ HSCs as assessed above.
Values are mean +/- s.e.m. with propagated error. *: p<0.05.
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In order to stably inhibit miR-145 in CD34+ HSCs, we generated a lentiviral vector
encoding a miRNA sponge to miR-145 (Ebert et al., 2007). When transduced into CD34+ HSCs,
inhibition of miR-145 by its sponge caused a significant increase in the ratio of megakaryocyte
to erythroid cells, as expected for a factor whose loss contributes to 5q- syndrome (Figure
A2.2B). Moreover, when compared to MDS patient samples wild type for 5q (5q+ MDS),
samples from 5q- syndrome patients (5q- MDS) have reduced levels of miR-145 (Figure A2.3A).
Taken together, these results suggest that miR-145 regulates the megakaryocyte-erythroid
lineage decision in a manner consistent with its role in 5q- syndrome.
We then examined which predicted targets of miR-145 could contribute to its effects on
differentiation using the miRNA target prediction program TargetScan (Friedman et al., 2009).
One of the highest scoring predictions was Fli-1, as it had multiple binding sites highly
conserved across mammalian species. Fli-1, an ETS-family transcription factor originally found
as an insertion site of the Friend leukemia virus, has been previously shown to play a role in
megakaryocytic and erythroid differentiation. First, overexpression of Fli-1 in leukemia cells
induces megakaryocyte differentiation while suppressing erythroid differentiation (Athanasiou et
al., 1996; Athanasiou et al., 2000). Moreover, in Flil- - embryos, there is a severe defect in
megakaryocyte differentiation, resulting in thrombocytopenia (Hart et al., 2000).
We thus wanted to explore the relationship of miR- 145 and Fli- 1. When we
overexpressed miR-145 in human erythroleukemia (HEL) cells, we observed a substantial
decrease in Fli-1 protein expression; conversely, inhibition of miR-145 by its sponge caused a
substantial increase in Fli-1 protein levels (Figure A2.4A). To determine whether miR-145
regulated Fli-1 via its 3' UTR, we generated a reporter in which the Fli-1 3' UTR is placed
behind Renilla luciferase. We found that overexpression of miR-145 caused a significant
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Figure A2.3. Altered expression of miR-145 and Fli-1 in 5q- MDS. (A) Quantitative real-time
polymerase chain reaction (Q-RT PCR) was performed for miR-145 in MDS patient samples
wild type for 5q (5q+ MDS) and in samples from patients with 5q- syndrome (5q- MDS).
Expression levels were normalized to snoRNA-142. Values are mean (n=4) with propagated
error. *: p<0.05. (B) Quantitative real-time polymerase chain reaction (Q-RT PCR) was
performed for Fli-l in MDS patient samples wild type for 5q (5q+ MDS) and in samples from
patients with 5q- syndrome (5q- MDS). Expression levels were normalized to GAPDH. Values
are mean (n=4) with propagated error. **: p<0.0005.
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Figure A2.4. MiR-145 regulates Fli-1. (A) HEL cells were infected with control lentiviruses,
lentiviruses overexpressing miR-143 or miR-145, or with lentiviruses expressing miRNA
sponges target miR-143 and miR-145. Western blotting was performed for Fli-1 and actin. (B)
Luciferase assays were performed in 293T cells co-transfected with control lentiviruses or
lentiviruses over-expressing miR-143 or miR-145 and pRL-TK containing bulged siCXCR4
binding sites or murine Fli-1 and c-Myc 3' UTRs. Firefly luciferase (pGL3) was used as a
transfection control. Expression was normalized to pGL3 levels and subsequently normalized
relative to pRL-CXCR4 expression. Values are mean +/- s.d. (n=6) with propagated error. (C)
Luciferase assays were performed in 293T cells co-transfected with lentiviruses expressing
sponges targeting miR-143 or miR-145 and pRL-TK and pGL3 vectors as described above.
Normalization was performed as described above. Values are mean +/- s.d. (n=6) with
propagated error. (D) Luciferase assays were performed in 293T cells co-transfected with
lentiviruses over-expressing miR-145 and pRL-TK containing either the wild type murine Fli-1
3' UTR (FLI wt) or combinations of point mutations in miR- 145 binding sites (FLI mutl-
mut4). Firefly luciferase (pGL3) was used as a transfection control. Expression was first
normalized to pGL3 levels and subsequently normalized relative to FLI 1 wt expression. Values
are mean +/- s.d. (n=6) with propagated error.
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repression of the Fli- I1 reporter (Figure A2.4B). Conversely, inhibition of miR-145 by a miR-145
sponge caused a modest but significant derepression of the Fli-1 3' UTR (Figure A2.4C).
Notably, neither overexpression nor inhibition of miR-145 affected expression of a similar
reporter targeting the c-Myc 3' UTR, even though miR-145 has recently been suggested to target
c-Myc (Sachdeva et al., 2009). Furthermore, we believe that the repression of Fli-l by miR-145
is direct, as mutation of the predicted miR-145 binding sites in the Fli-1 3' UTR led to
progressively greater derepression, with mutation of all four sites achieving a near complete
restoration of reporter expression (Figure A2.4D). Overall, these results indicate that miR-145
regulates Fli-1 through its 3' UTR.
To characterize the functional consequence of Fli-1 derepression via loss of miR-145, we
sought to overexpress Fli-1 by lentivirus. In particular, we expressed the Fli-1 open reading
frame without its 3' UTR, so that it cannot be regulated by miR-145. When the Fli-1 lentivirus
was transduced into CD34+ HSCs, there was a significant increase in the ratio of megakaryocyte
to erythroid cells, similar to that seen with the miR-145 sponge (Figure A2.5). Furthermore,
when we compared 5q+ MDS samples with 5q- MDS samples, we observed a significant
increase in Fli-1 mRNA in 5q- MDS (Figure A2.3B). As it has been shown that targets strongly
regulated by miRNAs at the protein level overwhelmingly exhibit changes at the mRNA level,
this change in Fli-1 transcript levels likely reflects differences in miRNA-mediated repression
(Baek et al., 2008). Taken together, these results indicate that Fli-1, which is overexpressed via
loss of miR-145, regulates megakaryocyte and erythroid differentiation as expected in 5q-
syndrome.
While the above results suggest a role for miR-145, and its regulation of Fli-1, in
suppression of 5q- syndrome, it has been shown that at least one protein-coding gene, RPS 14,
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Figure A2.5. Fli-1 overexpression phenocopies miR-145 inhibition. Relative to a control
cDNA (LacZ), overexpression of Fli-1 promotes megakaryocytic relative to erythroid
differentiation in CD34+ HSCs as assessed above. Values are mean +/- s.e.m. with propagated
error. *: p<0.05.
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contributes to the disease state (Ebert et al., 2008). Thus, we wanted to combine miR-145
inhibition with loss of RPS 14. When we combined the miR- 145 sponge with three short hairpin
RNAs (shRNAs) targeting RPS14 in CD34+ HSCs, we noted a significant increase in the ratio of
megakaryocyte to erythroid cells compared to loss of RPS14 alone (Figure A2.6). Thus, loss of
miR-145 appears to cooperate with loss of RPS 14 in the megakaryocyte-erythroid differentiation
effects seen in 5q- syndrome.
Taken together, these results provide substantial evidence that loss of miR-145 promotes
5q- syndrome via up-regulation of Fli- 1, a known transcriptional regulator of megakaryocyte
development. Therefore, it is likely that this up-regulation of Fli-1 specifically contributes to the
thrombocytosis observed in 5q- syndrome. It also appears that loss of miR-145 cooperates with
loss of RPS 14 to promote development of 5q- syndrome, making it a coordinate gene deletion
syndrome. This is an important finding, as it is the first example of a miRNA undergoing
coordinate loss with a protein-coding gene in a chromosome deletion syndrome. Moreover, it
suggests that other chromosome deletions, many of which occur in cancer, might involve the
combined loss of protein-coding genes and non-coding RNAs. Thus, future genomic analyses in
human disease should examine the effects of deletions on coding and non-coding genes. Finally,
an intriguing feature of 5q- syndrome is its exquisite sensitivity to lenalidomide, which potently
induces erythroid differentiation in this context (List et al., 2006). However, the mechanism of
action of lenalidomide in this context is largely unknown. The results presented here provide for
the intriguing possibility that lenalidomide alters the expression of miR-143 and miR-145, thus
promoting erythroid differentiation only within the context of the disease.
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Figure A2.6. MiR-145 inhibition cooperates with loss of RPS14 in the megakaryocyte-
erythroid lineage decision. Relative to a control lentivirus (LacZ) co-infected with a series of
shRNAs against RPS14 (shRPS14 #1-3), expression of a miRNA sponge targeting miR-145
promotes megakaryocytic relative to crythroid differentiation in CD34+ HSCs as assessed above.
Values are mean +/- s.e.m. with propagated error. *: p<0.05; ##: p<0.005.
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Materials and Methods
Cell culture. HEL cells were acquired from ATCC and were cultured under standard conditions.
CD34+ cells were acquired and grown as described previously (Ebert et al., 2008).
Construction of miRNA overexpression vectors. pLVX.miR-143.puro was initially generated
by amplification of miR-143 (plus approximately 250 bp flanking sequence) from wild type
mouse tail DNA with 5'-GAACTCGAGGCATAAAGAGACGGATGGGGGGC-3' and 5'-
GCCAGATCTGTTGAGAAGGGTTCCGAGGGTG-3', digestion with XhoI and BglII and
cloning into pLVX.puro to generate pLVX.miR-143.puro. pLVX.miR-145.puro was initially
generated by amplification of miR-145 (plus approximately 250 bp flanking sequence) from wild
type mouse tail DNA with 5'-TAACTCGAGCTGGAGGACCGCAGCGAGAAG-3' and 5'-
GCCAGATCTCAAGGTCTACAGGGAAGGCATG-3', digestion with XhoI and BglII and
cloning into pLVX.puro to generate pLVX.miR-145.puro.
Construction of miRNA sponge vectors. MiRNA sponges were generated against miR-143
and miR-145 as described previously with some modifications (Ebert et al., 2007). In particular,
synthetic miRNA binding sites were generated via minigene synthesis (Integrated DNA
Technologies). To generate pLenti6.miR-143 sponge.blast, the miR-143 sponge was amplified
from the minigene with 5'-CACCGAGCTACAGACGATCATCTCACCGG-3' and 5'-
TGAGATGATTGCCTGTAGCTCTTTGTGAGATGAC-3' and cloned into pLenti6.D-TOPO-
V5.blast per manufacturer's instructions (Invitrogen) to generate pLenti6.miR-143 sponge.blast.
To generate pLenti6.miR-145 sponge.blast, the miR-145 sponge was amplified from the
minigene with 5'-CACCAGGGATTCCTGCCTTAACTGGACCCGG-3' and 5'-
GTCCAGTTGAAGCAGGAATCCCTTTTGGTCCAGTTG-3' and cloned into pLenti6.D-
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TOPO-V5.blast per manufacturer's instructions (Invitrogen) to generate pLenti6.miR-145
sponge.blast.
Construction of Fli-1 overexpression vector. pLenti6.Fli-1.blast was generated by
amplification of human Fli-l from the pOTB7.Fli- cDNA with 5'-
CACCATGGACGGGACTATTAAGGAGGCTC-3' and 5'-
CTAGTAGTAGCTGCCTAAGTGTGAAGGCACGTG-3' and cloned into pLenti6.D-TOPO-
V5.blast as described above to generated pLenti6.Fli-1 .blast.
Construction of Fli-1 3' UTR reporter. pRL.Fli- 3' UTR.TK was generated by amplification
of the murine Fli-1 3' UTR from wild type mouse tail DNA with 5'-
GAACTCGAGAACTAACACCAGTTGGCCTTCTGG-3' and 5'-
GACGCGGCCGCGCACAATTTATTAAGGTCAAATTATTTTAC-3', digestion with Xhol
and NotI and cloning into pRL.TK to generate pRL.Fli-1 3' UTR.TK.
Mutation of miR-145 binding sites in Fli-1 3' UTR. Site-directed mutagenesis of the predicted
miR-145 binding sites in the Fli-1 3' UTR was performed per manufacturers' instructions
(Stratagene). Mutagenesis oligonucleotides were as follows:
Mutl forward:
GGCACAGTAGCCTTGAAGAGATAAGAAAACACCTTGTTCTTTCTTTTGGATAGAACC
TTTG
Mutl reverse:
CAAAGGTTCTATCCAAAAGAAAGAACAAGGTGTTTTCTTATCTCTTCAAGGCTACTG
TGCC
Mut2 forward:
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CATCGAATGAGTTAAATATTTAGGTTACACCTACGGTTTATACCATGATTCTGAGAA
AGGAG
Mut2 reverse:
CTCCTTTCTCAGAATCATGGTATAAACCGTAGGTGTAACCTAAATATTTAACTCATTC
GATG
Mut3 forward: GGACTCAATTCAGTGGATGGCAACACCTACACTGGCTCTGAGGCCAG
Mut3 reverse: CTGGCCTCAGAGCCAGTGTAGGTGTTGCCATCCACTGAATTGAGTCC
Mut4 forward:
GCTCTGAGGCCAGTGAAGTTTTTTGCCCAACACCTATTTAAAAGATGTGTGTC
Mut4 reverse:
GACACACATCTTTTAAATAGGTGTTGGGCAAAAAACTTCACTGGCCTCAGAGC
Lentivirus production and infection. Lentivirus production was performed as described
(Rubinson et al., 2003).
Luciferase assays. Luciferase assays were performed as described previously (Doench et al.,
2003).
Quantitative reverse transcription (Q-RT) PCR. Q-RT PCR of miR-143, miR-145, and
snoRNA-142 was performed using the corresponding Taqman miRNA expression assays. Q-RT
PCR of human Fli-1 and GAPDH was performed using Taqman assays Hs00231107_ml and
4333764F. Synthesis of cDNA and Taqman qRT-PCR of Fli-1 and GAPDH were performed as
described previously (Sweet-Cordero et al., 2005).
Western blotting. Western blotting was performed as described previously using antibodies
against Fli-l (ab53077 from AbCam) and actin (A2066 from Sigma) (Kumar et al., 2008; Kumar
et al., 2007).
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APPENDIX 3: Development of lentiviral
vectors to combine Cre-loxP technology and
RNA interference in the mouse
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Introduction
Genetically engineered mouse models provide an important tool in the study of
tumorigenesis in the context of a whole organism (Frese and Tuveson, 2007; Van Dyke and
Jacks, 2002). In particular, the development and application of conditional genetic strategies
based upon, among others, the Cre-loxP site-specific recombination system has been invaluable
for several reasons. First, this technology allows the examination of cancer genes whose
germline loss of function is either lethal or compensated for during embryonic development, both
of which obfuscate relevant results for tumorigenesis. Second, such systems provide temporal
control of recombination, so that the Cre-mediated mutation can be induced at a specific time
point as in the adult, which is when the preponderance of cancers is believed to initiate. Third,
Cre-loxP regulation can be controlled in specific cells and tissues or in response to specific
inducible signals, such as delivery of small molecules like pIpC or tamoxifen. Overall,
conditional genetic systems generated via Cre-loxP have provided a novel set of reagents for
examining tumor development.
While conditional genetics in the mouse has allowed for an unprecedented ability to
engineer specific mutations in particular cells at particular times, it faces some practical
limitations. First, generation of specific conditional alleles, though largely standardized in recent
years, is still a laborious and time-consuming process. Second, once conditional alleles of
interest are generated, combining individual alleles together is at best a long-term experimental
approach and at worst impossible because of the lack of secondary conditional alleles available.
Finally, the above time and labor constraints, based upon crossing pairs of conditional alleles,
make systematic reverse genetic screens, in which one activates or inactivates a set of genes of
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interest, essentially impossible. Thus, the development of methods that could combine Cre-loxP
with other approaches to gain or loss of function genetics would be useful both in terms of
experimental tractability and the capacity for reverse genetics.
RNA interference (RNAi), besides representing a novel method of gene regulation, has
provided a new experimental reagent for engaging in loss of function of a given mRNA
(Dykxhoorn et al., 2003). Moreover, since this method, which relies upon perfect base pairing of
a small RNA with its target mRNA and subsequent cleavage and degradation of the transcript,
regulates directly via the mRNA sequence, it has been possible to generate RNAi libraries
against all known transcripts within a genome (Berns et al., 2004; Kolfschoten et al., 2005;
Paddison et al., 2004; Westbrook et al., 2005). These libraries have provided a powerful method
for probing a wide collection of transcripts in vitro, allowing for the discovery of new regulators
of signal transduction pathways. In addition, the use of both retroviruses and lentiviruses has
allowed for the development of transgenic mice in which RNAi can be regulated either by
doxycycline-regulated transcription or Cre-loxP-mediated recombination (Dickins et al., 2005;
Dickins et al., 2007; Kolfschoten et al., 2005; Stegmeier et al., 2005; Tiscornia et al., 2004;
Ventura et al., 2004). In total, this data allows for the exciting possibility that RNAi screening
can be performed in vivo.
While the above technologies (Cre-loxP and RNAi) have been demonstrated to be
powerful tools for examining tumor biology, they have yet to be effectively combined so that one
can coordinately engage in Cre-loxP recombination and RNAi in vivo. Here we describe the
development of a bifunctional lentiviral vector for the combined delivery of Cre recombinase
and short hairpin RNAs (shRNAs) to the adult mouse. We demonstrate that for several distinct
targets knockdown occurs within mouse models of lung cancer and soft-tissue sarcoma.
275
Furthermore, we show that this knockdown can, in fact, functionally recapitulate results
previously found using traditional genetics. Taken together, these results open the possibility of
developing RNAi screens in Cre-loxP-regulated mouse models of cancer.
Results and Discussion
To combine Cre-loxP with RNAi, we generated a lentiviral vector, hereafter referred to
as U6.Cre, composed of two independent transcriptional units (Figure A3. 1A). The first is a U6-
driven shRNA cassette, which is transcribed via RNA polymerase III (Ventura et al., 2004). The
second is the Cre recombinase gene expressed via the phosphoglycerate kinase (PGK) promoter,
which we have shown previously to allow for effective expression of Cre in target tissues upon
infection (Kumar et al., 2008). To test the efficacy of this vector in achieving knockdown in
vitro, we developed a series of shRNAs targeting Mapkl4, whose product, p38alpha, was
frequently shown to be a tumor suppressor in a K-Ras--driven model of lung cancer (Ventura et
al., 2007). When U6.Cre viruses targeting p38alpha were transduced into mouse embryonic
fibroblasts, we observed potent suppression of the target with all three shRNAs, with near
complete loss of target protein for the last two (Figure A3. 1B).
In order to see if these U6.Cre shRNAs would work in vivo, we intratracheally infected
KrasLSL-GI2D; Trp53f mice, which have been shown to experience a severe lung adenocarcinoma
in response to Cre, with these lentiviral vectors (Jackson et al., 2005). Twelve weeks after
infection, we collected tumors from these animals and examined p38alpha expression. Though
not as robust as in vitro, we observed substantial repression of p38alpha in the tumors of mice
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Figure A3.1 Development of a lentiviral vector for combined expression of an shRNA and
Cre. (A) Diagram of the bifunctional lentiviral vector. (B) KraSLSL-G2D MEFs were infected with
U6.Cre vectors containing shRNAs against Renilla luciferase (shluc), Cyclin Dl (shCyclin D ),
CDKN2A (shCDKN2A), and against p38alpha (shMAPK14.1-3). Western blotting was
performed against p38alpha, with N-Ras as a loading control. (C) KrasLSL-GI2D; Trp53fmice
were intratracheally infected with lentiviruses expressing Cre and either shluc, shMAPK14.2, or
shMAPK14.3. Twelve weeks after infection, tumors were collected and Western blotting was
performed against p38alpha, with actin as a loading control.
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infected with the shRNAs targeting p38alpha (Figure A3.1C). These differences could further be
explained by normal tissue contamination within the tumors, as the lung adenocarcinomas in this
model frequently are infiltrated by both stromal fibroblasts and macrophages. In total, this data
suggests that a bifunctional lentiviral system should allow for combined expression of an shRNA
and Cre in vivo.
To ensure that this vector is applicable to additional targets, we designed an shRNA
targeting NEMO, an important regulator of the canonical NF-kappaB signaling pathway (Karin,
2006). When infected into a murine lung cancer cell line, we observed significant repression of
NEMO (Figure A3.2A). Similarly, when infected into KrasLSL-Gl 2D; Trp53ff mice, we observed
significant repression of NEMO within a tumor from a mouse infected with the NEMO shRNA
(Figure A3.2B). In sum, this data further supports the use of U6.Cre in knockdown of target
genes in combination with Cre.
While the above studies suggest that it is possible to knockdown target mRNAs in vivo
with U6.Cre, it is possible that such knockdown will be insufficient to affect tumor biology. This
has been demonstrated categorically for p53, in which greater than 90% loss of p53 protein is
insufficient to abrogate its ability to respond to DNA damage (Hemann et al., 2003). Thus, we
applied U6.Cre to a mouse model of soft-tissue sarcoma, in which Cre expression in the
hindlimb of KrasLSL-Gl2D; Trp53f or KrasLSL-G2D; Cdkn2afcauses the development of an
extremity rhabdomyosarcoma (Kirsch et al., 2007). In this model, complete loss of the pl9Arf-
p53 pathway is required at the onset of tumorigenesis; animals that are heterozygous mutant for
either of these components are unable to form tumors after hindlimb injection. We speculated
that an shRNA targeting the mRNAs produced from Cdkn2a might be able to recapitulate the
effect of complete of pl 9Arf. Importantly, for this to be true, tumors from animals that are
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Figure A3.2 Knockdown of NEMO in vitro and in vivo with U6.Cre. (A) Mouse lung cancer
cells were not infected with an empty U6.Cre virus or infected with U6.Cre virus expressing an
shRNA targeting NEMO. Western blotting was performed against NEMO. A higher molecular
weight, non-specific band (n.s.*) was used as a loading control. (B) KraSLSL-2D; Trp53 f mice
were intratracheally infected with lentiviruses expressing Cre alone or with a U6.Cre virus
expressing an shRNA against NEMO. Twelve weeks after infection, tumors, normal lung, and
normal liver were collected and Western blotting was performed against NEMO, with the non-
specific band used as a loading control.
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heterozygous mutant at this locus should retain the wild type allele, as the target is being
depleted by RNAi and does not require deletion.
When we intramuscularly infected KrasLSL-G12 D; Rag2--; Arf FP/GFP animals with U6.Cre
vectors targeting luciferase, E2F 1, or CDKN2A, we generated tumors that failed to express
pl9Arf, as expected (Figure A3.3A). Surprisingly, when we infected KrasLSL-G12 D; Rag2-;
ArfFP/+ animals with U6.Cre vectors target CDKN2A, we were able to generate sarcomas,
which does not occur normally with Cre delivery alone. Moreover, these tumors have sustained
knockdown of both mRNAs produced from the Cdkn2a locus, p 19Arf and p16Ink4a.
Furthermore, these tumors do not lose the wild type allele of Arf, suggesting that RNAi-mediated
knockdown is sufficient to suppress p 19Arf and allow for soft-tissue sarcoma development
(Figure A3.3B). In addition, sarcoma-free survival of KrasLSL-G1 2D; Rag2 --; ArjGFP/+ animals was
comparable to that of KraLSL-GI2D; Rag2-; ArFP/GFP animals when both were infected with the
shRNA to CDKN2A (Figure A3.3C). In contrast, while KraLSL-Gl 2 D; Rag2--; ArfFP/GFP animals
infected with U6.Cre shRNAs against luciferase formed tumors readily, KrasLSL-GJ2D; Rag2-;
ArjFP/+ animals infected with the same virus never formed tumors (data not shown). Taken
together, this data suggests that U6.Cre-mediated RNAi allows for recapitulation of genetic loss
of function in a mouse model of sarcoma.
Overall, these results indicate that the U6.Cre vector is an effective means of combining
Cre-loxP technology with RNA interference in vivo. In particular, this system allows for
infection of several cell types, as we were able to achieve viral delivery and knockdown in both
the lung epithelium and hindlimb skeletal muscle. Moreover, this vector allows for delivery of
Cre and an shRNA in the adult, providing the capacity to model tumorigenesis in adult animals.
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Figure A3.2 Knockdown of pl9Arf by U6.Cre recapitulates pl9Arf loss in a mouse model
of soft-tissue sarcoma (A) KrasLLSL-G2D; Rag2-; ArGFP/GFP mice (referred to as KR
ArfGFP/GFP) and KrasLSL-Gl 2D; Rag2--; Arf FP/+ mice (referred to as KR ArfGFP/+) mice were
intramuscularly infected with lentiviruses expressing Cre and either shluc, shE2F 1, or
shCDKN2A. KraSL-G2D; Trp53 mice were intramuscularly injected with adenovirus
expressing Cre as a positive control. Sarcomas were collected and Western blotting was
performed for pl9Arf, pl6Ink4a, GFP, p-ERK1/2, and tubulin. (B) DNA was prepared from the
KR ArfGFP/+ shCDKN2A tumors described above and PCR was performed at the Arflocus. (C)
Post-infection sarcoma development was measured in KR ArfGFP/GFP and KR ArfGFP/+ mice
infected with shRNAs against CDKN2A.
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Finally, these findings provide the potential for reverse genetic screens by RNAi in conditional
genetically engineered mouse models of cancer.
Materials and Methods
Cell culture. KP lung cancer cells were generated by trypsin digestion and propagation of a lung
tumor from a KrasLSL-G12 D; Trp53f mouse (Jackson et al., 2005). KrasLSL-GI2D MEFs were
generated as described previously (Tuveson et al., 2004). Cells were grown under standard
conditions.
Construction of U6.Cre. The U6 cassette was Xbal and Xhol digested from the pSicoR vector
described previously and cloned into the Xbal- and XhoI-digested UbiC.luciferase.PGK.Cre
vector (a kind gift of M. Dupage) (Ventura et al., 2004).
Design and cloning of shRNAs. ShRNAs were designed using pSicoOLIGOMAKER and
cloning was performed as described (Ventura et al., 2004). The oligonucleotides used for shluc
were described previously (Kumar et al., 2007). The additional shRNA oligonucleotides were as
follows:
shMAPK14.1:
TGGCATCGTGTGGCAGTTAATTCAAGAGATTAACTGCCACACGATGCCTTTTTTTC
TCGAGAAAAAAGGCATCGTGTGGCAGTTAATCTCTTGAATTAACTGCCACACGATGC
CA
shMAPK14.2:
TGCAGGGACCTTCTCATAGATTCAAGAGATCTATGAGAAGGTCCCTGCTTTTTTC
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TCGAGAAAAAAGCAGGGACCTTCTCATAGATCTCTTGAATCTATGAGAAGGTCCCTG
CA
shMAPK14.3:
TGGAAGAGCCTGACCTATGATTCAAGAGATCATAGGTCAGGCTCTTCCTTTTTTC
TCGAGAAAAAAGGAAGAGCCTGACCTATGATCTCTTGAATCATAGGTCAGGCTCTTC
CA
shNEMO:
TGGACATGCTGGGTGAAGAATTCAAGAGATTCTTCACCCAGCATGTCCTTTTTTC
TCGAGAAAAAAGGACATGCTGGGTGAAGAATCTCTTGAATTCTTCACCCAGCATGTC
CA
shCyclinD 1:
TGCATGTTCGTGGCCTCTAATTCAAGAGATTAGAGGCCACGAACATGCTTTTTTC
TCGAGAAAAAAGCATGTTCGTGGCCTCTAATCTCTTGAATTAGAGGCCACGAACATG
CA
shCDKN2A:
TGCTGGGTGGTCTTTGTGTATTCAAGAGATACACAAAGACCACCCAGCTTTTTTC
TCGAGAAAAAAGCTGGGTGGTCTTTGTGTATCTCTTGAATACACAAAGACCACCCAG
CA
shE2Fl:
TGGAGAAGTCACGCTATGAATTCAAGAGATTCATAGCGTGACTTCTCCTTTTTTTC
TCGAGAAAAAAGGAGAAGTCACGCTATGAATCTCTTGAATTCATAGCGTGACTTCTC
CA
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Lentivirus production and infection. Lentivirus production was performed as described
(Rubinson et al., 2003).
Intranasal, intratracheal and intramuscular infection. Mice were infected intratracheally and
intramuscularly as described (Kirsch et al., 2007; Kumar et al., 2008).
Western blotting. Western blotting was performed using standard methods. Antibodies were as
follows: p38alpha (9212 from Cell Signaling Technology); N-Ras (sc-31 from Santa Cruz
Biotechnology); actin (A5441 from Sigma); NEMO (sc-8330 from Santa Cruz Biotechnology);
p16Ink4a (sc-1207 from Santa Cruz Biotechnology); p1 9Arf (sc-32748 from Santa Cruz
Biotechnology); p-ERK1/2 (9101 from Cell Signaling Technology); tubulin (2128 from Cell
Signaling Technology); GFP (NB600-597 from Novus Biologicals).
Deletion analysis of Arf locus. Deletion at the Arf locus was performed by PCR as described
previously (Zindy et al., 2003).
Mice. KrasSL-G;2D; Trp53fanimals were generated as described previously (Jackson et al.,
2005). KraSLS L-Gl2D animals were crossed to Rag2-- animals to generate KrasLSL-G12D; Rag2 +-,
which were interbred to produce KrasLSL-G12D; Rag2- - animals. These animals were bred to
ArfFP/GFP animals to produce KrasLSL-G12 D Rag2 ArfFP/+ animals (Zindy et al., 2003). These
animals were backcrossed to KraLSL-GI2D; Rag2-/-animals to produce KrasLSL-GJ2D; Rag2-;
Arf FP + animals, which were intercrossed to produce the experimental cohort.
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